var title_f31_53_32592="Nystatin: Drug information";
var content_f31_53_32592=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Nystatin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block inc\" id=\"F12805652\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12805653\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?11/17/11539?source=see_link\">",
"       Nystatin (oral): Drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/39/14963?source=see_link\">",
"       Nystatin (topical): Drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9712 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-F0948400E7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_53_32592=[""].join("\n");
var outline_f31_53_32592=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?11/17/11539?source=related_link\">",
"      Nystatin (oral): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?14/39/14963?source=related_link\">",
"      Nystatin (topical): Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_53_32593="Ultrasound showing stone";
var content_f31_53_32593=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F62309&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F62309&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Transabdominal ultrasound showing common bile duct stone",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 400px; height: 330px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of ML Freeman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_53_32593=[""].join("\n");
var outline_f31_53_32593=null;
var title_f31_53_32594="Edema (swelling)";
var content_f31_53_32594=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Edema (swelling) (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?31/53/32594/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/53/32594/contributors\" id=\"au5356\">",
"       Richard H Sterns, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?31/53/32594/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/53/32594/contributors\" id=\"se323\">",
"       Robert H Fletcher, MD, MSc",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"mobipreview.htm?31/53/32594/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/53/32594/contributors\" id=\"de7812\">",
"       John P Forman, MD, MSc",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"mobipreview.htm?31/53/32594?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      EDEMA OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Edema is the medical term for swelling caused by a collection of fluid in the small spaces that surround the body's tissues and organs. Edema can occur nearly anywhere in the body. Some of the most common sites are:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       The lower legs or hands (also called peripheral edema)",
"      </li>",
"      <li>",
"       Abdomen (also called ascites)",
"      </li>",
"      <li>",
"       Chest (called pulmonary edema if in the lungs and pleural effusion if in the space surrounding the lungs)",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     Ascites and peripheral edema can be uncomfortable and can be a sign of a more serious condition. Pulmonary edema, which can be life-threatening, is a symptom of heart failure and is discussed in more detail separately. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/5/33877?source=see_link\">",
"      \"Patient information: Heart failure (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      EDEMA SYMPTOMS",
"     </span>",
"    </p>",
"    <p>",
"     Symptoms of edema depend upon the cause but may include:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Swelling or puffiness of the skin, causing it to appear stretched and shiny. This typically is worse in the areas of the body that are closest to the ground (because of gravity). Therefore, edema is generally the worst in the lower legs (called peripheral edema) after walking about, standing, sitting in a chair for a period of time, or at the end of the day. It accumulates in the lower back (called sacral edema) after being in bed for a long period. Pushing on the swollen area for a few seconds will leave a dimple in the skin (",
"       <a class=\"graphic graphic_picture graphicRef61706 \" href=\"mobipreview.htm?15/43/16050\">",
"        picture 1",
"       </a>",
"       ).",
"      </li>",
"      <li>",
"       Increased size of the abdomen (with ascites).",
"      </li>",
"      <li>",
"       Shortness of breath (with edema in the chest).",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      CONDITIONS ASSOCIATED WITH EDEMA",
"     </span>",
"    </p>",
"    <p>",
"     A number of different problems can cause edema.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Chronic venous disease",
"     </span>",
"     &nbsp;&mdash;&nbsp;A common cause of edema in the lower legs is chronic venous disease, a condition in which the veins in the legs cannot pump enough blood back up to the heart because the valves in the veins are damaged. This can lead to fluid collecting in the lower legs, thinning of the skin, and, in some cases, development of skin sores (ulcers) (",
"     <a class=\"graphic graphic_figure graphicRef79766 \" href=\"mobipreview.htm?3/48/3840\">",
"      figure 1",
"     </a>",
"     ). (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/17/35091?source=see_link\">",
"      \"Patient information: Chronic venous disease (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Edema can also develop as a result of a blood clot in the deep veins of the lower leg (called deep vein thrombosis [DVT]). In this case, the edema is mostly limited to the feet or ankles and usually affects only one side (the left or right); other conditions that cause edema usually cause swelling of both legs. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?12/44/12998?source=see_link\">",
"      \"Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H5\">",
"     <span class=\"h2\">",
"      Pregnancy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Pregnant women retain extra fluid. Swelling commonly develops in the hands, feet, and face, especially near the end of a normal pregnancy. Swelling without other symptoms and findings is not usually a sign that a complication, such as preeclampsia (sometimes called toxemia), has developed. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/58/40867?source=see_link\">",
"      \"Patient information: Preeclampsia (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Monthly menstrual periods",
"     </span>",
"     &nbsp;&mdash;&nbsp;Edema in women that occurs in a cyclic pattern (usually once per month) can be the result of hormonal changes related to the menstrual cycle. This type of edema is common but does not require treatment because it resolves on its own.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Drugs",
"     </span>",
"     &nbsp;&mdash;&nbsp;Edema can be a side effect of a variety of medications, including some oral diabetes medications, high blood pressure medications, non-prescription pain relievers (such as ibuprofen), and estrogens.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Kidney disease",
"     </span>",
"     &nbsp;&mdash;&nbsp;The edema of kidney disease can cause swelling in the lower legs and around the eyes. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?13/5/13398?source=see_link\">",
"      \"Patient information: Chronic kidney disease (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H9\">",
"     <span class=\"h2\">",
"      Heart failure",
"     </span>",
"     &nbsp;&mdash;&nbsp;Heart failure, also called congestive heart failure, is due to a weakened heart, which impairs its pumping action. Heart failure can cause swelling in the legs and abdomen, as well as other symptoms. Heart failure can also cause fluid to accumulate in the lungs (pulmonary edema), causing shortness of breath. This can be a very dangerous condition requiring emergency treatment. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/5/33877?source=see_link\">",
"      \"Patient information: Heart failure (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Cirrhosis",
"     </span>",
"     &nbsp;&mdash;&nbsp;Cirrhosis is scarring of the liver from various causes, which can obstruct blood flow through the liver. People with cirrhosis can develop pronounced swelling in the abdomen (ascites) or in the lower legs (peripheral edema). (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/3/44084?source=see_link\">",
"      \"Patient information: Cirrhosis (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Travel",
"     </span>",
"     &nbsp;&mdash;&nbsp;Sitting for prolonged periods, such as during air travel, can cause swelling in the lower legs. This is common and is not usually a sign of a problem. Table 1 provides tips to minimize leg swelling during travel (",
"     <a class=\"graphic graphic_table graphicRef71028 \" href=\"mobipreview.htm?16/37/16987\">",
"      table 1",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     If your leg(s) remain swollen or you develop leg pain hours or days after the flight, contact your healthcare provider. Continued swelling and pain can be signs of a blood clot (DVT). (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?12/44/12998?source=see_link\">",
"      \"Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H12\">",
"     <span class=\"h1\">",
"      DIAGNOSING THE CAUSE OF EDEMA",
"     </span>",
"    </p>",
"    <p>",
"     If you develop new swelling in one or both of your legs, hands, in your abdomen, or around your eyes, you should call your healthcare provider to determine if you need to be evaluated. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/36/34375?source=see_link\">",
"      \"Clinical manifestations and diagnosis of edema in adults\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H13\">",
"     <span class=\"h1\">",
"      EDEMA TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     Treatment of edema includes several components: treatment of the underlying cause (if possible), reducing the amount of salt (sodium) in your diet, and, in many cases, use of a medication called a diuretic to eliminate excess fluid. Using compression stockings and elevating the legs may also be recommended. (See",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/50/30503?source=see_link\">",
"      \"General principles of the treatment of edema in adults\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Not all types of edema require treatment. Edema related to pregnancy or menstrual cycles is not usually treated. Peripheral edema and ascites are usually treated slowly to minimize the side effects of rapid fluid loss (such as low blood pressure).",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Reduce salt (sodium) in your diet",
"     </span>",
"     &nbsp;&mdash;&nbsp;Sodium, which is found in table salt and processed foods, can worsen edema. Reducing the amount of salt you consume can help to reduce edema, especially if you also take a diuretic. Guidelines on how to reduce sodium are available separately. (See",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/61/39890?source=see_link\">",
"      \"Patient information: Low sodium diet (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h2\">",
"      Diuretics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Diuretics are a type of medication that causes the kidneys to excrete more water and sodium, which can reduce edema. Diuretics must be used with care because removing too much fluid too quickly can lower the blood pressure, cause lightheadedness or fainting, and impair kidney function.",
"    </p>",
"    <p>",
"     You may have to empty your bladder more frequently after taking a diuretic. However, other side effects are uncommon when diuretics are taken at the recommended dose.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h3\">",
"      Compression stockings",
"     </span>",
"     &nbsp;&mdash;&nbsp;Leg edema can be prevented and treated with the use of compression stockings. Stockings are available in several heights, including knee-high, thigh-high, and pantyhose. Knee-high stockings are sufficient for most patients. Some stockings can cause skin irritation or pain, although proper measurement and fitting of the stockings can reduce the risk of discomfort. More detailed compression stocking tips are available in table 2 (",
"     <a class=\"graphic graphic_table graphicRef57705 \" href=\"mobipreview.htm?12/29/12764\">",
"      table 2",
"     </a>",
"     and",
"     <a class=\"graphic graphic_figure graphicRef52484 graphicRef53659 graphicRef80635 \" href=\"mobipreview.htm?15/26/15784\">",
"      figure 2A-C",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     Effective compression stockings apply the greatest amount of pressure at the ankle and gradually decrease the pressure up the leg. These stockings are available with varying degrees of compression.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Stockings with small amounts of compression can be purchased at pharmacies and surgical supply stores without a prescription.",
"      </li>",
"      <li>",
"       People with moderate to severe edema, those on their feet a lot, and those with ulcers usually require prescription stockings. A healthcare provider may take measurements for stockings or may write a prescription for stockings and then have a surgical supply or specialty store take the necessary measurements.",
"      </li>",
"      <li>",
"       The white \"antiembolism\" stockings commonly given in the hospital do not apply enough pressure at the ankle and are not adequate treatment for edema.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h2\">",
"      Body positioning",
"     </span>",
"     &nbsp;&mdash;&nbsp;Leg, ankle, and foot edema can be improved by elevating the legs above heart level for 30 minutes three or four times per day. Elevating the legs may be sufficient to reduce or eliminate edema for people with mild venous disease but does not usually suffice in more severe cases. In addition, it may not be practical for those who work to elevate their legs several times per day.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H18\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H181\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18218459\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/35/28212?source=see_link\">",
"      Patient information: Chronic kidney disease (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?20/42/21155?source=see_link\">",
"      Patient information: Swelling (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?27/53/28498?source=see_link\">",
"      Patient information: Preeclampsia (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?36/31/37363?source=see_link\">",
"      Patient information: Glomerular disease (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?17/26/17826?source=see_link\">",
"      Patient information: Growth hormone treatment (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/36/33346?source=see_link\">",
"      Patient information: Tricuspid regurgitation (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/52/14146?source=see_link\">",
"      Patient information: Tricuspid stenosis (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?13/40/13956?source=see_link\">",
"      Patient information: Diastolic heart failure (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?7/32/7684?source=see_link\">",
"      Patient information: Systolic heart failure (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18218501\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?43/3/44084?source=see_link\">",
"      Patient information: Cirrhosis (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/5/33877?source=see_link\">",
"      Patient information: Heart failure (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?13/12/13510?source=see_link\">",
"      Patient information: Premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?34/17/35091?source=see_link\">",
"      Patient information: Chronic venous disease (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?12/44/12998?source=see_link\">",
"      Patient information: Deep vein thrombosis (DVT) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?39/58/40867?source=see_link\">",
"      Patient information: Preeclampsia (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?13/5/13398?source=see_link\">",
"      Patient information: Chronic kidney disease (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?38/61/39890?source=see_link\">",
"      Patient information: Low sodium diet (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H20\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/36/34375?source=see_link\">",
"      Clinical manifestations and diagnosis of edema in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/31/20981?source=see_link\">",
"      Idiopathic edema",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/52/1866?source=see_link\">",
"      Clinical manifestations and diagnosis of lymphedema",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/1/33817?source=see_link\">",
"      Prevention and treatment of lymphedema",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/10/36008?source=see_link\">",
"      Pathophysiology and treatment of edema in patients with the nephrotic syndrome",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/13/39128?source=see_link\">",
"      Mechanism of action of diuretics",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/43/25271?source=see_link\">",
"      Neurogenic pulmonary edema",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/18/32041?source=see_link\">",
"      Overview of heavy proteinuria and the nephrotic syndrome",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/34/36393?source=see_link\">",
"      Pathophysiology and etiology of edema in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/40/650?source=see_link\">",
"      Treatment of refractory edema in adults",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/50/30503?source=see_link\">",
"      General principles of the treatment of edema in adults",
"     </a>",
"     <br/>",
"    </p>",
"    <p>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/edema.html\">",
"      www.nlm.nih.gov/medlineplus/edema.html",
"     </a>",
"     , available in Spanish)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Institute of Diabetes and Digestive and Kidney Diseases",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.niddk.nih.gov/\">",
"      www.niddk.nih.gov",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Kidney Foundation",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.kidney.org/\">",
"      www.kidney.org",
"     </a>",
"     )",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 20, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"mobipreview.htm?31/53/32594?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f31_53_32594=[""].join("\n");
var outline_f31_53_32594=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           EDEMA OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           EDEMA SYMPTOMS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           CONDITIONS ASSOCIATED WITH EDEMA",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H12\">",
"           DIAGNOSING THE CAUSE OF EDEMA",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H13\">",
"           EDEMA TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H18\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?3/48/3840\" title=\"figure 1\">",
"           Venous insufficiency PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?42/14/43232\" title=\"figure 2A\">",
"           Applying stockings A",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?25/48/26368\" title=\"figure 2B\">",
"           Heel pocket out method PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?11/25/11664\" title=\"figure 2C\">",
"           Stocking donner PI",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          PICTURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?15/43/16050\" title=\"picture 1\">",
"           Pitting edema PI",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          TABLES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/37/16987\" title=\"table 1\">",
"           Travel tips PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_table\" href=\"mobipreview.htm?12/29/12764\" title=\"table 2\">",
"           Tips for using compression stockings PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f31_53_32595="Gastric anatomy";
var content_f31_53_32595=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F68173&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F68173&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 549px\">",
"   <div class=\"ttl\">",
"    Gastric anatomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 529px; height: 508px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAH8AhEDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKzr3VIbS5MMpw20N+Bz/hUMmvWkUDTSPhFIBPpk1POtrmqo1GrpGvRXOax4z0XSNJuNRvLorbQANIVUkgEgdPxrln+NPhPYXinnkA9IyKaaexEoSi7SVj0yivGbv9oLw1Ck7Jb3cnlKWOFxkCu4h8aWtzdwwwDKyg7T68ZpSko7l06M6t+RXsddRXHXXiWXy38sYIBxXUabMbnTrWc9ZIlc/iAaUaim7Iqrhp0kpS6lmiiirMAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOK8aKF1aFgeWgA/Jj/jXN6pubQ9QA5IQOPwOa6zx1DiWxuAOPniJ+uCP5Gub2ebDcRdpImX9K4KitUZ9DhJXoRfb9GcRrNsdY8HatZjJa4s5UUf7RQ4/XFeCaHL51ip/vKG/MV9EeHHxtUnOOK+fVtP7K1rUtOxgWl1LAo/2Vchf/AB3FbYd6NHNm8LSUjKkQm8mh7SKV/MYr6B8AX5u9H8L3vVpY4Vb/AHsBW/XNeDalH5d/G44yea9T+Fl/t8M+QD8+m3zhR6IxEq/+hkfhVYhe7czyqX71w7o9mlXDuvoSK7vwrJ5nh+z5ztUof+Akj+lcPdY85iv3Www/Guk8B3BMN7asf9XIJF+jD/EH86xoO07HTj489Dm7WOqooortPCCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAxPGMHnaFKwGWhYSj8Dz+hNcVC22VG9CK9MuYluLeWF/uSKUP0IxXl4R4meGX/WxMY3+oOK5MQrSUj2ctnzQlB9P1OWgT7B4gu7Y5AWQlfoeR+hryL4rWX9nfEO6mAxHfQxXQ9M48tv1jz+Ne0+LYTHqFlfp0lXy3/3h/n9K81+Oliz6foOtJnEUj2cv0cbkP5oR/wACpUHaVjozKPtKCmec6wm6BZF7V03wtu9mu3Vof9Xf2u4f9dIj/VXP/fNc/GRc2RHtVLRNTfR9St7xAWaxmEzKOrJyHA+qFq6px5otHi4ar7KrGfY+rNJuPtej2sh++i+S/wBV/wDrVteGrn7JrsBY4ScGFvqeV/UY/GuT8KXMTTT2iOGS4UTwsDwTjt9Ritpiy4ZOJEIZfYg5FeenytSPo6tNSUqff9T1Siq2nXaX1jBdRfclUNj0PcfgeKs16Sdz5ZpxdmFFFFAgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK8/8V2rWmvPJtxDdKHU9t44YfyP416BWH4ytDdaDO0a5lgxMn4df0zWVaHNE68FV9lVXZ6HnutW5vNGuIlGZI/3yfUdf0zXJa7pw8T+BtU0pBuuZIfMtx/02T5k/wDHgB+NdzaSjKSDlT/KuYlT+yfEEsK8IT5kfup/zj8K4oytZn0LgqkZU2fOGg3CyQjHGRnB7VBfx/ZtQEoHytwR610HxB0xtA+IF8qoEtL1vtluR02ucsB9H3DHpiqGowie2yOuM16Kd1c+VnFwk4voei/DHVJ5dDEKP/pWjyKsTZyWhIzHn6AMn/Aa9kt7lL60hvIsBZlyR/dbuPzr5f8AAetjRdetbq4bbaNm1u89BE5GH/4CwU/TdX0JoEx07UpdPuDi3uTmM9lk7fn/AIVx1ocsvU+gwVb21FfzR/I77wXfmC6fT5D+6lzJF/st/EPx6/nXZ15XKrqQUYxyxtuVh1Vh0Neg+H9TXVdPWU4WZPklQfwt/getaYepdcrODMcPZ+1js9zTooorpPMCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigApGAZSCMg8GlooA8uurM6ZqNxYn7sZ3Rn1Q8j8un4VieLbZpbOG/jBMlqdr47oe/4H+deg+O7EGCHUo1/eQHZJjvGT/Q/wAzXMIUYMkoDxONrqehU9a8+pDkk0fTYWv7SEanVb/r955P8UdE/wCEh8HLe2y7tQ0rdcRgdXix+8T8gGHuoHevKNLuFuLbbnPFe+yBtG1aWzfmHd8m7kMh6fpXhvjPRD4Q8WvbW4I0y5Hn2Z7CMnlM+qnj6bfWt6E7+6zgzTD8rVaOzMSdBbXjLIMxSgqwPcHrXt3gDUh4h8IrbvKzanpW2CRmPzOoGY5PxUY+qtXkWpW63drvX7w5BqfwR4hm8O61BqC5McY8m8jH/LSAnnj1X7w+hHetasOeNjiweIdCqpdD6e0u+/tOwE7YFxGdkyj17H8a0tI1FtI1AXHJtpMLOo9OzfUVyayjTrmPUbNlmtZlBcIcrIh5yP5g10ZMckaSQuHhkG5GHcVw3ad1ufQ1IRkuX7L/AKt/keoI6uiujBlYAgg5BFOrjvCOriB1026bCE/6O56D/YP9Py9K7Gu+E1NXR81XoyozcWFFFFWYhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAyWNJonjlUPG4Ksp6EHtXmV5ZSaXfTWcgO1DmJj/FGTwf6fhXqFc94y0xruyW6t13XFtlto6un8Q/qPp71jXhzRut0d2Ar+yqcr2Z5z4n07+0dNE0Q/0q1BYAfxJ3H4VwPizRj4t8Jy2cAX+0rY/aLMtxlwOUz6MMj64PavUIJRhZEIKkZHoRXJ67p50fUEubXP2Oc7l/6Znutcak0+ZH0HIqsHRn12PnrR7nKmGQMrAlSrjBUjggjsQeKjv7d7a48+MfLnJrsvi34fNlex+JtOjxaXbhbxV6RzHgP7Buh/2v8AernoJEvLXnqRyK9CMlJXR8tWpSozcJdDufhD4lRNvhu/f/RZstp8jH7jdWgP6lfxHpXpenXh0a7a0uyfsMxyG6+W3r9PWvmKRHtLgxSM6oWDI6HDIwOQwPYg817p4I8R/wDCX6TJa6jsGs2ajzduAJ07SqPfoR2P1Fc9an9pHrZbi017GpselyoCCpIIPIIP5EGuz8Ma2L1BaXZxeIvDH/lqo7/X1FeXeHdRMTrpd82MHEEp/wDQT/StyRXBBjd4pkOVdTgqawpzcHdbHZisKqq5Jb9Geq0VgeFNcbVInguwqXsP3gOki/3gP5//AF63674yUldHzlWnKlJwlugoooqjMKKKKACioLm8trUZubiGEf8ATRwv86zpfEmlIxAuvMI/55ozD8wMVLkluzSNKc/hi2bFFYQ8VaXuIeSZR6mFsfoKePFGkE/8fTAYzkxOP6UvaQ7l/Vq38j+42qKoWur6ddYEF7AzHou8A/keav1SaexlKMou0lYKKKKZIUhYDGSBk4Ge9LXD6Qf+Ey8SjWmO7w/pUrx6an8NzcDKSXPuq/Miep3t/dNAGVrHxQNj8Rb/AMKrb6FbtaxwOLjVda+xmcyjO2NPJfcw9M+nrXQ23xF8LXM9nDBqm6W8vZtOgH2eUb7iLHmJ93jGRyeD2Jq5p3hSxsPGWr+JYZblr/U4YYJo3ZTGqxAhSoxkHnnJP4VzFn8IdDtNctdRh1DVwlrqU2qwWhkiMUc0ow+P3e8qcDgscY+tAGhpfxV8Gamsb2us7YpbWW9jluLWaBJIYyRIytIihtpByAc8GuasvjNpjeKdca+mW28JWOnWt5FeyWFzHM7TSBAdrLuKEsuCE75yRV22+CfhiHSdI017jVJ7XTbK7sIlkmTLx3LMzliqD5gWOCMY4yDTZvgroV1Yala6jqut3ovrG3055JZIVeOKBw8W3ZEo3AqvJBzjnNAHRX3xJ8KWN1e2txqjfa7S8SwlgjtZpJDO4JWNEVCZCQD9wGum068i1CyiuoEuEilGVW4geCQc45RwGX8QK88m+D2kzx6utzq+qXL6tcJc3j3MFlP5kioUBCvblVOCTlQDnoR0rtfCPh6z8KeG7DQ9MadrOyj8uIzyb3IyTyfx+g6CgDXooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAoJHGe9FFAHnXiLTW0rVGCLizuSXiPZW6sn9R/9as64t47+zls7g4ST7p/ut2Nel6rZR6hYTWsvAccN/dbsfwNebtHLBNJb3K7J4jtdf6j2PWuGtDkldbM9/BYj20LP4l/VzhjArR3ekatAJIJFMM0L9GU/wCcgj614fr+lXHhLxDLp8pd7Y/vLaVv+WsRPB/3h0Pvz3FfTHiHTW1CBLm2GbyAYK/89E/xFcL4k0a18U6FJZy4SdD5lvL3hk7H6HoR3H4UUqnI7PY3xuGWLp88fiX9f8MeSXdot9ZeamCRz9KzNJ1G90jU4Lmzm8i+tyTDIRkc9VYd1PQj+uKs6bc3OiapLZalCYpYm2TQtzjPcHuCOQe9X/EGkxywi7sjvhbkEdj6V27nzWsX2aPY9F1K18XaCuo2gEV0h2XEG7LQSDqPcdwe4NdT4e1VtQT7Jdn/AE+McE/8tFH9RXzJ4U1+98P6zHe2R/foNksLHC3EeeUPv3B7H2zXutre2muWEOs6HMSu7P8AdeNx1Vh2IPb+lcVWnyO62PpMDiliYezn8SO7VpYJ0uLZzHcRnKt/Q+or0XRtQTU9PjuFG1j8rp/dYdRXl2i6qmsQMGAS+iH71BxuH94VtaHqJ0vUFkY/6LLhZh6ejfh/KilPkfkzLG4Z1Y7e8v6/4Y9FopFIYAg5B5BFc54t1l7QLZWZIuZVy0gP+rX/ABNdkpKKuzw6VKVWahEl13xJFYSNbWqfaLsfeGcJH/vH19h+lcrdanqF2pFzeS4P8MR8sD245/MmqkUfRUBJP61kaz4m0zStyF/tdyOPKiPyg+7dPyzXDKrKfkj6ChhKdPSKu/6+41IreNWJSMbjznqTVkW8pGdhA9+K8v1Pxnqt5lYJRaRdkgG0/i3WufluJriTfNI8j/3nYk/rWV0egsNN7u34nt3lN6p/32KUQSEZC5Hsc14iMkZzQsjxtlGKn1BxRddh/VX/ADfh/wAE9qePH30x9RU1td3Nr/x7XEsXsrcfkeK8lsvEWsWoHk39xj0Zt4/I5resPHU67V1K1inXu6fI/wDhTTS2diJ4abWya/rueo2nifUICBcLHdJ3JGxvzHH6V0OmeILG/IjDmGc8eXLwT9D0NeX2HiLSNQZViuTbynolwNv69Kf4nv10bSXuZYTcSORFbwIQTcStwqL9T37AEngGtoVZrzPMr4Ki91yv+un+R2fjO6uNY1CHwjpMzxTXUfnalcxnDWtpnBAPaSQgovcAO38Iz1VjaW9hZwWllCkFrBGsUUUYwqIowFA7AAV5V4Be98L20j3brf3d64nvn6FpMAAIx52qAFVT2HqSa9R03ULbUYDJaSbgOGU8Mp9CK6oVYz2PJr4WpR1a0LdFFFaHMFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFc54u0g3cH220j3XkK8qOsqf3fr3H5d66OiplFSVmaUqsqU1OJ5VbzblWSMkfzFYPiTTXhkbVLBcrnNxEv8P+0Pb1r0fxRoPzSahYL85+aaFR9/1Ye/qO/168xDKCA6EMpH4EVwTg4OzPpMPiFUXtIfNfoeSeOfC0PivT1u9P2R6vbr+7J4Eq9TGx9O4PY/jXmfhvVjY3MlnqETrHuMcsUgw0bDqCPWvfNe0htJkN/p5JsWPzJ3hJ7fSvPvH/hiPxBCdT0pVTWI1G9BwLpR/CfRx2P4HtjWjV5XyyMMfgVWj7ajv1/rucP4o8P+WPttid8LcgjtUXgvxXceHdVa4jR5YZQFu7UHHmgdHX/bHb1HHoRY8L68Y/8AQL7P2dyVIdcFD0II7EVD4s8PNat9qtBlTyCveutpNWZ4MJypyUo7o9jgvYpVtNb0K4WSJh5iOvQjuCPzBFd/Z3UWpWMd7ABskHzr12N3Br5Z8F+KptBuXEgZ9PlbNzABkqf+eiD19R3HvXsGk61cacwu9LmSaznUPgfMkinoa4KkPZuz2PqMNWWNp3j8aPXtP12+sbUW8ZikjUYQyAkoPTryKzj5lxcvI7F5pDudj3/+tXL2/jfT3TN1Z3ET9/LYMP1xWD4m8Zve272mmRvbW78SMx+dx6cdBUOV1ZsqGFcZNxjZvdl/xd4uCCXTtIYY+7LcqeW9QvoPeuEJyKjjBZsmrMUZdgAOKhu56NOnGCshkcRIyeBTghz8vSrJiy4QVM8YjjJ9Kk3SKexqTYR1q9HFuhDGmpGGWkVZMjiUGnPECOlOMDL93NAd1+8KLkuHYrOhQEk4A5yag8L63fHVINW3eZZ225bCGX5kAYYeXHYt0BH8P+8asalbQ6laNbTO6RuRvCnBdc8qfY9D7GpTCqqFjACgYAHAAq07bbmFSnzu01p+v/APTNF8R2WrssTL9ku26Kxyjn2Pr7VtW089jdia2YxzLwcjhh6EdxXi6MUOK7nwv4mSQLZ6tKewiuG7eze3vTjK78zmr4XlTcdV2PZNB16HU8wyAQ3ijJjJzuHqp7j+VbNeWSRvHKrKxjljO5HU8g+oru/DmsDU7fZNhbyMfvFHRv8AaHt/Ku6lV5vdlufN4zBqn+8p/D+RsUUUVuecFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcd4n8PvHI9/pke4H5poF7+rL7+o712NFROCmrM2oV5UJc0TyyCZWXcu142GCCMgj0Nch4h8OS2spvNEjaW3IzLbA/NH7qO49q9c8R+HPtJe700Kl31eM8LL/g3v+frXII7LIyMrxTxnDIwwyn3rhnBw0lsfQ4bEqouem9eq/r8z568c+HRqLNq2kJ/po/4+IBx5wH8Q/wBsfqPfFZfhPxFGYls79g9q/Cse1fQWveHLXVt09vttNR6iRRhJT6MP614P458KzWtzdXtrbvHdRnN3aKOWPeRPf1A69evXajV5fdlsc2OwarJ1qK97qv1Rl+LvDrWcgu7L54W+ZWWqvhPxPLo8jQzlm092JdOpgY9XX/ZPcfiO9aPhnXo5LcWV6wkgf7jE5Aqj4p8OyafN9qtvngbkFeldMoqaszxqFedCaqQeqO6e885QyOGRhkMvQimKoY815/4b1gacywzt/oDNjn/l3J/9lJ/L6V6NDGDhgQR1BrzalN03Zn2WDxUcXDnW/VD40zgdq0Y4wi8VViH70e1XwPlNZHdaxFbDdKx/CpbpCYWwO1MsfvNn1rQ8sFcGgUnZlWxKyQYPbtTJInjYmLp6UksEkDFouV7iljvFPDjB96B67oZ9oIGHUg/SnLMjHBxUpeFx1GaiMSN2FAx7RxuOgqu8LpyvK+lL5bx8ofwNSxy5+Vhg0AVSA6nHWmocZU1bmgyNy9aqODn3FA15Ha+DvEK7E0zUXwucW8p/h/2T7eldfma3nWSFzFcRnKsOx/qK8ZI716J4N15tThTT7vm7iT91J/z0Udj71pGV9Op52Joct5x26/1+Z7BoGqpqtn5m3ZOnyyx/3T7exrTrzXTNQfSr5bpQWjxtmQfxL6/Udf8A9dejxSJNEkkTBkcBlYdCDXoUanOtdz5XGYb2M7rZj6KKK1OMKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKy9a0W11VMyDy7lRhJk+8v19R7GtSik0mrMqE5QfNF2Z5bPFJa3c1pcY86E4JAwGHYj2Nc/4005bzSnvY0/0y0XduHVo/wCIH1x1r0fx5ZKbeDUVGJIWEbn1Rjjn6HH5muYiRZWMUgykgKMPUEYrz5w5Jcp9JhsR7Smqq3R8ueMdDFrK+o6bH/o7EvPEg+4f76j+Y/H1qx4Y8QJLB/Z+olZYJBhWPP611F0hgmlhb70blT+BxXB+JdGaylkvbNSbRiWlRR/qT/eH+z6jt19a2oVvsyMMzy7evRXqv1E8S6G+nTNPbrut29sgirPg7XxYvHZXkh+xOQsMjH/Ut2Qn+6ex7dPSrXhvXEuITp+pYaNhhWNY3iDRn0y6ZlQPbSfiCK6JwU1ZnkYXEzw1RVIf8Oeoxf601oIMpXnPgzxAIJIdPv5P3TYS2mY/lGx9fQ9+nXr6VAhOK8ycHB2Z9rQxUMTTVSH/AAxThby5mDetaEcoPORST6eJsEHBpItL/vu2PrUam7lFrUSa4Q/xCoP3chwNpq62nxIv3QagazRvujafahjjJdCE2qntTGt3jG5CcDtU0ZeGURy8jsa01hDJ07Uhyk0Z9sBLGDRcQBl44Iq1a2jRM3cE8VZaDI6c07EOVnoZVq+5SjfeFQ3UOTuWrCQkXrgelTtEd1BV7O5lbOKdZXElpcRzQOUljbcrDsavSxAIfWs0IcsKBq0kz122uo9QsYLyLAWZcso/hbuPzrqvBOon59NmPMY3wH1Tuv4E/kfavKvAGoorTaZO2DKd8JPTcByPxFdhHLJa3MNxFkSwuHA9fUfiMiuinPlakeDi8NzKVJ/L9P8AI9RoqK2mjubeOaFt0cihlPqDUteifLtW0YUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVyvxT8QXnhb4ea7relwCe9s7YyRKy7gDkDcR3C53H2FdVTZEWRGSRQyMCGVhkEHsaAPND4luPCfheLVtU8WWeuS3dtBLFb32y3DO5AzCbeFnKnJAUxuSQPmHNc7bfHHUL5NPttL8GS3Ws3Wp3mlmxN/wCRtkt40fO6WJTgh+jqhXB4J4r1GLwZ4Xhsruyi8N6KlndsrXEC2MQjmKnKl124YgkkZ6VLY+FfD2nywSWGg6TbSQStPE0NnGhjkZQrOpA4YqACRyQAKAPG/E/xE1fXvE3huHTrabSdPtPGEej3TpfsJbl0X95G0SqAYsnqWOcD5fS1b/GabT/BFpqP2QapfOL2Z7W5u2+1GOCVl3AW9oU2YU/M4QDHLHk16zJ4T8Oyav8A2rJoGkvqfmLN9sazjM3mL919+N24djnIqO48GeF7mCCC48N6LLDAXMUb2MTLGXOXKgrgbjycde9AGda+NvtOjaRqkOga1cWWo2MV8s1rEkyx+Yu7yyofeWAx0XHIwTyA/wD4WH4bjOL+7udMPf8AtKynswOM/elRR+OcV09nbQWVpDa2cEVvbQoI4oYkCJGoGAqqOAAOMCpaAObvNY0bxFoV7FpGraff74WK/ZblJckDI+6T6VyFq2Whb1INdtrnhTw/rEUp1XQ9LvGKn5ri0jc59ckZryGz8I6UII3tDfWTYB/0O+mhH/fKtt/SuXEJXTPXy1ycJRRwfiqLyfEWpp6XEn/oRNZ0SBjhgCCOQaseMtGurXxPqEUGsXrYkyDcLHLnIB5O0E9fWs21i1RLlFlns5ocjcRE0bY/76IJ/KuSS13Po6U24q8Xt5f5nIeJvD76Kfttnn+zmbkd7cn/ANlJ/KtHR9Vi1C1FjqGD2Vj2r0AxRywPFIivG6lWVhkEdwa8s8U6I3h++WS23/2dIcISc+S39wn09Cfp6V10K1/dlueFmmW+zvWpL3eq7f8AA/Ira3pUmnzupG+3f9RXYeDPFc0gi03UG8yfb+4uD/y1A7H/AGgPz6+tZWk6jFqFt9kvgG4wGPUVhavYvp1xgFvK3BlZTgqQeCD2IrapTVRWZ5uDxc8LU5o7dV3PZU1Bhyc1J/aEhHyqfrXOeANZTXYzZXzp/aUS7gw4E6f3wOxHcduvQ12Z0vaPlNeZKEouzPtKNejWgpw2ZFbu8qckn1qeNDnBFV1je3fjrV62vUUYnjIP0qUayT3iBsll2lhyKuCEInNM+3JjEKMx9hUTRXlzkk+WOwxTMbSfxaFuBFcHHagw/NVPTZpLe88i47961rhGUF48ZxxTWpE04ysYN5EY7jfjFQmfGcAmtUXkMg23ShJB61WnntE5DKT7VJvFvZoypnkcHEZAquFCkg9a2Yp4pyVQVQ1CIKdw4NI0T15bWKILRyK8bFXU5VgcEGvUtMvBqel294Mb3G2QDs46/wCNeVsH644rs/h5eb4L2wbqMTp/Jv6VcH0ObGQvDn7Hq3ga6LWc9m5yYH3J/uNzj8Dn9K6avPfDt0LTW7dnOElzCx+vT9QPzr0KvRoS5oHx+Pp8lZtddQooorY4gooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigBHGVI9RivItNyLOIN1Awa9ePAzXkOnkG3Ujkdq5MV0PYyrafy/U85+IQx4vvyOh2H/yGtYlou6TJrZ+ILbvFuoHGMFR+SKKybLoTXJPdn0tD+HH0RpoUwBVXVLWO4gZJY1kiYFXRhkEHsaQSfvdtXsB4iD6VFze1tzyLXNGm8P3a7dzWErYt5s5wf+ebH1HY9x75rRsbiHU7U21zjzMfKTXpCafbanptxY3sYkglBVgf0I9COoNeSa7pd34b1b7NcMZARugnAwJlH8mHcfjXo0K3OrPc+SzTL/q8nUp/C/wKV3a3Gl3qskjxNG++KVOqMOhH+HevWfBfihtatCsrIuoQKPPiHGR2dfVT+nSuGgki1iz8uXAmUcGsSN7rR9TimtpDFcQNmN+xHdW9VPcVVakqi8zny/HPCT11i90fQzRC5thIOvtUMMyxjEq5x7VR8Aa7b69ojywjy5Y22TQMctE3p7j0PcVpkLHOwYZrzpJrc+vp1I1FeLuuhZt7+3ToB+ValrdxT88VnwJBPGQYxVDzP7PuwOfKY4+lCdiHTjO6W5oa5ZeYqzQjDpUNhqKyKI5/lYcc1oxyiWHjkVi3dsq3YDj923f0oemqCn7y5JdDTntoLheQprOfS7cdqmj0+UY8iZvxplxZ3y/8tM0n6FRdtFIhWCK3B2gCqE6+dMf7oq8bdlBMjEtVG0z50iN1qWbR6u5XmUDipfD10bDXrSZfulwjgd1bg/zpbuLBJrNJZXyOCDkGmnZ3Hy88Wu56zdRkrIgOGHQ+hHSvStLuxfafb3KjHmoGI9D3H4HNecCZbq3t7pMbZ41fj1xzXWeBpSbG5gPSKXK/Rhn+ea7aDtJxPlswhzUlPqjpaKKK7DxAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigBsnEbemDXkWkLi0gHsK9U1aQRaVeSMcBYXbP/AAE15lpi8wL7iuTE6tI9jLNITfp+p5j48w3inUf98f8AoIrJtRhata/L9p1u/lHIe4cj6bjUMY2R5rjk9T6mhG0Egi5mJrSj4SqVohxk96uMeAi/ebipNXqT6Z/Ee2areLtGg1rS/s9xlTkNHIv3o37MP8O9atpBsUKKfqSYVB7002tUYyjGo+WSumeCTw3uiapLa3ieXcwkbtv3XU9HX2P+I7VtNDFqtkXGPOA5969J8Y+E08S6QrQbYtUtgWt5T0b1Rv8AZP6HBrxq2uJ9OvHinjeGWJzHJG3VGHUGvTo1faLzPjcfg3hall8L2Lmg6ve+GtaW7tBukUbJYScCePPKn37g9j7E17lpd9a67Ywahp8m+3mGRngqe6kdiDwRXjV/bR6lbiWHHmDrR4K8Sy+FtWY3AZtPnIF1GBkrjpKo9R3Hce4FRXo86utzbLcc8PLkn8L/AAPeoQIUI71Qv4/PVjV62eG7t454JUkhlUOjqchlPIINSG2JUlCDXBY+njNJ8xjaZqLRN5UvVeOa2HaK5ixwc1h6xZnBkQYYdao215LEAQcipvbRnQ6Sqe/Hc6GOWezJBy0fr6Vdg1BJeCefSqOk3y3J2P196dqtmUxLDwR6VSel0YSinLlnozQuYBNHvjGCOtYF7bMreZHw4q/YaiWQKzYI6irkiJMDtYZodpBFypOzMBZFlG2QbXqndQAEkCtbUrEbM8A+orNVi0B3ckcZqTeLT1idl4OuDceHRGxy1tKUH+6eRXZ+DrjytYeEkhZ4jgerKcj9Ca828BzH7TfW/wDC8Qk/FT/gxrttLl8nV7CQcfvlX/vr5f61vTlZxZ4+OpXVSHf/AIf8z0qiiivSPlAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDD8a3Ag8N3XPzSbYx75YA/pmuEs3EKtK3SJGc/gK6X4kTAWthbA8vKZMeyjH/s1cR4hm+y+F9SlzgmIRD6sQP5VxVn+89D38vp/uP8T/4B5VuLyEscsTkmpX5VVHeq8HJ5q1GNzZ7CuNn08Ni3bjCj2qxYJ5l0WP8AD0qGEYWrWkDMjH1NCJlszYthmYLRq8LM8e0dDToBtuk9Ca17+3yUcDiqtoc3PyTRWtU2Q88cV518T/B/9ppJrOlIP7QiT9/Co/4+EH/s4HT1HHpXpMx2w47ms0SPb3W2QfK33TVRm4O6MatCOJg4zPnzRb8IVAbKNyp9avavZCdBcwcMOoFbnxS8LJpNyda0xNljO/8ApMY6RSE/fHorHgjsee5rB0m88yMxydehFelCamro+QxFCWHm4TNn4e+K59Mli0e6kAsZX227t/ywcn7h/wBknp6E46EY9csr2SKYJMCCeOa+ftVsxE7OozE/BFei+BPE76raHTtSl36jarujlbrPF0yf9ocA/ge9cuIpW9+J7mU41TX1ar8n+h6bdQCaPI7iuUu7c205UjKE8e1dVp8wktxzniq2pWizIRjntXLJXVz3KNR05crMCxk8i7Ujoa7CQ+bZgn0riSGim2N1U12FqxNiPpSiXiltI54xH7Y6IdrdRVjzriD7yZ9xTX41RD61ryRblBA46Ukhzna1zJe5nnXYEK56k1E8QSDFa5jABXHSs6Uht4HY4NAoyvsTeC32eIY0IP71HT/x0n+ldq0hiKSjrG6uPwINcZ4Pj3eJLdu0Ydz/AN8n/GuuvObObHXaa0jsceKSdW3kv1PWaKZA4lgjkHRlDD8RT69U+KegUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB5x45nM/iRYh923iUY9zyf0xXGfEOcReGra3H37ifcfooP9SK6PUp/tmt39xnKtKVU/7K8D9BXB/Ei58zULO0XG2CLcR6Mx5/kK82bu5M+swlPlVOHb+vzOUhGBVmPgCogMR5qeJckVgz3IrQtIcIau6GMkms+Q7IzWnoSkJnHWhbmdT4WanRwfQ10EDCeyBPUVzszbTzW1pT5tjz2q47nFVj7qZXnx5oB6Umo24ltcgfMOQfSm3J/fj61ckP+inIoC7VmjnJEj1CxeC4QOjgpIjDII7g14h4s0GfwlrSQqWewmy9rIe6jqhPqv6jB9a9qify7+VAOCc0/wATaBb+J/DsthcHY5+eGYDJikHRh/IjuCRV0KnI/IxzPBqvT03W3+R4xGy3lqO+RWZG1zp93FNaP5dzC2+Jj0z6H2IyD7GltDPpmpXGn3yhLiCQxyKDkAj09iMEexq9qUPmQ716jmvS0aPkPehLs0ev+CNcg1jTI54jsY/K8Z6xuOqn3B/xrqgrOvNeAeAtcGka8izkLaXjrFKf7knRH+h4U/h6V9BWR3QA+1edOnySt0PrcPiliaSqdevr/wAE57XbZUxMBg5wa19Obdp6/Sq+uoGtWH403SpcWCL7YrHZne7zpIqXAxfRMOu6ugjObc5HANYFyf8AT4BjJJre37LUg96cSa20So7AMxNZQIPmt2LHFOvLgu4ij+8aLsLbWyKOTikaxjb5l3wXzq1yf+nd/wCa11cozA4/2TXIeDZVTXURjtEyNH+JGR/KuwYYVgeuMVa+E4sVpV+49F8PuZNB05mOSbePP/fIrQrJ8JZ/4RvT884iArWr04/Cj4+srVJLzYUUUVRmFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABWd4gvjp2jXdyp+dEwn+8eB+pFaNcd8QrrKWdkvVmMz/QcD9SfyqKkuWLZvhaftasYnI2UYVFDHjqSfTvXlerXjajq1xdP/AMtHJA9B2H5Yr0vX7kWXh69mJAZ0MKZ7luP5ZrypBmQV5ktEfY4aN25E8mPLAq1EoCioJl5UVMx2wmsz0OhHIfMfaOma6fSYQkQrn9OgMky8fKvNdVDiOKqiY13pyopalKEI+tbGlvttc46iuX1WXfcIgP8AFXU2q7LNR7U4vUzrRtTSK7Ze5rSvDssx64qvaRHzS+OnNVtbvRsKqeBT2RjbnkkjBibffu3qa6S1TbAKw9Jty7h29c1uyMI4qmJvXd2oo8h+Lvh5pZZddso/3tsALoL/ABRf3vqv8s+lcnpdwLm32seRxXvWmQLci4M6h0kypVuhB7V4DrekSeEvFdxpzbjbf6y2cnO6Inj8Ryp+nvXdhql1ys+bznDKE/ax67+pQ1O3WKcqy5ikGGHtXu3wr17+2PDIiuJS9/ZN5E5bq3GUf/gS4/EGvH7+IXFtuXk4yKl8C66fD/iO2u3JFs/+jXY/6ZseH/4C2D9C1a1oc0ThwOI9jU12e57nrkg8pl9jUGkri0XNQarL5k4jXlicAVfiTyYAPQV5nU+zty00iCNfN1RR12itDWJhBDtB5A5qrpaMXkn9TxVXUm86UIT1NF7IXLzTS6IZpcJkdpn+8entUOtSYkVe9bEEXlxADsK5/UG8y/IP8JpPRGtN887j7GR4ryGVCQ6OpBH1r026XbcyADjOa8wQZZQOCTXqF3/x8v7Y/lWkNmceN+OPz/Q7jwoc+HrH/c/qa1ayfCf/ACLtj6bP6mtavTh8KPjK/wDFl6sKKKKoyCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigBCQASTgCvLNWv/AO09VuLtcmNjsiH+yOB+fJ/Gu38aXrWehSrEcS3BEKnPTPX9Aa8+WWKwtJruYfubaMvj1PYfnXLiJXaiexllK0XVfojjfiLqObq302M8W43Se7t/gK5WNfmX61Hd3Ul9qE1xMcySOXY+5qxEMstcMndn1VCnyRUSaQZkSp1i3gDtUJH74ewrVtI/lBIqUbTdlcltEEQFaMxK25PtVGEh7gIO1aF4uLYj2qkc0l7yucy2Xl8wnndXbwDNsn0riI1LSxqOSWrtoz5VqPYUQLxfRIrXt4tqpGcE9awQ8moXOekQP503VJWnuiCeBWhpUYSIcUr3Y4xVKHN1L9siwx+lVrqczuIYuSep9KZqNzsUIp+Y8AVpaLZKsPmSfeNUtdDB2gueRJbQi3tcdwK88+KugS614fm1S1j3XOl5mAA5aL/loPy+b/gNeh3smFKirunIiWpUqCGHIPetIPlkmuhyV4+0pSjLqfMOi3Qng2k54496q30KxXLbhmNxhh6g1p+JtGPhXxje6dGCtpuE1t/1ybOB/wABIZf+A1HqcYltt4HOM16Sd1dHyE4OEnF7o9I+F162q6btun33dgRbuT1YY+R/xXH4g12OpSbVEa/ebgV4z8M9Y/szxRbeY+2G8X7JKD0LcmM/nlf+B17JZoby/MjfcTpXnVockrLqfX5diXiKKnPeOhqQxCKxRPasRxnUQPTmt+f0HQCsGRCupKT3rJnXRd7s19v7uuVuedRl+tdeq/ufwrkrjH9oT5pSNMM9WTWSGW8t4x1eRVH4mvSbpsyzN6E1wfhyIy67ZKvaQOfoOT/Ku01Bj9muHXqQcVcdjmxjvUS8j0TwugTw5poHQ26N+Yz/AFrTqvpsH2bTrWDGPKiVPyAFWK9SKsrHxdR802/MKKKKZAUUUUAFFFFABRRRQAUUUUAFFFFABRRVa/vrawgM13MsSe/U+wHU0N23Gk5OyLNFcTfeLrmcFdOgECZ4klG5iP8Ad6D9axLm6u7vP2u6mmB6qWwv/fI4rnliIrbU9CnllWWs3Y9Fm1SwhfZNe2yN6NKoP86YNY0wkAahaZP/AE2X/GvNlhA+6g/AU7ymx9w/lWf1mXY6f7Lp9ZHqEF1bz/6ieKT/AHHDfyqavJmjXOSuD69DV+y1fUrIjyLtnQf8s5vnU/1H4GqjiV1RnPK39iX3npVfO/iceLNd+KPxC0rwzc64b60OlnT5YtUaCz0/dGGkaSIyAOGAPAR+Qemcn2LSvFkE8gh1CP7JIeFfdmNvx7fj+ddKCCAQeK6IzUldHnVaM6TtNWPIrb4g+KD8V38DS6fp5uUvBc/axDIEOmeWWLY3n97uwmfu5P3a81+H/wAR9W8JfC7QLGyGl2cEWk3moxT6lG7i/mW8lUWkO11xIRz/ABHkfLjmvpK28O6XbeJbzX4rXGr3cKW8tw0jsTGvIUKTtUZ54AyeTmqfiPxPFo/iDw1o6Qie91q5kiRN+3ZHHE0kknQ5xhRjvuqjI81i+I3jjU/EGuwaXpGjW1ppGk2+pT214kxuleW1aURAKcMwkAByF4B6k8Ytp8cNa1CJv7OHhmSUeGYdUJnufs8SXjTpE8TSPIFUAMcISCTgbhmvoaigDifhJ4um8ZeHLm/uZEkkhu5LYvHZi3jO0LnaRPMsgyT86vg+nHPbUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVheMNVOm6WVi5ubjMcf+zxy34D9cUpSUVdl06bqSUI7s5DxLqf9q6yzRtm1t8xxejH+Jv6fQVw3xI1D7PY22mx/fl/fy/Too/ma6i3SKCB5pztt4ELufYdq8n1rUJNW1We8m6yNwv8AdHYflXmzk3dvqfXYWik1GO0f6/4JTtkzya0LZdzk9hxVaLGOOtXkPlxgD7xrBnsQVkS20XmTEjpWq2IYsmo9Ng2oCRzTbnM9wIk6Z5p7Gb96Vuha0eIsWkI+8an1iUJAR7VZgQW8IHoKxb8ve3ixJ0HWm9EZx9+d+iDQ7Yy3Cuegrpb0iO1YnsKi021W2hVe4FVNcn3R+Uh5PFNKyM5y9rU8jGt0NzcYUZJNbwi8iLB4IFLodiIo92PmNO1J/vA0krK5U6nPPlWxnWsJuL/cwyo6V0UjeWiotZ2jJkF6uSt8+fSqWiMaz5pW7FG+Y+YorXhO22Ue1c/czF9QjjXp1Nbiv8gFCYqsbRSPL/jlpXnafZ6xEv7yxbZLjvE5AJ/Btp+ma89sn861Kk5IFe7+KbeK80+a1uF3RToY3X1BGDXz7YRy2F5LZXBzLBI0Ln1KnGfxGD+NduGndOPY+fzbD8jjWWz/ADRRkiYTSxKxRjyjD+Fhyp/AgGvo7wHdx6r4YstSQAGeP94o/hkHDr+DAivnzWk8uRZFr1H4Ian/AKFqumM3CSLdxg9g4wwH/Alz/wACp4iN483Yyyus4VHT6S/Q9Kk+9j3rJv123cZ98VeEm65A9Ko6u2Jov96uFn1FJWlY2YBmDn0rj7sY1Of0zXYwcWwPtXAatpFteavcTStdq5wCYbyWIfkjAUO3UeHck5cp1ngyMtq0kgHEcLk/y/rXVtGZWt4VGTLNHH+bAVxHhLwjYSWF3cPPrCkuI1Kavdp7npKM9R1rotJ8I282t6fD/aWugNIWJGpzggKpPHzeoFaQitEefi6sueUmtvPsr9j2iiuU/wCELiU/ude8Sxg9R/acj/8AoeTSnwa3VPEviVWHQ/bQcH6FSD+Ir0j5M6qsOLxf4am1g6TD4h0eTVBIYTZrexGYOOCuzduyMHjGa17SE29rDC00s7RoqGWXG9yBjc2ABk9TgAV86xfD7xgvi27mTSroxf8ACZya5bG4ntDYCEnHnMFb7R5uOij5emRnNAH0fWUfEOljxSPDhuv+JybP7eLfy2/1G/Zv3Y2/e4xnPtXjtr4d+KK66kkd3fxXy3F81zf3GoiTT54WQ/Z1jtt52FTj/lmuMHls1g2HgTxh9pvdU1d9a0e5TwjLaXGr3OriWRb5ZxLuRkmZkiIXoNoA3DAycgH0rRXmHwAudd1vwjJ4n8T3VxJday6yQ27SMYoIY1CKUQ8KXIZyR13DNen0AFFFFABRRRQAUUVzPizXGtVNlZPi6cfO4/5Zqf6mpnJQV2a0aUq01CJLr/iOOwY21oBPd9Dz8sf+97+38q4uZ5ry5M91I00543HsPQDsPpSW8JYhUGTXLeJfGMdkGtdFcPMPlkuMcL7Lnr9a4KlRz1ex9HhcGqfu01d9/wCtjf1TU9P0dc6jPtkIysKDc7f4fjXKX3j9w2NOsYkH96clz+QwB+tcRPM88rySuzyMcszHJJpgXNYufY9ingoL49X+B0Fx4w1yZift7oOyxqqgfkKpyeIdYd9zaneZ9pmH6A1mbaMVPM+50KhBbRX3G3B4s1yE8ahI4xjEgDj9Qa6DTPHaNsj1WzA9Zrc4/wDHT/Q1w22mkUKbInhacltb00PaLO5tNRgMtjcR3MX8W3qv1XqK19I1u70to4wfOshwYm6qP9k/06V4LaXM9ncJPayvFMpyGQ4Neo+FfEEWvRpbylYtUA5Tos2O6+/tWsJ6+7ozzMVg+WPvax/L+u57Jp1/bajB5tpKsi9x3U+hHavLNGz4k+Og1liWtNPs7u2s88gCOSOJnHu0jXK57iFazvE+q3ehabLeaS5j1WUra2v+1LIQqgjuATk+gBPat34Sm0Gv6rb26+V/ZdhY6UkbPlj5aySu/uWM6knr0JrupVeffc+axWEdF3jqj1GiiitjiCiiigAooooAKKKKACiiigAooooAKKKbI6xRtJIwVFGWY9AKAI7y5is7WW4uHCRRqWZj2FeYaheyaxqb3bhgrfLCjfwJ2H1PU1d8S6wdZuxFCWGnxHKjp5rf3iPT0rn/ABBq8Ogae0hIN9KpEEfdf9o+1cVapzuy2R7+BwjpLma95/h/XU574h655SHRrNgUXBuHH8Tf3foOK4JMk0SO0rlmJJJySamgTmuSUrn0dGiqceVFq3XAya0dPhM8oZhwKpwoZGCKK6SxtxFGABzUrU3nLliJO/koEjGZG6Crem2QjTzJB855NSRQorea4AOOtMluHmPlwD5emas5HJtWRDqU7MfKg5buRU2m2Xlje/Lnqau2GnbBuYc1bnTy1+UfNTS6mcqqS5IlK7nFvESTzWZZQvdXHmSDjtV5rd5n/ejjNX41SFAFHNFrhzqCstxzEQxYXjisHUZwXC55Y1a1S8EfGcsewrPs7Z5ZPNlHJ/Sk2XRhyrnkbGmt5Vt05pl1NsUnPJpS4ijOTgCsa7uDM5WPLMegFDdkKEOeVyWwBlu3c+uK3FbFZ+nw+TEoPXFS3E4Rcd6FoFT35WRT1CT7RdKi/dWvIfidp40zxpHcRDEV/Csp9PMT5W/TYa9aDhWLtgVxXxjsGl8O2Gpgc2t0oJ9EkBU/+PbK1w8rT9TjzWlz4ZrtqcPrUAk09HUdRUnw21E6d4r05y2En32cn0Ybl/8AHkA/Gp4AbjQ2HXbXLJKbQvOpw9vIk6/VGDf0r0Jrmi0fKUKns6kZ9mfSWnzGW4c4+UHim3RE2oRKexzRpYCWwcHIYZB9ais8y6kzdhXkn3dldtdDoJDst8e1cjLzPK3941uatc+XDtB5PFZNpA11dwwJktIwX86b10FQXLFyZ3WjwfZdDso/4nHmt+PI/Suj8HxCXXXkPPkQH8CxA/kDWTNjzSF+6gCj6Cun8CQEafcXR/5eJTt/3V4/nmumkrzXkeDjKlqMpPd/r/wDpqKKK7j54KKKKACiiigAooooAKKKKACiiigCjrV+mm6dLctywGEX+8x6CvNUEk0rPIxkmkbczHqSa3PGeoG51QWUZzFbDL+7kf0H865bxBqg0XRZblSBcyfu4M889z+Arhrz5pW6I+hy/DuFNO3vS/pf5lHxl4gg0qxmsbSQSX8qlHKn/VA9efWvLM5PNSSyvNKzyMWdjkknkmporcsM4rklK59JQoKjG3V7kCpmp0i4qUxbe1PQZrO52KKRAY6VYs1a8rJqRIaAbRTMRqN4iK1BFSNCCOlK4roxWGOtPgmkt545oHZJY2DKynBBHQ1aubcjkCs26mS1t5Zpm2xRKXY+gAyTVp32InZJt7HpFpqQ8X+IdOu9oEWl2/m3AH3TeSBkGB/sxhm/7arU/gkM9tfanC5SW51K4lSRTzhHMSn8VjU/jS+GrL/hFPh+kl8u288qTU70Hqsjru2H/dRUT/gNW/B1o9l4T0e2l5mS0j804xlyoLH8SSa6p6Hy9Ozd1s7/AHdPwPRdL8VwNEqamrxTAYMiqWRvfjkfStGTxJpKLua8XHsjH+lcSlpI0RlYLHEOryMFX8zVdvsnIOoWWR282r+sSitTmlgKEpXTfyO/g8R6RP8Acv4V/wB/Kf8AoWK0oZ4phmGWOQeqMDXmaae0y7rZ4bhf+mUgaqj2ht5t2xoZR0IypFWsS92jN5bTlpCf9fget0V53YeItUs2HmSC7iH8EvDfg3X8811ejeIrLU2ESkwXP/PGXAJ+h71tCtGZxVsFVo6tXXkbNFFFanIFFFFABRRVLU9TtdMh8y7lC5+6o5Zj6AUm0tWOMXJ2irstyOscbPIwVFGSScACuA8Q66+rEwW26OxB5zwZfc+g9qh1fWbvVnZWJhs88Qjq3ux7/TpWPqupW2iWZuLoqZiP3MOeXPr9PeuSrW5tI7Ht4TA+zalNXl0QzVdRttCtBcXY3SN/qoAcFz6n0FeT6tqE+qX8t1ctukkOT6AdgPapdX1O61W8ae7lLueB6AegHYVUVK5JSvsfRYehyavcbHHk81chjLHCimwRF2AArc0+zHHHNRudTagtR2mWm0Akc1tjbEm5u1JbwBFFRyA3NysK/d/iqkrHNKXO9RIlm1CQBQREP1rorLTIraMNJjNTWsMdrbAkAYHFY+rat5YI3c9hWllHVnK5TrPlhojWluUUERj8aoSTqW+ZxXLS6ncynhyF9qiVrqU4Usc96hzubxwfLuzp3u4l/iFUrjUC52W6lm/lVO002aTBldvpWzbWCQLnbijVg1Tp+ZSttPJPm3B3Of0qa5nhtIizkDHQetRX98Y3MUPLetU0tHny8/J96XoUk5e9N6EE1zNecL8iHsOtWrG0EXOOe5qeKBY1z0AqGW6dpPKth83c+lBfNf3Y7Fq4uEt0+YjPpWb5k1zJ+7jPPc1etrAOd87F396040hgXIAyKdrmfPGG2rKFnpJLB7ls+3asT4sLHL4B1e3XGUiWUe2x1f8A9lre1DVFjXapyx6AVyXigy3Xh3WUl6vZTAD/AIAcVUWoyVjKrSlWpyc+zPOfDTGfTZk9VzXN3EQNzNF/fVl/MYrf8Dvvib3Q1h3nGruP9qvVPhz3fwpc/afB2kXJPMlnEzfXYM/rV7Rjl3f15rn/AAW23wBpKg9Iin5MRXQWY+z2pY9cV5MtJM+8oPmoJ90iHVZPMnCg1reDbbzNSe5YEx26Fs9tx4A/n+Vc+WLysxrufDluLbRYiBiS4JkY+3QClDe5WKlyUuVddC/KxWMlQWc8KB1JPAFelabarZWFvbKBiJAvHcgcmuI8OW4u9cgVhlIB57fUcL+vP4V6BXdh46OR8rmVS7VNeoUUUV0nlhRRRQAUUUUAFFFFABRRRQAU2V1iieRzhVBYn2FOrH8XXRtdAuip+eQCJf8AgRwf0zSk7K5dOHPNRXU89hdrh5LiT/WTuZG+pOa4T4nXgk1iGzQ5S1iAP+83J/TFeh2SDzY1PTNeNa7cteaxeTv1eVjj0GeB+VeVJ+6faYSF6t+yKSDJ4rU05sNtYcVUtY9xFaiQbQCOtZHrabMku7UhdwHBqrFHg1r2biVDHJ1qpNF5UxHaixMZv4WMjjyasJD6CnQjOKvQpg1LMpTsUzAcZxUbREVteVkVVuECg1DdiI1bmTOihfmrAv7UXeraZYqAyyzC4nX0hjIJz9WKL9Ca6FUa4mJ/hHb1qp4MdJ9Q1HUphlJ3+z25P/PKMkZH1cufptohLlfMRXk2uTv+XX/L5nqni/Sf7c02+tFkYW2oRMnmoN2UYYI/IkVbupoNFthPeKHuWH7m3/q3tXJ2+rXlipjs7p44z2zkCqU9w88rSzyNLK3VmOSa0nilb3VqefHByvaT0/Fj9TvrrU7ky3UhY54XPyr7AVXRCKd8ze1OCnHWvPlNt3Z2JKKsgG5TkcGtSy12+tQEExkiH/LOUbh+tZbA44NRMWB5FEJOLvF2JlCM1aSudjb6rYXvEqmzm9R8yH+oqa7syoUSqCp5Vgcg+4NcZC/PFbml6nLaqUwssJ6xv0P09DXTDF20qfec06LhrD7jstG8UTWZWDVN01v0E45df94dx79frXawzRzxrJC6yRsMqynIIryK11Oxv5Whik8i6U4NvMcE/wC63Q/zq3Abqyc+Q89uT1CMVB/DpXrU67S11R5mIy+NR3j7r7Hq2azL3XdNsmKTXaGQfwJ87fkOn41wMk17d5EtzdyqeNvmMQfw6UxrQW0e6VUgQfxSEKP1q3iG/hRhDLYp/vJfcbuqeK7m4Bj02I28Z6yyYL/gOg/WsIRyTytJIzyyn7zu2T+ZrD1PxRpdguIXN7N/diOFH1b/AAzXHaz4k1DVA0RYQWxP+pi4B+p6muadRv4mevhsDyq1ONl3f9XOx1rxVYaXGyWbLeXvQbf9Wh9Se/4fpXm97d3F9cyXF3I0kznLM1CwM3tU6Wyj7xrJybPUpYeFLbVlJELH5RVyGzZiN3AqzGEThVzVu2gmmPyqQKRq3yiQxpEAFGW9K29LtpMF5RjPQU/T9NWIh5OWrTC5+UdKpI5KlW+iKdxv2bYhlulX9HshbRGSXljyTUsNuoG4iq+pXyxRlEOTVJW1Zg5Oa5IkWsaiApCn6CufS2kuZPMkHB6Vdhha4cSSfd96nnmjt1xxUvXc6YWprljuMgsEQAkCrcaRJ1xWLPqpHCVX+23Dn5Rj60rpFexnLdnUfaY4x1AFUr7U96+VByx9Kx1WafHmTYHoBWhbi3t8MTk+pp3bJ9lGGr1ZNY2IQb5eXNW5SkSFmOBVOTVI1yEBY+1QwpNqEoDZWP09aPQlxk3zT0QyWSW9k2QAiP1q/bWa2kWW4PfNaUVvFaRZwOBXM6xqL3Exig4UdTQ1bcIN1Xyw0RNd6tFC+1eT6CoI57u+OF+VT6U3TdKadwWGc9yK6mG0hs4OcZoSbLqTp0tI6sxodOWAbpPmf1NYmtDzbHUh2+zyD/x01uajehiVU1jaguzQdWnf7qWsrE/RDQt9BNv2cpS7Hj/gInycj+5/Ssq7IOsyf71a3ghDFbMT2SsaXLa0+P71eufAnr3gFi/g3Soz2Mp/8ivXR3cmIwgrm/AXy+EdGP8AegMn/fTFv61uudzZNeTU+Jn32DjahTv2X5Eum2b3t5DbR/ekbBPoO5/KvQ32g4TiNAFX6CsDwha+VDNfN958xR/1P9K6KztWv76Cyj/5aHLkfwoOp/pVRWll1OTF1U5u+0f6Z13g2yNtphnk/wBbdN5n0X+Eflz+Nb9IihFVVACgYAHalr0ox5VY+Qq1HUm5vqFFFFUZhRRRQAUUUUAFFFFABRRRQAVyvj+TNrZQf35TJ/3yP/shXVVwvjp9+tWkefuQFsfVv/sayru0GdmAjzV4+RjJJHbo1xPII4Yhvd26ACvFr2Zbm/uJ1G1ZJGcD0BOa9F+Ic/k+G4YR96efJ/3VH+JFeaRrlq82b6H2OCho6nfT7jW0+AOMq3PpWgFK8OMVUs4WVAy1qQSLKPLlGD2NQdcmU2zG4ZatzqJbcSDrimTRGNtrcg9Kdan70Z6EcUCbvqQ2xywFa9soNYmDHIatx3RVetKxFSLextsVVKyb+QBDz1qJ704+Y8UaNaXuvag0dhbSTiPrgcD6k8Cs5Qbehjy+zTlJ6GRq96bTSGhtG2X12y21uSPuu5xu/wCAjLfRa7Cx0WxXTLW1tBsjt4liT2CjArOGgXN34puWubUm10SMROVYMBcyqGOcHqsZX/v7VxBJZSZTPl56VFROCUZI54zVaTnB7aCSaS8bcPke9C2Uo6EVrpJ5qA9eKiE0eSCcEVzMtTkURZP3NKbYitFcMMqaa8bdqhoXOzNeBh0qLYT94Vokuv31/EU0lT1pp2KuymkPPSrcUZFOGwd6lRl7VE3ciTZheJdN82L7TEP3i/ex3FYkGu6tbIEh1C6VRwB5hIH513h2spBGQeK4rW7P7JdHj923INdWErfYbOihJTXJJXIZfEWtyDDandgf7MhX+VZs8lxcPvnlklb1dix/Wp8rT0C12cze50qnGPwqxVWJvSpkiYdqtIVqVWWgepXWNz0FWIrWRyM8CrURz91M1cihlbGcKKaRnKdhLLToxgsMmtiGFIwAAKgtoVj5kkzVvzUHCIzH6Va0OSpJyZIAT0p5dIhliKqSNdN9yMKPeqzWc0pzO5PsKLkKCe7JbzVc/u4up44qtDbGR/MmJI9KtRW0cQ4UZqtqV2IEwBljwBSfmaxt8MBL69WBAkY56ACqUVhcXjbpWIU9hVnTrPeTPcH5jzj0q3PqMdsNqcn2o33L5nH3aa1GwaHEoGRzVhNKgBxxWadQu5T+7XApy/b35DYouuxLjU+1I020uJVyMVRuLNApLdBVi3W4IAlY0mofJCQabIi5KVr3MVIg10sa9G7V1lhbLbQbj1rA0CHz7ppSOAeK3tTuBHGQOgFEe4YiTlJU0Y+u35P7qM/M3AqLRdIadtzjjqSaq6ZE17qRkYZUHArtXZbS2CrgHFEVzasdWfsYqnDdlVmis02oBkVganfvISM1JqV0F3EmsB5GmfameeppSl0Kw9D7TJRmaVVXk561D8RJxp3w91ds4MsPkD3MhCf+zVs6XaeWu4ivPvjbqiyLpeiwtl3l+1SgdlUYUH6sc/8AAaujG8kYZlXUKMrdjl9Fxb6PLMR24rlTKd15c/3I2YfXHFdRqzCy0BIujMM1k+FbP+0dT06zxn7TdoHH+wh3v/46p/OvTbsrnxcIuclFdT2bTLMafpOn2eMG3t44T/wFQP6Vp6baPfX0NtHwXbBPoO5/Korg5kP1rq/DGnG0tDdyjE042xj0TufxryUuZ3Pvak1RpJLfZGuViiRY4QFghXao9vWuq8DWO20fUZV/eXPCZ7Rg8fmefyrmbSxk1S9isYQQjfNM4/gTv+J6CvS4o1iiSONQqIAqgdgK7KELvmZ8zmNblgqSer3/AK8x9FFFdZ4wUUUUAFFFFABRRRQAUUUUAFFFFABXnfiyTf4pnHaOJE/mf616JXmmuMJPEepP38xV/JQK58S/dPSyxfvW/L/I4X4muTFpkfbEjfqB/SuLs490grtfiXC5h0ydRlAHjJ9DkGuU0yMlhxXnz3Pr8K17FfP8zZgjCxilZOcjqKmVSFHBoxSLTJEK3MW1uHHSqfMU2D1BqfmNw6/jUeqsqosi9SKAWjsVr6QKxapdJ0nVNWBeztj5IODNIdiD8T1/Cuo0DSLT+xrW5vbVZbqbL4lydq5446dOfxramuMKokYBRwqAYA9gBVqC6nLPFte7TXzZzUXgpcKb/Vlz/FHbRF//AB4kD9K6VJE0/ThZ6VAYbdATtBG+VvVm9TU8dpeSRh00+8KEZB8o8/1qqsiOzKCQ68MrDBB9xV6x2VjjlUdZ+/K9vT9P1KXw+gudIsrWG8Ia7u5TNfKDlWllbLj3AztHsop+p2sa3d1Ao+VJGUfQGtGyjDXtv/10X+dU70/8Ta9B6+c386wxLvBN9yacVCfu9jJ0slGaCTqvT3FW7q0DDeg57imXVuQwlj++PSrNpcq6gPww6150jpk38UTKAaJsrn6VbhnVxg8Grs9mkvzIcE1UNhJntUbD54yWpMACOMGmNHEThhioLlZbC1mudjyiJS5ROpA64rkpviLaYIj06Z/96QL/AENd2DyvF49N4aHNbzX6s83GZphcC0q87X9f0R2f2ND92nLaY6GvPH+IcwOYNPRP96Ut/QV3mjXd5PpsE19Ekc0i7yi5woPQc98Yqsfk2LwEFPEx5b6LVN/g2Rgs4w2Pm4YaXNbV6NfmWhbH1qjrGmC7tWU/eHIOK0xOf7tI0hPavJT5XdHpRlKLujzo2Qjcq45BqVYE/u1teI7ZkYTxLwfvVz/mSHvXrU5qceZHqwk6kblpIoh/CKnTyV7CqCB2PJNaFpasx5UmtEKaS3ZKJCeIY8mtOysZ5sFztFS2VqI13NippdTit1wSKtLucc5t6QRcg0+CMZc7j71MzwRLhVAFcvda87ttgH41nzajdvwZOvtT50tiVhKktZM7FryIelRNcLIDtxXLWkd5cyD5zt966K2tWgj+bk0JtinRjT66jJW2qSaxox9rvS7fdXpV7VJv+WUXLtxSw262luCfvmk9TWHuxv1ZHdymJMLmobKy8xvMm781YjiMr726UXt0ttGQnLdhSGm/hjuWWaCBcnAHvT7XUkdtkUYPvWJBC93KDKxYnt6V0VhZxwr0Aqk2Z1Ywgve1ZY3kjJArA1mbcdi9ScVq39yIlIU1h2sTX15nBKL3ok+gUI2997GvoEYhhJqlrl1hHUdScVqTstpbBV61yt7KZ7tR1yaUnZWKox9pNzZv+GrXy0EjVc1S63OR2FS6cBHZDjnFYerTbSxzTeiMor2tVtmPqExnuNgPAPNaek2Bf5iMKKzdKhNzc5Pc11UxW2thGn41MVfU668+RKESjf3S20RCkDA6k9K8HSRvFHi661DcXhd9sRI6RL0/Plv+BV1HxW8QOEGi2T/v7lczsDykXTH1bp9Aay7GFPD3h0TkBbiVflHtXdhofbZ8znGJTaw8emr9TnfF915lyYE5CnFdJ8LbADVprt+lnb+Wo/25Dk/kq/8Aj1cC0hub5pZWwi5dz6Ac1758JvCcp8NQ3d6TbLdsbmQkfMS33VA9lCj6g1ddtQsupy5VTjKupz2jr/kb2g6a2o3gLjFvGQ0rH09Pqa7G6nIG5ULMSEjjUck9ABTbeKG3t1t7VPLgU55OSx9Sa3fBmmNd3p1O4X/R4iVtwf4m7t+HQf8A1q5IQ5nyo9rF4lJOpLZbL+u5v+FdLfTdOzc7TeTHfKR29F/D/GtqiivRilFWR8tUqOpJzluwooopkBRRRQAUUUUAFFFFABRRRQAUUUUAFeZaqMa3qX/Xc/yFem15lqg/4nWo/wDXdq5sT8KPUyv45en6nC/Ea/cTWunJgRogmb3Y5/kP51zumSshBwDWp8Ryf+EjGRj9wn8qy9LGTXBP4j67DpKjE3UvgAA6cVMskE3CnDelVQnHSmNCD04PtSux8sX5FuWIopPUVf8ABIZpr+4Cg+UFRHIzgk84/AVitcvDGyyfMvrXZ6FBDbaFai3OROPPdvViOn4YxVw3uc2JbjDlfUnnkZQXbc7k4A6lj2Art/C+gLp8S3N6qyag4yWIyIh/dX+p71heDrMXutyTyDMNkAVHYyNnB/AfzFd+eRXZh6f22fOZjiWn7GPz/wAgrL1/SY9Ts2AVBdICYpCOVPpn0PetSiulpNWZ5UJyhJSjujymIurEOpSVGwynqrDqKreI0aLUVvFH7q6UOD/tdGH5103jSx+y6il6i4huflc9hIBx+Y/lWT5A1OwksWOJVzLCf9oDlfxryq9JtOHXofTUaylGNZbdf68mZUEyuAD0qSS2jk+ZOG9RWKhdGwDgjsauw3Mq9sj2rzN9ztlTa1iywBNEcA5qQTsOqmovtTY5Q0onz/BWUkTZvdD2uD6GvHfG2kf2Vq7NEm21uMvHgcKe6/h/IivYASf4ayvFekLrOjywAATr88JPZh2/HpXt8PZn/Z2LUpP3JaP9H8vyueHn2WLH4Vxivfjqv8vn+djxOur0PxzqmnbY7ki9tx/DKfnA9m6/nmt/TvBVk+hQrfrJHfsN7SK3Kk9Fx044/Wua1fwfqNjue3X7XAO8Y+bHuv8Ahmvu5ZtlGaSlha7Ts2lzaX84vz9Uz4hZTmuWxWJop6pN21t5Nf8AAaPSNC8WaTrBWNJPIuW/5YzcEn2PQ/zrfwh6Yryb4baQ9zqcl7Ih2W3yrkfxn/AfzFeqR2zEfM2K/PuIMFhsFi3QwzbSSvfo30+6x9xkeLr4zCKtibJt6W6pdfvG3MEc0TIwBBFcZe2RtrhkI4HSu88sKMVl61ZieAso+dR+deVhqvJKz2Z71CtyO3Q5SBMNWrBJHEuWNc1f69pmm3cdtfX9vbTSchZXC8ep9B9a6rSNPjuYlmd1eNxlSpyCPrXrqLOmrUhrd7EEtzPd5S2RtvrUSaFcysGk6d811cKW9suFAwKJNQjAx8oquVdTmWJktKcTno/Dp7scVcg8PxJgt2rSW9Ev3CDj0pkk5wSzYFNJEutWejYi28VvwgFZ+pXuwbE+aQ9AKZNdTXLGO147Fqu6dpKxHzZyXkPUmlvsNJQ96b1KWnae+DPP99vXtUz23z5Y5rVlIHC8AVmX1ysSHByaGrCjOU2Ub+4W3jOKyI4nmkEsn3m6CtFLR7s+ZNwg5AqSCHdc4X7oqbXOuMlBWW5d0u0EabnqS+uliQgHGKnkYRQdaxpIjeOQchc1T02OaK55c0tioEm1G4AXIiz19a6CJIrGAKoGcU6CGO1gGAM4rH1O7xu5pbFtus+VbEGsX2QQDzVTQ7Nrq6EjD5QarRQyX0+B9zPWuqsY0soABgECpWruzoqSVKHLHcuXciwW+wGuO1WYzS+Wnc81oazfk5APNUtKtDPN5j5IBzmiTu7E0Kfs488jU0a3FtCHcc44rB+IXimDw9pRc7ZL6bK28GeXPqfRR3P9SKi8d+OdP8NR/Z0xdamR8lqjdP8Aac/wj9T2FeWaVpl94o1SXV9fuDtP3nIwAo6Ig7D/APWea6aNFy1ex4+PzFUrqGs/yJ/B+iy6jcT6xq0haPeZJZX48xvb27Y7CszxrrIvrxxFxEvyoo9K1PGPiaKKBLDTVEdrEu0Ad/euGso57u7jKxmSWV9kUf8Afb/AdSfSu7ZHzWs33bO2+FfhT/hJvEcNrcoxsLfbc3zdtgPyx/VyMY9Aa+m2YyMAAFRRhVHQDsK5T4Y+Fj4U8K+TcZOoXsgnnYjBPHGR29h2GK6uGKa5uY7OyTfcy9PRB3Y+wriqzc3ZH0GEoKhBuW5b0rT5NWvxaxZECYa4kHZf7o9zXpEUaRRpHEoREG1VAwAPSqWh6ZHpOnR20bb2HzSSEYLsepNaFdNKnyLzPIxmJ9vPTZbf5hRRRWpyBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXmeqnOt6iPSc/0r0yvOPEC7fEWojGMsh/8AHFrmxPwo9PK3+8kvL9UeefEmALq9vM7ZaSBePTBIrF0h4Ef58n6Vf+Iwf/hJW3E7TChXntj/ABzWZpMRZ+BXDP4mfXUF+5jd9DoBc2v9xqeslrLwGK/Wq4iOPu01owOq4qR8sehHqdswT90fM3cADrXaaJbS2fh+wguVKzqrMynqoLEgH864V7qSwuYrmEgtE4cKehwc16PNIJm81fuuocfQjIq47NnLinL3Y9N/6+86z4fR40J5sYM1xI5Prg7R/wCg101YXghdvheyB/2z/wCPtW7Xp01aCPj8U71pvzYUUUVZzlTVbCLUrCa1nyEccEdVI5BH0NeblZrO5aNztubd9pI9R3+h616nXJeN9MYhNTt1JaMbZ1HdOzfh/L6Vz14XXMt0ejl+I5Jezls/z/4JxviW0XMeo24xDOfnUfwSd/zrOtZRwDXQWrwyRyW9yc2s4wxH8J7MK5vU7GbTbxoJOccqw6MOxFePiKdnzrZn0NCV17KW629P+AaQdO4FDSRqMnAFZ1tc8gNWnF5bjkCuR6jlHl3IGukH3eaj8136A1oLFF/dFSr5a9BWUiedLZGZHC7nofxq5FaKOW5NWDKoHFVpbg9FrJsXNKWxMfKgB2qoJOTgdTUYnZm4HFVcljzSvKkS5Zgo9zSbbGoWLZfHU1BPKFhkkf7iKWP0ArMn1i0RsebuPoKwfGPic2Xh+WW2izmWGMluwaVVJ/I1rTw9So0kgqQlTg522Vzzb4iaHIXaVf8AVX0iNIzHmSYyooX/AHUUHHb86zotH8Q+Gd03h+/ubVD8xSJt0Z9yhyp/Ko/iV4nknn06zyd1sBLLGvSM4O1frySfoKyLLxfKkYUTN9Ca+rowlGmoz3Pk5VHzucWdHYfFjV7Z3tddtjcSJj99bgIxB9VPGeOxH0rrvDXjTQNYnVJ9WS1lPSK6BiP0yflP4GvKNMlj1LUbu7ucbZHCjHoox/PNdH/wiFlqEO61uIw5/halLDQlqd9HN8RSXK7Nfj957zvgtLYOjKUIyCDnNVoRLqDbmJSH9TXz+fCfiDQ2M2ly3Nuuc5t5MKfqvQ/iK2NN+Jfi7R8Raha22oRr1MkZik/76Xj/AMdrGWGktjupZvSa95NP7z6Cgjgto8RqBTJ76NAdzjFeQWfxdsLxgupWt5p+erBRMo/75+b/AMdrpdJ8ZeCryQbvENsG9LkNAP8Ax8Cs3Ca6HVCvh5e85pnTz6k8xKW6Mx6ZFTWGmO5WS7OT1xV/S7rSriINp93a3CesMiuP0NS3d0qKeQBU8ttzX23NpTRn6xLHbW52DnoAPWqulqxXc/Ujmqs0jX12NvMaH8zWomIYfQ4qd2bNckOXqV71y7bFqxZRrEvzCqkXzzFz0qS4u0jGM80XBptcqJL+cBTzXNzKbibb1B61amma4lwuSKJ7zTdHj83U721tR1zPKqfzNT8RtFqhG7LlnCltGMKM1W1C92A4PNclrXxP8PQKy2VxLeyDtbxHH/fTYX9a4S/8d6zqsrR6TaR2qno7/vZPy+6P1rSNGctEjjnj8NT96crvstT0i/vba1ha81W6jtrVeryHA+g9T7DmuD8RfEq8vCLHwnHJbQn5TdOgMsn+6pztHuefYVk2ng7UtUuRe63dOM9ZZ33Nj0HoPYV0Md1oPhmIx2Ea3FxjmV+x9q6qeGjHWWp4+MzmpX92muVfiZXh7wkke7U/EMrfMfMKuxLyH1Ynk1W8UeJUZWgswIoRwFWsrxL4mm1KZgGJJ4CjoKq+G/DGq+JtS+x6Xatd3QAZxu2pEP70jHhR7dT2Brp2PHScnoZMEU2oXaAJJK7uEjjRdzyMeiqO5NfS/wAMPh7beFrSLUNXgjn8QyLnBO5LRTyEXsW9W9enFXPh38P7DwZF9oZ0vtckXa93twsI7pEOw9T1P6Ds41eW4S3t0MtzJ9xB39z6D3rkq1r+7E9jB4P2f7yoJia4uI4YR5t1MdqD+p9AK73w3okej2zbm827lwZpfU+g9AKTw5oaaTCXlZZb2QfvJccD/ZX0H862a0pUuX3nuc2Mxntf3cPh/P8A4AUUUVueeFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXn/iyLyvEc7f89Ykf+a/+y16BXEeOIiur2sv8MkJT8VbP/s1YYhe4d+WytWt3TPMPiVD+/wBNuv78RjP/AAE//XrntOZgwCHrXe+LdPGpaBLg4ltCZ1J7qB8w/rXnljP5Mg2DJrz573Pr8LO9Ll6o6W3inOMnj3q6bcSL82AfWsu3uHuDsE6bx1QMMj8Km8qU/wDLU/nSG1d7le/00z3cECOF811Td6ZOM138yLG3lIPljUIPoBivOdREqqCHOexzXb6BcvqGg211KxaYExSk92B6/liqj1Rhik7Rk3pseh+CHD+HLcAYKM6nn/bNb1cl4BuPkvrQn7jiVR7MMH9R+tdbXpUneCPkMZHlryXn+eoUUUVocwUjqGUqwBUjBB70tBoA808QaUdGuQqEtZyk+UT/AAH+6f6VSZU1K3W1nbbMn+okP/oJ9q9J1awh1Gzktrld0benBB7Ee9eaajp0+m3Rtrk7j1jkH8a+v1rgr0uXpoz6HBYlV48sn7y/r/hzFa2aKV45lKupwRU0SvH91sitQqmoAJLhbtRhXP8Ay0Hofese6vIrF2Sdtrr1XvXiV6UoS01TPUjNz922peSZu604zHHSuduPESDIhjJ9zWdPrFzPkeZtB7Cs44apLfQ2jhZPdWOpuLyOMfvJFX8ay7jXIEyIwXNc65MnLOSfc1GVA71vHBxXxO50Qw0Vua0+uzvkRgIKy7m7mlz5kjHPvUZI6Dmpre1Z2DMOK6Y04x+FG8YQhrYbbRE8mptQso9QsZbKaPzIpRtZeR+o6HvV2GEL2rUs4kGDgZrWKMKtRPdXPNZfhKskbmz1MxhyXMd3EJQSevzAq34nNcB4q+HOt6SGl+xrJbqfmntJPOVR67cB/wBCPevo+6lihXMh/Cqq6raKcACuqNecd9Tw62W0KusVZ+R8sW0dzawg2rCaId0Oau2uvzwMNwZSO4Ne/a1o3hjWZTNeaZC1yes0OYpCfdkIJ/GuP1D4YR3js2lX5Re0d5GJB/30u1h+Oa3jiYPc82rlFeCvHVfccnpvj25twB5xK/3W5rftfGenXf8Ax+2kTk9SKwNZ+F2v2gZhphuEH/LSxmEg/wC+W2t+QNcXeaXPp83lTPJbTD/lnco0TfkwFbqSezPOnSnT+JWPWGh8KakfmBgY+lU7jwJo12xNpqahfcV5kGv4QCMsvqOaki1e8hPO8UzM7ib4YTF99ld28hHIP3TSHwr4vsflttS1BU9Irt8flnFcrH4ovYiCssg/GtCDxvqK4/0mXA96TSe5UZOOsXY6K3/4WBZkLDqGoDH95Uf/ANCU1bfUviWFAe7uHHbdaw/0SsCL4iarH926f8RUr/EnV3QBrt8D2FLkj2NFiay2m/vZsDWPiSo2iWQD2tI//iagkm+Id03z3dyoP923iX9dtZR+ImqkEfanx9KqS/EDVmBUXcmD6UvZw7FfW6/87+9m1L4c8ZXw23Gp6jtPVTcFF/IECqy/Dz7M3majewRsepJ3N+dYUvi7VJxhrmdv+BGqcmoX9118w/WqSS2MZTlPWTudmml+G7D/AI+Ltrhh/dGBTpPGOm6ZCYtLsIkPTzGHNcDPHOOZ5kiH+2wFWbDRbm8INvbXFwD0fbsT/vpsZ/DNDaW44U5TdoK7NHU/F97ejbvYj0BrIbz7mRRM7KX+6igs7fRRya7fw/8AD69vZQGDue8VnGWP4uR/ID616x4M+GdppT/aNTt0gQ8+SG3yy/7zZJx7Z/KsZV19nU9Cnlk96r5fLd/cef8Aw7+Et3rUSahrUj6ZpeeFGDcTj0B6IPfk/Tt7zpGnWGjaamnaLZRWVknOyMcsfVj1Y+55q0zb8KqhIkG1VHAUegrOfwvqXiDUBe+H72TT7mFPLNxJl7eUDJCNH0PJPzLgjPXscHOVR8qO6NClho89jVtbae7uFtrOPzJm654VB6sfSu80LRodKhJGJLpx+8mI5b2HoPaue8G6xaWFyuhatZnSNfcbvLlk3peY6vBLgCQd9uAy91HU9tXRSoqGr3PMxeNdb3Y6R/MKKKK2OEKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArl/HsR+w2twP+WU21vowx/MCuorP1+0+3aNdwAZZkJX/eHI/UCoqR5otG+Gn7OrGT7nmGsRPNoepJHnebdiAO+OcfpXk8e8JIY879pIx64r3Ow02eQqWQ7WGGB9D1rlY/h1cw3Ljd8oY7Tjt2rz3Tk7NI+roYylT5oykcvo5ikkYxnMVtBhQP4snJx6/dH4mkshDaeS4aGVI4SZPsy/MpJGd3PuePY8GvRrPwZJGAGY/lWknhH5eT+lWqUuxlPH0U/iPJFtIbqQSW0gK7nmYBshSeFB9yMnHauu8ELs0W+j3ZInDFfTIHP6V1cngoOpG7Gfao9G8HS6bfvIshMUq7XXHWhUpXvYmePoypuPN5jvCM5g8TomcLcQsn1I+YfyNeh1yMHh6W3v7a4jOTDIG+o7/pXXV1UE4xszwsfOFSopwfQKKKK2OEKKKKAEIrO1rSYdVtDDL8rjmOQdUPrWlRSaTVmVCcoNSi9Tye9spbS5a2ul2zJzx0Yeo9qq6jYW+rwCO7YRXaDEdwRwR6N/jXqmq6ZbanB5dwnzDlJB95D7GuB1fTLjTJxHdKGibhJl+63sfQ+1cNSk4arVH0GFxqrW1tJf1p/kecahpU+nXHlXsJQnlW6qw9Qe9VzaIRkGvQp7mGCxlXUViksEUu4mOAgHVg38P1rz9/Dk3jIyzaW7weHs5jgnbZNfD1HpF6ZwW74H3sfZ31R6yx9tJ7/h/wAAztLmt9TEz2nmPbxvsWbGEkPcoe4HTPT0zWklgpPNTG3mtMQND5PlgKI9u3aB0AHpSjzx0xWbSudilK2rJYbNF7CpiFHCjJqBVmbG5sCr0CqmD1NNGcm+rIVtJJD6VoWtgoA3uaikvI4+GYCojq0KdCTVaIyftJLQm1bSRLDmNiSK5O706aJjlTXRtri4wEJ/GqtxqDzjAiH40OSCFKotznC0kIp8WpyxngmthNJkujuf5Qe1LJ4dwPlbmgcrLRlOPXZgMZNMudZMsTI/zKwwQeQaLnR3i75qq2k3G3dtOKLiUYrUyJdD0G8cvd6XZlj3SMI35rg1SufBnhyT/UreW/8A1zuWI/Jt1bMlpKhwVOaYbeReoNUpyWzM54ajU1lFfccvL4A05ifK1S7Qf9NY43/koqF/h9Eo/d63AfZ7E/0krqmhk/umhYJW6Kfyq1XmupzyyzDS+z+ZxT+BZF+7qdmf+3Rv/i6i/wCEJm739pj/AK9W/wDi67v7JN/canLYTk8Rt+VH1ip3F/ZeF/l/F/5nA/8ACFSj/mIW/wCFof8A4ulXwTzltQH/AAG2A/mTXoK6VdN0ib8qlj0a4J+YYo9vU7jWW4RfZ/F/5nBxeDbcY8y+vG/3BGn8lq3H4V0tf9bHPOf+ms7kflnFdwNJWMZkfmtLTvCl3ftlITDB1M03yr+Hr+FT7Wb0ubLBYamuZxS9TitM0e2hlWPTrCJJGOAIohuJ/Dk16f4e8H21hGtxrSLPdnlbbOUT/e9T7dPrW1o2k2mixkWaiS5Iw1wy4P0UdhVxtqDdIfxPeltvuZynf3YaIkE0pUIh8uMcBUG0AUw4DqmGeRzhUQFmY/QVs6Z4evr9Q8g+xwHozrlz9F7fj+Vddo+jWmlRkW6FpG+9K/Lt+P8AQVtCjKerPPrY6lR0jq/L/M53RvC8s7LPq37uIHK2wI+b/fP9BXYxxpFGqRqqIowFUYAFOorrhBQVkeJXxE67vNmfrujadr2nPY6vaRXVqxDbHH3WHRlI5Vh1DAgjsa5fz9d8GYW7+1+IfDy/8vKrvvrNf9tR/r0H95fnHcP1ruKKsxKek6nZaxp8N9pd1Dd2cw3RzQsGVvxHf1HarlcrqPhR4dUbVvC94NJ1GV91zF5e+1vOmfNjyPnwOJFIb13DiqXxI8XXvh++8O6VpMdoNQ1u6eBLm93GC2RE3u7AEFjjou5c+vFAHb0V5dcfFay0SxtHv7m28USXt21rav4VjFxvZYw5Vo/MYq3PADNwQTinRfG3wrJ4qt9B23yXct4mnlpBEvl3DD/VtGZPNGD8pYIVDcbqAPT6K8e8SfG/T7W116z0mwmbXrCwmvIYpJrW4iby+DuMM7bcfeKsVbaDgE4BfcfHLRtF0XRpPE1ld2+q3mmx6jNbRtbjbG2BvXdN8wY5KopaTHVRzQB69RXBaL8UNJ1vxo/hzStN1u5kRIpJL+O1DWkaSwedGzyBsqCvAyAS3A9a0pvG1ufGF14b0zStT1S/skie9e1EKxWgk5Te0kiZJHzYUMcflQB1dFea6b8ZPD+oLojQ2eqqNXjvpIN8UY2i0DGTdh+M7TtxnPfFV9M+NugXlvpV5c6V4g0zTNSlMMF/f2ixQFvLLj5t5JBwQCoIyPxoA9Sory7WfjVoOjaBpes6jp2pwWWo2y3UQkltEmEbOVB8lpxI3GG+RWG1h3yBmWnxlezfxxe6/o11/Ymg3cUMM9mkZd1kZFUMGmyWO8MCAAFBzhsAgHslFeb638YdB0ebVoprDWZ5NN1OHSpEt4EkaSaVWZdi78sPlI6ZzjANUL347eFbDUIbLULfVLO5Ig+0RXKRRSWjTAFVkjaQOSAQW2K+3POKAPV6KKKACiiigAooooAYsSKPlUCh1HpT6KB3INnPAp+D6VJRSsFxmPak6HpUlFMLgKKKKBBRRXh/7QWreI9U1jSfBvgSfU49XaCXVLp9NnWKVIlUrGpYunys55GewwCcCgD3CivnpfjRr+oaXaTaIukB4/C02tXf2u3kdvtMEhSWLCyJtBKnHHGQeRVdPiD4itvFusa1NqlnBDP4Qi1my0m6WQxSyfZ2lKxDzQCwYEswBJUEYH3qAPo2ivDE+KPizS7Xwbd+KYvDdtZ+Ibe6uhNAJgkai1jlt0LOwAkaRmBXnIwFOcmsSP41+LLjR1vIbfQo3j8MHXpVe1lcO4u2hMa/vRtUqAcnJBz16AA+jqz9fu9NsNHurrW5IItOiTdK833QP6n0A5J6c1xPw28a6r4g8V+INH1eKxxY21ldwS2sbx5W4i3lGDM2SvA3DGfQV1eoeHLbUvEFpqeoyzXMdmoNtZSbfIimyf323GWfBwCSdvJABJNA07ao84fwZqXiqVdRubaS00NXD2mjXTFZZQOkk/4jKxE8cFueFu3ED203k3EbQyj+FuPy9fqK9VqG5toLqPy7mFJU/uuoIrCdBS20O+hmEqek1f8AM8vl8u5TZexLOnYnhh9DWfc6HBKc2VyI/wDpnMP616De+E7Z9zWMrwMeiMdyf4j865690TULQnzLZpU/vw/OPy6/pXNKlKO6uerQxtOXwSt5f1p9xxtxpN/ADm2eRf70XzA/lWXc/a4eGgmj/wB5CK7XcEcjdscdQeCKmW4lUcSt+JzWVkd8cRJbpP8Ar5nnBhdmy+cn2p4tx3BNejG7mH/LX9BUbXrr96fH4ilyruafXJv7P4/8A4iGyZsbbeVj7ITWjbaZcgBvsU/4oRXSCWWUFkllYdypJFQMxckCZiw7FqdkiHiJSMx1eD5ZI2Q+jDFVZrzHC/erokknVNvmkr6N8w/Wm567oLZweoMQFGhCqNbq5zUKh23ztn2p1zdRquxMZ6VsXWmWN2OVltH/AL0Z3L+R/pWU3heYSEwXlvMvbcSh/Kiz6G0atOWsnYowQq7lioLVOthGxJdRV5ND1FOAbcf9tBQ2j6j3kth/21pcr7DdWD2kiGKwskGXQGpvJsUHEa00aHet965tV+rk/wAhVmLQI/8AlvqHPcJEf5mnZmcpQ6y/Mpu9svSJMVF9phDYVFz2wK210fTEIJjnnP8AtvgfpV2DbbKVtIYoAeMovJ+pp27sj2kOiZi29pe3IBhtGCn+JxtH61OuhrnN7dKvqkIyfzrQlmGf3s2fYmrdrp19dgNa2Uzqf4mAQfm2M/hTSvsrmcqrirtpL+urM+3tLK1bNraJvH/LSX52+vPT8KmnnZ3AkdncnCoBkk+wFdTY+EiwDajc/WODj/x49fyFdFYabZ6em2zt0jz1YDLH6k8mto0JPfQ8+tmNKL933n/XU4uw8NaheoryFbKI/wB8bn/757fjXVaZoNjYbWSISzj/AJay/M2fUdh+GK1aK6YUow2PLrYyrW0bsuyCiiitDlCiiigAooooAKyPEvhvSfE1pDb63Zi4SCUTQsHaOSKQdHR0IZW9wQa16KAOR0/4ceFrC4tbi302Q3FtevqMc0t3PLIbh1CtIzM5LkgD7xIqyPBGhJrdxq0EF3bXlxMs9wLa/uIIp3H8UkSOI3zjncpz3zXS0UAcNY/CfwXYgLb6O3lrbz2qRSXk8kccU2fMREZyqhsk4AGCSRg1ZT4b+Goo7EQW+oQSWUH2W3nh1W7jmSHOfK81ZQ5QHohJA7AV2FFAGNo3hnStG1XU9S0+2dL7UhCLuZ55JGm8pNked7HkLxkcnqcnmq994O0W98QDXHguYNVKoj3Fpez2xlVTlVkEbqJAPRgeOOldDRQBxFj8K/B1jew3VrpLxyQ/aPJX7ZOY4vPUrMEQvtUMCeABjqMGruo/D3wvqPg228K3ulLLoNtt8m2M0g2bc4w4bf3PfvXVUUAcdrvwz8Ja5O02oaUSz2i2DiC6mgWSBTlY2WN1DAYGMg4wPQUXnw08J3g1VbjSmaLVY0jvYhdTLHNs27WKB9ocbFw4Abrzyc9jRQBxkXwx8JR7z/Zssjvewai8k17cSO9xCCI5CzOSSAT1OD3zWhf+C9Evdbl1dory31GYIs01lf3FqZgnC+YInUPgcDcDxxXR0UAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAEFzaW1zj7TbwzY6eYgb+dUn0DSWOTYQD/dXH8q1KKTinui41Jx+FtGWPD+k5B/s+3P1XNXoLS3txi3giiH+wgX+VTUUKKWyCVScvibYVDcWtvcri4gilHTDoG/nU1FMlNrVGHceGNNlyY43gY943OPyORWZN4QkHMN8re0kX9Qf6V19FZulB9DohjK0NpfqcBc+GtUib93DDOPWOXB/8exVV9F1RDhtOmz7Mh/ka9JorN4aJ0xzOqt0n/XqeanSNRUZOn3H4AH+Rpv8AZt+P+Yfdf9+69MopfVo9x/2pU/lR5wukaiwyLCf8QB/M1NH4f1V2x9kEY9XlXH6E16DRT+rRE8zqvZL+vmcXB4TvXz59zbw/7imT+eKuReDrU4N1dXM3qqkRqfy5/Wuooq1RguhhLHV5fasULDR9PsMfZLSGNh/Hty3/AH0eav0UVoklsc0pOTvJ3CiiimSFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAf/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Regions of the stomach include the cardia, fundus, body, antrum and pylorus. During endoscopy, the endoscope usually proceeds along the greater curvature of the stomach toward the pylorus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_53_32595=[""].join("\n");
var outline_f31_53_32595=null;
var title_f31_53_32596="Amobarbital: Patient drug information";
var content_f31_53_32596=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Amobarbital: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?36/7/36982?source=see_link\">",
"     see \"Amobarbital: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/17/43286?source=see_link\">",
"     see \"Amobarbital: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F134276\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Amytal&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F134277\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Amytal&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10018435\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10018437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692082",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat sleep problems.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10018436\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701509",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to amobarbital or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703367",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: A block in the airway, liver disease, porphyria, or shortness of breath.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10018441\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have been taking this drug for many weeks, talk with your doctor before stopping. You may want to slowly stop this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697302",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor. You may be more sensitive to this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697307",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have mental illness, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696708",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Birth control pills and other hormone-based birth control may not work to stop pregnancy. Use 2 kinds of birth control while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10018442\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697935",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698074",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10018444\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low mood (depression), thoughts of killing yourself, nervousness, emotional ups and downs, thinking that is not normal, anxiety, or lack of interest in life.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698646",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Driving or doing other tasks or actions that you do not remember doing after taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10018439\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696091",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use this drug only for short periods of time (7 to 10 days).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695976",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle or vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10018440\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696549",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is used on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10018445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10018446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11076 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.25.216.6-A93D27A9D4-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_53_32596=[""].join("\n");
var outline_f31_53_32596=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134276\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134277\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018435\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018437\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018436\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018441\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018442\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018444\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018439\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018440\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018445\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018446\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?36/7/36982?source=related_link\">",
"      Amobarbital: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?42/17/43286?source=related_link\">",
"      Amobarbital: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_53_32597="In situ hybridization";
var content_f31_53_32597=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F77315&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F77315&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Representative example of in situ hybridization of nasal biopsy specimens in allergic rhinitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 393px; height: 261px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Expression of IL-4 mRNA after antigen challenge (A) and diluent challenge (B). Expression of IL-14 mRNA after allergen challenge and (D) colocalization of IL-4 and IL-13 mRNA after allergen challenge.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Christodoulopoulos, P, Cameron, L Durham, S, Hamid, Q. Molecular pathology of allergic disease. II: Upper airway disease. J Allergy Clin Immunol 2000; 105(2 Pt 1):211. Copyright &copy; 2000 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_53_32597=[""].join("\n");
var outline_f31_53_32597=null;
var title_f31_53_32598="Congenital cholesteatoma";
var content_f31_53_32598=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F72870%7EPEDS%2F73085&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F72870%7EPEDS%2F73085&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Congenital cholesteatoma of the anterosuperior quadrant (right ear)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 371px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Congenital cholesteatoma of the anterosuperior quadrant. A white mass (arrows) behind an intact drum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Isaacson G. Diagnosis of pediatric cholesteatoma. Pediatrics 2007; 120:603. Copyright &copy; 2007 by the AAP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 519px\">",
"   <div class=\"ttl\">",
"    Foreign bodies in the ear canal and on the tympanic membrane",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 499px; height: 251px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Panel A) A pearl in the ear canal (a foreign body - not a squamous pearl). Panel B) Sand on the tympanic membrane after swimming in the ocean.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Glenn C Isaacson, MD, FAAP, FACS.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_53_32598=[""].join("\n");
var outline_f31_53_32598=null;
var title_f31_53_32599="Primary lymphoma of bone";
var content_f31_53_32599=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Primary lymphoma of bone",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/53/32599/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/53/32599/contributors\">",
"     Ann S LaCasce, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/53/32599/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/53/32599/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/53/32599/contributors\">",
"     Thomas F DeLaney, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/53/32599/contributors\">",
"     Julie R Park, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/53/32599/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/53/32599/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/53/32599/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary non-Hodgkin lymphoma of bone (PLB) presents as solitary or multiple, destructive bone lesions. The clinical presentation, diagnosis, and treatment of PLB will be discussed here.",
"   </p>",
"   <p>",
"    A more general discussion of the approach to the patient with non-Hodgkin lymphoma is presented separately, as are discussions concerning the pathophysiology, diagnosis, and treatment of diffuse large B cell non-Hodgkin lymphoma, the most common tumor type found in this setting. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/61/27610?source=see_link\">",
"     \"Clinical presentation and diagnosis of non-Hodgkin lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/18/15658?source=see_link\">",
"     \"Initial evaluation and staging of non-Hodgkin lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/45/24282?source=see_link\">",
"     \"Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/45/26330?source=see_link\">",
"     \"Initial treatment of advanced stage diffuse large B cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary lymphoma of bone (PLB) is a rare disease that accounts for less than 2 percent of all lymphomas in adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32599/abstract/1\">",
"     1",
"    </a>",
"    ]. In the pediatric population it represents approximately 3 to 9 percent of non-Hodgkin lymphoma cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32599/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. It is estimated that PLB accounts for 3 percent of primary bone tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32599/abstract/6\">",
"     6",
"    </a>",
"    ] and 3 to 5 percent of all extranodal non-Hodgkin lymphomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32599/abstract/7,8\">",
"     7,8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Men are diagnosed slightly more frequently than women with a male:female ratio ranging from 1.2 to 1.8 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32599/abstract/9-11\">",
"     9-11",
"    </a>",
"    ]. The vast majority of patients present over the age of 30 years (92 percent) with the largest cohort consisting of those over age 60 (56 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32599/abstract/9,11\">",
"     9,11",
"    </a>",
"    ]. While PLB occurs in children, pediatric PLB is considered a distinct clinical entity and the approach to treatment differs from that of adults.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients present with bone pain not relieved by rest. A palpable mass due to soft tissue extension of the bony disease is seen in about one-half of the cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32599/abstract/10\">",
"     10",
"    </a>",
"    ]. Swelling, pathologic fracture, cord compression and systemic \"B\" symptoms (ie, fever, weight loss, night sweats) may also be present at the time of diagnosis. Occasionally, symptoms may persist for many months before the patient seeks medical attention.",
"   </p>",
"   <p>",
"    The axial skeleton is affected more commonly than the appendicular skeleton (63 versus 37 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32599/abstract/9\">",
"     9",
"    </a>",
"    ]. The weight-bearing bones are the likeliest sites of pathologic fracture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32599/abstract/12\">",
"     12",
"    </a>",
"    ]. Additional osseous lesions represent the second most common site of involvement at presentation. On occasion, regional lymph nodes may be involved.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vast majority of cases of PLB are pathologically diagnosed as diffuse large B cell lymphoma (DLBCL) (",
"    <a class=\"graphic graphic_picture graphicRef54630 \" href=\"mobipreview.htm?32/23/33143\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef67828 \" href=\"mobipreview.htm?7/31/7670\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32599/abstract/9\">",
"     9",
"    </a>",
"    ]. Rarely, indolent lymphomas, such as follicular lymphoma, small lymphocytic lymphoma and marginal zone lymphoma may present as PLB. Highly aggressive subtypes, such as Burkitt or lymphoblastic lymphoma are rare. Anaplastic large cell lymphoma (ALCL), typically alk-1 positive, has also been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32599/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A tissue microarray study of 63 cases of primary DLBCL of bone revealed that 42 were of germinal center derivation and 21 of non-germinal center [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32599/abstract/14\">",
"     14",
"    </a>",
"    ]. Fluorescence in situ hybridization performed on 32 cases showed 9 and 3 harbored rearrangements of bcl-2 and myc, respectively. One case showed both bcl-2 and myc rearrangements, and no cases had bcl-6 rearranged.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Histologic diagnosis may be obtained by percutaneous or open biopsy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32599/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. In the vast majority of cases pathologic examination demonstrates the presence of diffuse large B cell non-Hodgkin lymphoma (",
"    <a class=\"graphic graphic_picture graphicRef54630 \" href=\"mobipreview.htm?32/23/33143\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef67828 \" href=\"mobipreview.htm?7/31/7670\">",
"     picture 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32599/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/53/35673?source=see_link\">",
"     \"Bone tumors: Diagnosis and biopsy techniques\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/45/24282?source=see_link\">",
"     \"Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The evaluation of a patient suspected of having PLB (eg, lymphoma restricted to a single osseous site) necessitates a comprehensive history and physical examination with emphasis on identifying all involved sites and any evidence of constitutional symptoms. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Staging'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/61/27610?source=see_link\">",
"     \"Clinical presentation and diagnosis of non-Hodgkin lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/18/15658?source=see_link&amp;anchor=H29#H29\">",
"     \"Initial evaluation and staging of non-Hodgkin lymphoma\", section on 'Staging'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging of the primary site should include plain films as well as computed tomography (CT) or magnetic resonance imaging (MRI) for further characterization of the bone lesion and the extent of soft tissue involvement. Integrated positron emission tomography",
"    <span class=\"nowrap\">",
"     (PET)/CT",
"    </span>",
"    examination of the chest, abdomen, and pelvis is required to determine the extent of lymph node involvement as well as the presence of distant disease. While both (99m)Tc-MDP bone scintigraphy and gallium scanning are effective modalities for staging PLB, neither has been used routinely since the advent of FDG PET [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32599/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Plain films",
"    </span>",
"    &nbsp;&mdash;&nbsp;The earliest radiographic sign of skeletal involvement with PLB is diffuse medullary mottling (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef61322 \" href=\"mobipreview.htm?37/61/38878\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32599/abstract/20\">",
"     20",
"    </a>",
"    ]. Plain films of the primary site may demonstrate lytic or radiolucent lesions associated with a noncalcified soft tissue mass [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32599/abstract/10,21\">",
"     10,21",
"    </a>",
"    ]. Cortical bone erosion and a widened diaphysis may occur as a result of expansive tumor within the bone shaft.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Computed tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Computed tomography frequently reveals a predominant pattern of osteolysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32599/abstract/22\">",
"     22",
"    </a>",
"    ]. On occasion, an osteosclerotic or mixed pattern may be demonstrated (",
"    <a class=\"graphic graphic_picture graphicRef81794 \" href=\"mobipreview.htm?31/50/32559\">",
"     picture 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     MRI findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The appearance of PLB on MRI is highly variable (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef82588 \" href=\"mobipreview.htm?31/19/32063\">",
"     image 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef66388 \" href=\"mobipreview.htm?25/1/25631\">",
"     image 3",
"    </a>",
"    ). Soft tissue extension is frequently identified and is typically homogeneously isointense with muscle on T1-weighted images and high on T2-weighted images [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32599/abstract/23\">",
"     23",
"    </a>",
"    ]. The majority of patients have abnormal appearing cortical bone. The signal intensity of the bone marrow involvement is heterogeneous in approximately half of cases, compared with the soft-tissue component, and is high or intermediate appearing on T2 weighted images in the majority of cases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Positron emission tomography",
"    </span>",
"    &nbsp;&mdash;&nbsp;While bone scintigraphy reflects osteoblastic tumor activity, positron emission tomography (PET) allows characterization of metabolic activity within the tumor as compared with normal tissue. PET has been shown to be accurate in the staging of lymphoma, even in extranodal sites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32599/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/18/15658?source=see_link&amp;anchor=H15#H15\">",
"     \"Initial evaluation and staging of non-Hodgkin lymphoma\", section on 'PET scanning'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     STAGING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with lymphoma involving the bone should be staged in the same way as any patient with non-Hodgkin lymphoma, in order to identify the patient with stage 1E disease who might be treated with limited chemotherapy and involved field radiation therapy, rather than chemotherapy alone, if disseminated disease is found. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/18/15658?source=see_link&amp;anchor=H29#H29\">",
"     \"Initial evaluation and staging of non-Hodgkin lymphoma\", section on 'Staging'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The staging of PLB is according to the Ann Arbor classification (",
"    <a class=\"graphic graphic_table graphicRef73699 \" href=\"mobipreview.htm?36/59/37819\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stage IE represents disease confined to one extranodal site of involvement. For example, PLB limited to a solitary bony lesion is stage IE.",
"     </li>",
"     <li>",
"      If regional lymph nodes are also involved in a patient with a single bone lesion, as is the case in up to one-third of presentations, the disease is stage IIE [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/53/32599/abstract/1,27-29\">",
"       1,27-29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Multifocal disease may be classified as stage IV disease presenting solely in bone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/53/32599/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;As a result of the rarity of this disease, randomized trials addressing treatment alternatives for PLB are not available. Most retrospective studies report the results of patients treated with various therapeutic modalities. Historically, PLB was treated with radiotherapy alone with good local control (87 to 100 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32599/abstract/11,31-33\">",
"     11,31-33",
"    </a>",
"    ]. However, distant relapse rates were often disappointing, as more than 50 percent of patients failed systemically. Currently multiagent chemotherapy with or without radiation therapy is preferred resulting in approximately 70 percent of patients surviving five years.",
"   </p>",
"   <p>",
"    An analysis of the Surveillance, Epidemiology, and End Results (SEER) database included 1500 adult patients with PLB diagnosed from 1973 through 2005 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32599/abstract/9\">",
"     9",
"    </a>",
"    ]. Five- and 10-year overall survival rates were 58 and 45 percent, respectively. On multivariate analysis only younger age and localized disease were independent predictors of survival. Five-year survival rates were 87, 74, and 45 percent for those patients diagnosed at &lt;30, 30 to 59, and &gt;60 years, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Chemotherapy with or without radiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiagent chemotherapy with or without radiation therapy is the preferred treatment of adults with PLB. Given that the majority of PLB are aggressive B cell lymphoma, patients are typically treated with anthracycline-based, multi-agent chemotherapy, such as CHOP (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    &nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    &nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    &nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ) with the addition of the anti-CD20 antibody",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    . The use of radiotherapy is controversial, though a number of studies prior to the use of rituximab demonstrate a benefit of combined modality therapy. In patients with unifocal disease, consolidative involved-field radiotherapy administered at a dose of 40 to 45 Gy following chemotherapy is reasonable, but should be individualized with particular attention to the location of disease. Areas, such as the pelvis, which contain significant marrow production, should be considered carefully. &nbsp;(See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/45/26330?source=see_link\">",
"     \"Initial treatment of advanced stage diffuse large B cell lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following series illustrate the role of chemotherapy with or without radiation in this patient population:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The largest series of PLB described 131 patients with a median age of 63 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/53/32599/abstract/34\">",
"       34",
"      </a>",
"      ]. One-third of patients presented with disease involving the long bones and another third involving the spine. Eighty percent of patients had aggressive lymphoma and 78 percent presented with advanced disease. Rates of overall survival for the 103 patients with large cell lymphoma at 5 and 10 years were 62 and 41 percent, respectively. Patients over 60 years old and those with high IPI scores had poorer outcomes. Seventy-nine percent of patients received CHOP or CHOP-like therapy and 21 percent received CHOP plus the anti-CD20 antibody",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      (RCHOP). Rates of three-year progression-free survival were 52 percent and 88 percent for those who received CHOP or RCHOP, respectively. Radiotherapy was administered to patients with cord compression or residual disease following chemotherapy. The rate of 10-year overall survival for those who received radiation was 25 percent compared with 56 percent for those who received chemotherapy only.",
"     </li>",
"     <li>",
"      A retrospective multicenter Rare Cancer Network study described 116 consecutive patients with stage IE (80 percent) or IIE PLB diagnosed between 1987 and 2008, 78 percent of whom were DLBCL [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/53/32599/abstract/11\">",
"       11",
"      </a>",
"      ]. Patients received chemotherapy plus radiation (75 percent), chemotherapy alone (12 percent), or radiation alone (13 percent). Chemotherapy consisted of CHOP or CHOP-like regimens with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      added for 32 patients. With a median follow-up of 41 months, estimated overall survival rates at five and 10 years were 76 and 72 percent, respectively. On multivariate analysis, factors associated with improved five-year survival included IPI score &lt;2 (84 versus 59 percent), radiation dose &gt;40 Gy (95 versus 66 percent), and the administration of at least six cycles of chemotherapy (81 versus 69 percent). &nbsp;",
"     </li>",
"     <li>",
"      Another large series identified 82 patients with PLB [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/53/32599/abstract/35\">",
"       35",
"      </a>",
"      ]. Eighty percent had DLBCL and 81 percent had stage I or II disease. Fifty-seven percent received combined modality therapy (chemotherapy plus radiotherapy), 14 percent received radiotherapy only and 30 percent chemotherapy only. At a median follow-up of 67 months, rates of freedom from treatment failure and overall survival were 81 and 88 percent, respectively. In this series, age &lt;40 and combined modality therapy (CMT) were associated with favorable outcome in multivariate analysis. Compared with the series described above, however, these patients had earlier stage disease and only five patients received RCHOP.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Several other series have also demonstrated an improvement in overall survival using combined modality therapy compared with chemotherapy or radiation alone with overall survival of 73 to 100 percent at greater than five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32599/abstract/36-39\">",
"     36-39",
"    </a>",
"    ]. In the only prospective study in this disease, patients with localized disease that could be encompassed within a radiation field were treated with three cycles of CHOP chemotherapy followed by 45 Gy of involved field radiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32599/abstract/40\">",
"     40",
"    </a>",
"    ]. Thirty-three patients were enrolled; three patients received six cycles of therapy, and six patients received",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    . The study closed early due to poor accrual after rituximab became commercially available. With a median follow-up of 4.3 years, the five-year rates of local control and overall survival were 72 and 90 percent, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Surgical intervention",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of surgery is generally limited to diagnostic biopsy and stabilization of a pathologic fracture. Orthopedic management is important during the treatment and recovery period because the potential for fracture persists until there is complete bone healing. Rarely, patients with involvement of the weight-bearing bones may require internal stabilization or bracing until bone healing occurs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although cure of disease remains the ultimate goal of treatment, the focus of pediatric therapy has shifted towards minimizing long-term adverse effects. Three consecutive studies by the Pediatric Oncology Group (POG) reflect the trend towards using less intensive therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the early 1980s children treated on research protocols for primary lymphoma of bone received 9 weeks of induction chemotherapy followed by 24 weeks of continuation therapy and subsequent involved field radiotherapy to 37.5 Gy. Local control was 100 percent and, at a median follow-up of nine years, there were no reported treatment complications after attaining remission [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/53/32599/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      By the late 1980s the necessity of adding radiation in children with this disease was questioned. A randomized trial testing chemotherapy with or without irradiation confirmed the prediction that radiation was not generally needed in children with non-Hodgkin lymphoma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/53/32599/abstract/42\">",
"       42",
"      </a>",
"      ]. However, children with primary lymphoma of bone were not included in the study.",
"     </li>",
"     <li>",
"      Subsequent to the above study, a retrospective analysis of three consecutive POG studies enrolling 31 children with primary lymphoma of bone demonstrated excellent local control and survival using a CHOP-like chemotherapy regimen without radiation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/53/32599/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We recommend enrollment of all pediatric patients with primary lymphoma of bone in cooperative group trials. When this approach is not feasible, we recommend utilization of standard multi-agent chemotherapy regimens, such as CHOP. Radiotherapy is reserved for an incomplete response to chemotherapy or local disease progression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;After the completion of planned therapy, patients should be evaluated to determine the response to treatment and should be followed longitudinally for relapse. The response to treatment should be documented by history, physical examination, and laboratory studies (complete blood count, lactate dehydrogenase, and biochemical profile). When planning the post-treatment surveillance strategy, care should be taken to limit the number of CT scans, particularly in younger individuals, given concerns about radiation exposure and the risk for second malignancies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/17/21785?source=see_link\">",
"     \"Radiation-related risks of imaging studies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The post-treatment imaging study of choice is the",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    scan, which provides information on the size and activity of residual masses and allows for the distinction between active disease and fibrosis.",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    should be obtained six to eight weeks after completion of chemotherapy and 12 weeks after the completion of radiation therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32599/abstract/43\">",
"     43",
"    </a>",
"    ].",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    imaging obtained earlier than this is likely to demonstrate increased uptake due to an inflammatory reaction to treatment. If residual disease is suggested on the",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    imaging, a confirmatory biopsy of the PET positive area is required to confirm residual disease prior to proceeding with additional therapy.",
"   </p>",
"   <p>",
"    Using information gathered from the history, physical, and",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    scan, disease response is determined by the International Workshop Criteria (IWC) (",
"    <a class=\"graphic graphic_table graphicRef64921 \" href=\"mobipreview.htm?29/27/30140\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32599/abstract/44\">",
"     44",
"    </a>",
"    ]. A complete remission has been achieved if all of the following criteria are met:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is no evidence of disease or disease-related symptoms on history and physical examination.",
"     </li>",
"     <li>",
"      All post-treatment residual masses are negative on PET scan.",
"     </li>",
"     <li>",
"      The spleen and liver are non-palpable and without nodules.",
"     </li>",
"     <li>",
"      If a pretreatment bone marrow biopsy was positive, a repeat bone marrow biopsy must be negative. If morphologically indeterminate, immunohistochemistry should be negative.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A discussion of the accuracy of",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    in the follow-up of patients with lymphoma is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/18/15658?source=see_link&amp;anchor=H17#H17\">",
"     \"Initial evaluation and staging of non-Hodgkin lymphoma\", section on 'Evaluating response to treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Impaired limb function, post-treatment osteoradionecrosis, and pathologic fracture are the most commonly encountered complications of radiotherapy to the primary site and may be associated with radiation doses in excess of 50 Gy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32599/abstract/1,12,28,30,31\">",
"     1,12,28,30,31",
"    </a>",
"    ]. Acute hematologic side effects may be observed in conjunction with the administration of chemotherapy.",
"   </p>",
"   <p>",
"    Second malignancies are extremely rare in adult patients treated with combined modality therapy. However, in one series 2 of 11 pediatric patients treated with adriamycin,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    , and concomitant radiotherapy to the whole bone developed bone sarcoma within the radiation portal 5 and 7.5 years after treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32599/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Patterns of relapse",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common pattern of failure is the development of distant metastases. In one report of 37 Stage IE patients treated with chemotherapy plus radiation there was a 22 percent relapse rate, all at distant sites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32599/abstract/33\">",
"     33",
"    </a>",
"    ]. A larger series of 63 patients demonstrated a low rate of local relapse (7 percent) in patients who had a complete response after initial therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32599/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2982957\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary non-Hodgkin lymphoma of bone (PLB) is a rare lymphoma subtype that presents as solitary or multiple, destructive bone lesions and accounts for less than 2 percent of all lymphomas in adults. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The majority of patients present with bone pain not relieved by rest. A palpable mass due to soft tissue extension of the bony disease is seen in about one-half of the cases. Swelling, pathologic fracture, cord compression and systemic \"B\" symptoms (ie, fever, weight loss, night sweats) may also be present at the time of diagnosis. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The vast majority of cases of PLB are pathologically diagnosed as diffuse large B cell lymphoma of the germinal center subtype. Rarely, clinically indolent lymphomas, such as follicular lymphoma, small lymphocytic lymphoma and marginal zone lymphoma may present as PLB. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Histologic diagnosis may be obtained by percutaneous or open biopsy. The evaluation of a patient suspected of having PLB necessitates a comprehensive history and physical examination with emphasis on identifying all involved sites and any evidence of constitutional symptoms. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Imaging of the primary site should include plain films as well as computed tomography (CT) or magnetic resonance imaging for further characterization of the bone lesion and the extent of soft tissue involvement. An integrated positron emission tomographic",
"      <span class=\"nowrap\">",
"       (PET)/CT",
"      </span>",
"      examination of the chest, abdomen, and pelvis is required to determine the extent of lymph node involvement as well as the presence of distant disease. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Imaging studies'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12\">",
"       'Staging'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For adult patients with PLB, we recommend the use of multiagent chemotherapy with or without radiation therapy rather than radiation therapy alone (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). The role of surgery is generally limited to diagnostic biopsy and stabilization of a pathologic fracture. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Adults'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All pediatric patients with primary lymphoma of bone should be enrolled in cooperative group trials. When this approach is not feasible, we recommend utilization of standard multi-agent chemotherapy regimens rather than the combination of chemotherapy and radiotherapy or the use of radiotherapy alone (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). Radiotherapy is reserved for an incomplete response to chemotherapy or local disease progression. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Children'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      All patients should be evaluated after treatment to determine the response to therapy and be followed long-term to monitor for relapse",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      treatment related complications. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Follow-up'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32599/abstract/1\">",
"      Dubey P, Ha CS, Besa PC, et al. Localized primary malignant lymphoma of bone. Int J Radiat Oncol Biol Phys 1997; 37:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32599/abstract/2\">",
"      Loeffler JS, Tarbell NJ, Kozakewich H, et al. Primary lymphoma of bone in children: analysis of treatment results with adriamycin, prednisone, Oncovin (APO), and local radiation therapy. J Clin Oncol 1986; 4:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32599/abstract/3\">",
"      Furman WL, Fitch S, Hustu HO, et al. Primary lymphoma of bone in children. J Clin Oncol 1989; 7:1275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32599/abstract/4\">",
"      Anderson JR, Wilson JF, Jenkin DT, et al. Childhood non-Hodgkin's lymphoma. The results of a randomized therapeutic trial comparing a 4-drug regimen (COMP) with a 10-drug regimen (LSA2-L2). N Engl J Med 1983; 308:559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32599/abstract/5\">",
"      Lones MA, Perkins SL, Sposto R, et al. Non-Hodgkin's lymphoma arising in bone in children and adolescents is associated with an excellent outcome: a Children's Cancer Group report. J Clin Oncol 2002; 20:2293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32599/abstract/6\">",
"      Limb D, Dreghorn C, Murphy JK, Mannion R. Primary lymphoma of bone. Int Orthop 1994; 18:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32599/abstract/7\">",
"      Freeman C, Berg JW, Cutler SJ. Occurrence and prognosis of extranodal lymphomas. Cancer 1972; 29:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32599/abstract/8\">",
"      ROSENBERG SA, DIAMOND HD, JASLOWITZ B, CRAVER LF. Lymphosarcoma: a review of 1269 cases. Medicine (Baltimore) 1961; 40:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32599/abstract/9\">",
"      Jawad MU, Schneiderbauer MM, Min ES, et al. Primary lymphoma of bone in adult patients. Cancer 2010; 116:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32599/abstract/10\">",
"      Mulligan ME, McRae GA, Murphey MD. Imaging features of primary lymphoma of bone. AJR Am J Roentgenol 1999; 173:1691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32599/abstract/11\">",
"      Cai L, Stauder MC, Zhang YJ, et al. Early-stage primary bone lymphoma: a retrospective, multicenter Rare Cancer Network (RCN) Study. Int J Radiat Oncol Biol Phys 2012; 83:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32599/abstract/12\">",
"      Stokes SH, Walz BJ. Pathologic fracture after radiation therapy for primary non-Hodgkin's malignant lymphoma of bone. Int J Radiat Oncol Biol Phys 1983; 9:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32599/abstract/13\">",
"      Pant V, Jambhekar NA, Madur B, et al. Anaplastic large cell lymphoma (ALCL) presenting as primary bone and soft tissue sarcoma--a study of 12 cases. Indian J Pathol Microbiol 2007; 50:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32599/abstract/14\">",
"      Lima FP, Bousquet M, Gomez-Brouchet A, et al. Primary diffuse large B-cell lymphoma of bone displays preferential rearrangements of the c-MYC or BCL2 gene. Am J Clin Pathol 2008; 129:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32599/abstract/15\">",
"      Jelinek JS, Murphey MD, Welker JA, et al. Diagnosis of primary bone tumors with image-guided percutaneous biopsy: experience with 110 tumors. Radiology 2002; 223:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32599/abstract/16\">",
"      S&ouml;derlund V, Tani E, Skoog L, et al. Diagnosis of skeletal lymphoma and myeloma by radiology and fine needle aspiration cytology. Cytopathology 2001; 12:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32599/abstract/17\">",
"      Gianelli U, Patriarca C, Moro A, et al. Lymphomas of the bone: a pathological and clinical study of 54 cases. Int J Surg Pathol 2002; 10:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32599/abstract/18\">",
"      Suryanarayan K, Shuster JJ, Donaldson SS, et al. Treatment of localized primary non-Hodgkin's lymphoma of bone in children: a Pediatric Oncology Group study. J Clin Oncol 1999; 17:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32599/abstract/19\">",
"      O'Connor AR, Birchall JD, O'Connor SR, Bessell E. The value of 99mTc-MDP bone scintigraphy in staging primary lymphoma of bone. Nucl Med Commun 2007; 28:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32599/abstract/20\">",
"      Parker F, Jackson H. Primary reticulum cell sarcoma of bone. Surg Gynecol Obstet 1939; 68:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32599/abstract/21\">",
"      Baar J, Burkes RL, Bell R, et al. Primary non-Hodgkin's lymphoma of bone. A clinicopathologic study. Cancer 1994; 73:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32599/abstract/22\">",
"      Israel O, Mekel M, Bar-Shalom R, et al. Bone lymphoma: 67Ga scintigraphy and CT for prediction of outcome after treatment. J Nucl Med 2002; 43:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32599/abstract/23\">",
"      Heyning FH, Kroon HM, Hogendoorn PC, et al. MR imaging characteristics in primary lymphoma of bone with emphasis on non-aggressive appearance. Skeletal Radiol 2007; 36:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32599/abstract/24\">",
"      Buchmann I, Reinhardt M, Elsner K, et al. 2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial. Cancer 2001; 91:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32599/abstract/25\">",
"      Moog F, Bangerter M, Diederichs CG, et al. Extranodal malignant lymphoma: detection with FDG PET versus CT. Radiology 1998; 206:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32599/abstract/26\">",
"      Moog F, Kotzerke J, Reske SN. FDG PET can replace bone scintigraphy in primary staging of malignant lymphoma. J Nucl Med 1999; 40:1407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32599/abstract/27\">",
"      Rathmell AJ, Gospodarowicz MK, Sutcliffe SB, Clark RM. Localised lymphoma of bone: prognostic factors and treatment recommendations. The Princess Margaret Hospital Lymphoma Group. Br J Cancer 1992; 66:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32599/abstract/28\">",
"      Mendenhall NP, Jones JJ, Kramer BS, et al. The management of primary lymphoma of bone. Radiother Oncol 1987; 9:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32599/abstract/29\">",
"      Heyning FH, Hogendoorn PC, Kramer MH, et al. Primary non-Hodgkin's lymphoma of bone: a clinicopathological investigation of 60 cases. Leukemia 1999; 13:2094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32599/abstract/30\">",
"      Ferreri AJ, Reni M, Ceresoli GL, Villa E. Therapeutic management with adriamycin-containing chemotherapy and radiotherapy of monostotic and polyostotic primary non-Hodgkin's lymphoma of bone in adults. Cancer Invest 1998; 16:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32599/abstract/31\">",
"      Marshall DT, Amdur RJ, Scarborough MT, et al. Stage IE primary non-Hodgkin's lymphoma of bone. Clin Orthop Relat Res 2002; :216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32599/abstract/32\">",
"      Fairbanks RK, Bonner JA, Inwards CY, et al. Treatment of stage IE primary lymphoma of bone. Int J Radiat Oncol Biol Phys 1994; 28:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32599/abstract/33\">",
"      Fidias P, Spiro I, Sobczak ML, et al. Long-term results of combined modality therapy in primary bone lymphomas. Int J Radiat Oncol Biol Phys 1999; 45:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32599/abstract/34\">",
"      Ramadan KM, Shenkier T, Sehn LH, et al. A clinicopathological retrospective study of 131 patients with primary bone lymphoma: a population-based study of successively treated cohorts from the British Columbia Cancer Agency. Ann Oncol 2007; 18:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32599/abstract/35\">",
"      Beal K, Allen L, Yahalom J. Primary bone lymphoma: treatment results and prognostic factors with long-term follow-up of 82 patients. Cancer 2006; 106:2652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32599/abstract/36\">",
"      Catlett JP, Williams SA, O'Connor SC, et al. Primary lymphoma of bone: an institutional experience. Leuk Lymphoma 2008; 49:2125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32599/abstract/37\">",
"      Power DG, McVey GP, Korpanty G, et al. Primary bone lymphoma: single institution case series. Ir J Med Sci 2008; 177:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32599/abstract/38\">",
"      Ford DR, Wilson D, Sothi S, et al. Primary bone lymphoma--treatment and outcome. Clin Oncol (R Coll Radiol) 2007; 19:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32599/abstract/39\">",
"      Alencar A, Pitcher D, Byrne G, Lossos IS. Primary bone lymphoma--the University of Miami experience. Leuk Lymphoma 2010; 51:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32599/abstract/40\">",
"      Christie D, Dear K, Le T, et al. Limited chemotherapy and shrinking field radiotherapy for Osteolymphoma (primary bone lymphoma): results from the trans-Tasman Radiation Oncology Group 99.04 and Australasian Leukaemia and Lymphoma Group LY02 prospective trial. Int J Radiat Oncol Biol Phys 2011; 80:1164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32599/abstract/41\">",
"      Link MP, Donaldson SS, Berard CW, et al. Results of treatment of childhood localized non-Hodgkin's lymphoma with combination chemotherapy with or without radiotherapy. N Engl J Med 1990; 322:1169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32599/abstract/42\">",
"      Link MP, Shuster JJ, Donaldson SS, et al. Treatment of children and young adults with early-stage non-Hodgkin's lymphoma. N Engl J Med 1997; 337:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32599/abstract/43\">",
"      Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 2007; 25:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32599/abstract/44\">",
"      Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25:579.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4737 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-FDF33D9AD5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_53_32599=[""].join("\n");
var outline_f31_53_32599=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2982957\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Plain films",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Computed tomography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - MRI findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Positron emission tomography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      STAGING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Adults",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Chemotherapy with or without radiation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Surgical intervention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Patterns of relapse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2982957\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/4737\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4737|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?37/61/38878\" title=\"diagnostic image 1\">",
"      Lymphoma bone Xray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?31/19/32063\" title=\"diagnostic image 2\">",
"      Lymphoma bone MRI 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?25/1/25631\" title=\"diagnostic image 3\">",
"      Lymphoma bone MRI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4737|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?32/23/33143\" title=\"picture 1\">",
"      Lymphoma bone histology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?7/31/7670\" title=\"picture 2\">",
"      Primary lymphoma bone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?31/50/32559\" title=\"picture 3\">",
"      Lymphoma bone CT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/4737|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?36/59/37819\" title=\"table 1\">",
"      Ann Arbor system in lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?29/27/30140\" title=\"table 2\">",
"      NHL treatment response criteria",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/53/35673?source=related_link\">",
"      Bone tumors: Diagnosis and biopsy techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/61/27610?source=related_link\">",
"      Clinical presentation and diagnosis of non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/45/24282?source=related_link\">",
"      Epidemiology, clinical manifestations, pathologic features, and diagnosis of diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/18/15658?source=related_link\">",
"      Initial evaluation and staging of non-Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/45/26330?source=related_link\">",
"      Initial treatment of advanced stage diffuse large B cell lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/17/21785?source=related_link\">",
"      Radiation-related risks of imaging studies",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_53_32600="Thin-cap fibroatheroma";
var content_f31_53_32600=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F52661&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F52661&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 620px\">",
"   <div class=\"ttl\">",
"    Thin-cap fibroatheroma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 600px; height: 327px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Representative images of a thin-cap fibroatheroma, stained by hematoxylin and eosin, Movat pentachrome, and antibody against CD68 (recognition of lesional macrophages). Low-power views show prominent necrotic cores and overlying thin fibrous caps; the boxed areas represent the corresponding high-power views below. The thin fibrous cap is infiltrated by macrophages.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Finn AV, Nakano M, Narula J. Concept of vulnerable/unstable plaque. Arterioscler Thromb Vasc Biol 2010; 30:1282. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_53_32600=[""].join("\n");
var outline_f31_53_32600=null;
var title_f31_53_32601="Hysteroscopic myomectomy";
var content_f31_53_32601=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hysteroscopic myomectomy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/53/32601/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/53/32601/contributors\">",
"     Linda D Bradley, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/53/32601/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/53/32601/contributors\">",
"     Tommaso Falcone, MD, FRCSC, FACOG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/53/32601/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/53/32601/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/53/32601/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 31, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Uterine leiomyomas (fibroids) are the most common pelvic tumor in women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32601/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Abnormal uterine bleeding, the most common symptom associated with fibroids, is most frequent in women with tumors that abut the endometrium, including submucosal and some intramural fibroids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32601/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. This is likely due to distortion of the uterine cavity and an increase in the bleeding surface of the endometrium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32601/abstract/6\">",
"     6",
"    </a>",
"    ]. Submucosal tumors, which derive from myometrial cells just below the endometrium, account for approximately 15 to 20 percent of fibroids.",
"   </p>",
"   <p>",
"    Historically, hysterotomy or hysterectomy was performed to remove submucosal leiomyomas. This has been largely replaced by hysteroscopic myomectomy, a minimally invasive surgical procedure that effectively and safely removes these lesions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32601/abstract/4,7\">",
"     4,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hysteroscopic myomectomy is reviewed here. General principles of hysteroscopy and abdominal approaches to myomectomy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/17/9498?source=see_link\">",
"     \"Overview of hysteroscopy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/24/16775?source=see_link\">",
"     \"Prolapsed uterine leiomyoma (fibroid)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/3/12346?source=see_link\">",
"     \"Abdominal myomectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATIENT SELECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hysteroscopic myomectomy is performed for intracavitary fibroids, ie, submucosal and some intramural leiomyomas for which most of the fibroid protrudes into the uterine cavity. Appropriate candidates for hysteroscopic myomectomy are women with the following characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Symptomatic uterine fibroid(s)",
"     </li>",
"     <li>",
"      It is feasible to remove the fibroid(s) hysteroscopically",
"     </li>",
"     <li>",
"      An abdominal approach is not required to remove additional fibroids in other locations (eg, intramural or subserosal) or treat other pathology",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For women who are candidates for hysteroscopic myomectomy, this procedure is preferred over an abdominal approach, particularly laparotomy, for the following reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Outpatient procedure",
"     </li>",
"     <li>",
"      Minimal recovery time",
"     </li>",
"     <li>",
"      Decreased perioperative morbidity",
"     </li>",
"     <li>",
"      Minimal or no scarring of myometrium",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common indications for hysteroscopic myomectomy in the setting of intracavitary fibroids are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Abnormal uterine bleeding",
"     </li>",
"     <li>",
"      Recurrent pregnancy loss",
"     </li>",
"     <li>",
"      Infertility",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The effects of leiomyomas on reproductive function are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/60/30662?source=see_link&amp;anchor=H4#H4\">",
"     \"Reproductive issues in women with uterine leiomyomas (fibroids)\", section on 'Infertility and miscarriage'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Infrequent indications for hysteroscopic myomectomy include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Dysmenorrhea",
"     </li>",
"     <li>",
"      Leukorrhea",
"     </li>",
"     <li>",
"      Necrotic leiomyoma following uterine fibroid embolization",
"     </li>",
"     <li>",
"      Histologic evaluation of intracavitary lesions with uncertain findings on pelvic imaging",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Hysteroscopic myomectomy is also performed in selected patients with intracavitary fibroids who have conditions that are more commonly attributed to etiologies other than fibroids. In these women, hysteroscopic myomectomy is performed when other therapies have failed or it is reasonable to attribute symptoms to an intracavitary fibroid. Such conditions include: dysmenorrhea, leukorrhea, or a history of preterm delivery, postpartum hemorrhage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32601/abstract/8\">",
"     8",
"    </a>",
"    ], or a puerperal infection arising in or exacerbated by a submucosal fibroid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32601/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hysteroscopic myomectomy is contraindicated in women in whom hysteroscopic surgery is contraindicated (eg, active pelvic infection, intrauterine pregnancy, cervical or uterine cancer). Medical comorbidities (eg, coronary heart disease, bleeding diathesis) are also potential contraindications to hysteroscopic surgery. However, since this is a minimally invasive procedure, it is contraindicated in few women. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41735?source=see_link\">",
"     \"Overview of the principles of medical consultation and perioperative medicine\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Leiomyoma characteristics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who are appropriate candidates for hysteroscopic myomectomy must conform to appropriate indications and contraindications, but also must have fibroid characteristics that are amenable to this technique. Hysteroscopic myomectomy removes fibroids that have an intracavitary component (",
"    <a class=\"graphic graphic_figure graphicRef53241 \" href=\"mobipreview.htm?30/16/30978\">",
"     figure 1",
"    </a>",
"    ). Removal of fibroids that penetrate into the myometrium, are large, or are sessile takes longer, has the potential for increased perioperative complications, and may result in incomplete fibroid resection. In addition, for women with additional fibroids that are intramural or subserosal or who have other uterine pathology (eg, adenomyosis), hysteroscopic myomectomy may not provide symptomatic relief.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Myometrial penetration",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women with symptomatic fibroids, we suggest hysteroscopic myomectomy only for fibroids that are completely within the endometrial cavity or extend less than 50 percent into the myometrium. Removal of fibroids with deeper myometrial involvement requires advanced hysteroscopic skills or myomectomy using laparotomy or laparoscopy.",
"   </p>",
"   <p>",
"    The most commonly used classification system for the extent of myometrial involvement of a fibroid was described by the European Society of Hysteroscopy (ESH) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32601/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Type 0 - completely within the endometrial cavity",
"     </li>",
"     <li>",
"      Type I - extend less than 50 percent into the myometrium",
"     </li>",
"     <li>",
"      Type II - extend 50 percent or more within the myometrium",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Observational studies support the ability of the ESH system to predict complete fibroid resection; reported rates of complete resection rates by type were: type 0 (96 to 97 percent), type I (86 to 90 percent), and type II (61 to 83 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32601/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. In addition, depth of myometrial penetration appears to correlate with the volume of distension fluid absorbed. This was illustrated in a series of 339 hysteroscopic myomectomies that reported that the volume of fluid absorbed during the procedure increased significantly with the degree of myometrial penetration (type 0: 450 mL; type I 957 mL; type II 1682 mL) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32601/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the ESH system considers only the degree of penetration of the submucous myoma in the myometrium. Another classification system was proposed in 2005, which uses transvaginal ultrasound (TVUS) or magnetic resonance imaging (MRI) to assess the degree of penetration in the myometrium, as well as other fibroid characteristics: size, distance of the base along the uterine wall, and portion of the cavity in which the fibroid is located [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32601/abstract/13\">",
"     13",
"    </a>",
"    ]. Further studies are needed to validate this classification system.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Leiomyoma size",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hysteroscopic resection of large fibroids may involve increased perioperative complications",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    require more than one procedure for symptomatic relief. The definition of large is not well established. Only one prospective study of 122 women examined the effect of fibroid size; the risk of subsequent fibroid-related surgery within four years was significantly lower in women with fibroids that were &le;3 cm versus 4 cm or more (10 versus 60 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32601/abstract/14\">",
"     14",
"    </a>",
"    ]. Increasing size of fibroid requires exquisite hysteroscopic skill, complete understanding of fluid management, ability to quickly remove myoma chip fragments that might preclude surgical visualization, and techniques to decrease risk of uterine perforation when chip fragments are removed.",
"   </p>",
"   <p>",
"    There are no high quality data regarding the size",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    number of intramural or subserosal fibroids that preclude using a hysteroscopic approach. Physician skills ultimately determine the maximal size or number of fibroids that can be removed. For leiomyomas that are multiple or are &gt;3 cm, it is prudent to include in the informed consent the possibility of a two-stage procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Presence of other leiomyomas or adenomyosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many women have intracavitary fibroids in combination with fibroids in other locations (eg, intramural, subserosal). As the volume of additional fibroids increases, the surgeon must decide whether isolated removal of the intracavitary fibroid(s) will provide adequate treatment or if a laparoscopic or abdominal approach to myomectomy or a hysterectomy is preferable. Other factors that influence the choice of surgical approach include: desire for future fertility and presence of other pathology.",
"   </p>",
"   <p>",
"    The greater the volume of additional fibroids, the greater the likelihood that symptomatic relief will be provided only by a laparoscopic or abdominal approach to myomectomy and the less likely that isolated removal of intracavitary fibroids will provide symptomatic relief.",
"   </p>",
"   <p>",
"    Patients with fibroids that are both intracavitary and in other locations who have bulk symptoms (abdominal pain, pressure, or distension; urinary urgency, frequency, or retention; or constipation) are not likely to benefit from hysteroscopic resection alone.",
"   </p>",
"   <p>",
"    On the other hand, women without bulk symptoms and normal or slightly enlarged uterine size who have heavy uterine bleeding or conditions that appear to derive specifically from the presence of an intracavitary lesion, such as recurrent pregnancy loss or fibroid-associated leukorrhea, may benefit from the isolated removal of an intracavitary myoma, even if other leiomyomas are present.",
"   </p>",
"   <p>",
"    Women with abnormal uterine bleeding or dysmenorrhea who have both adenomyosis and intracavitary fibroids are also likely to have persistent symptoms after hysteroscopic myomectomy. These women may require a medical therapy alone or in combination with hysteroscopic myomectomy, or a hysterectomy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/35/27191?source=see_link\">",
"     \"Uterine adenomyosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For women with symptoms of abnormal uterine bleeding or dysmenorrhea who have an intracavitary fibroid in combination with diffuse adenomyosis, a hysteroscopic myomectomy is unlikely to provide complete symptomatic relief. However, patients with focal adenomyosis and normal uterine size should be offered hysteroscopic myomectomy; such patients should be counseled preoperatively regarding the limited evidence regarding outcome of this procedure among women with these two uterine pathologies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PREOPERATIVE EVALUATION AND PREPARATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preoperative evaluation and preparation are generally the same as for other hysteroscopic procedures. Issues specific to hysteroscopic myomectomy are presented here. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/17/9498?source=see_link&amp;anchor=H16#H16\">",
"     \"Overview of hysteroscopy\", section on 'Preoperative evaluation and preparation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Informed consent",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with symptomatic intracavitary fibroids should be counseled about other medical, interventional radiologic, and surgical options for treatment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/41/20122?source=see_link&amp;anchor=H16#H16\">",
"     \"Chronic menorrhagia or anovulatory uterine bleeding\", section on 'Medical therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/14/18666?source=see_link\">",
"     \"Overview of treatment of uterine leiomyomas (fibroids)\"",
"    </a>",
"    .) Women should be counseled about potential complications of the procedure and about the likelihood of recurrence of fibroids or symptoms (see",
"    <a class=\"local\" href=\"#H35\">",
"     'Complications'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H43\">",
"     'Recurrence of leiomyomas or bleeding symptoms'",
"    </a>",
"    below). Women with intracavitary myomas that are multiple, broad-based, large (&gt;3 cm),",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    penetrate into the myometrium should be advised that a second procedure may be necessary to fully remove all myomas (see",
"    <a class=\"local\" href=\"#H29\">",
"     'Two-step procedures'",
"    </a>",
"    below). This discussion should be documented on the surgical consent form and in the medical record.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;A thorough history is important to determine which fibroid-related symptoms are present (eg, heavy uterine bleeding, bulk symptoms) and whether these symptoms affect the patient's quality of life.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Evaluation of the uterus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of the uterus and cervix for fibroids (both submucosal and at other locations) or other pathology (eg, adenomyosis, endometrial polyp) with pelvic imaging or diagnostic hysteroscopy are essential prior to hysteroscopic myomectomy. Knowledge of these fibroid characteristics prior to surgery helps to select appropriate patients, as well as to prepare for or prevent blood loss (eg, measurement of preoperative hematocrit, preoperative endometrial preparation) and to ensure that the appropriate instruments and surgical expertise are available (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Leiomyoma characteristics'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H13\">",
"     'Preoperative medications'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    We suggest saline infusion sonography (SIS) where available, since it is a single modality that can evaluate the relationship of a leiomyoma to both the endometrial cavity and the myometrium. An alternative is to use a combination of office-based diagnostic hysteroscopy and TVUS. Hysteroscopy can define the extent to which a fibroid protrudes into the uterine cavity and TVUS can define the depth of myometrial penetration. It is useful for the surgeon to view the TVUS images to establish whether a hysteroscopic approach is feasible. MRI defines leiomyoma position well, but is prohibitively expensive to use routinely for this indication. Hysterosalpingography and computed tomography have limited use in delineating fibroid location. The use of pelvic imaging for diagnosis of leiomyomas is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/17/6426?source=see_link&amp;anchor=H11#H11\">",
"     \"Epidemiology, clinical manifestations, diagnosis, and natural history of uterine leiomyomas (fibroids)\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition, any woman with abnormal uterine bleeding at risk for endometrial hyperplasia or cancer should undergo evaluation of the endometrium prior to hysteroscopic myomectomy (",
"    <a class=\"graphic graphic_table graphicRef58600 \" href=\"mobipreview.htm?18/38/19052\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/53/38744?source=see_link\">",
"     \"Evaluation of the endometrium for malignant or premalignant disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Preoperative medications",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Prophylactic antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibiotics are not indicated during hysteroscopy for prevention of surgical site infection or endocarditis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/55/39800?source=see_link\">",
"     \"Overview of preoperative evaluation and preparation for gynecologic surgery\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/36/585?source=see_link\">",
"     \"Antimicrobial prophylaxis for bacterial endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     GnRH agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gonadotropin releasing hormone agonists (GnRHa) decrease the size of large fibroids; however, after use of these agents, it is more difficult to dissect fibroids from the surrounding capsule. While many surgeons use these agents, particularly for large fibroids (&gt;3 cm) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32601/abstract/1\">",
"     1",
"    </a>",
"    ], we prefer not to use GnRHa, since there are no high quality data that they make complete resection possible for large fibroids, or reduce intraoperative blood loss or distention fluid absorption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32601/abstract/12,15-18\">",
"     12,15-18",
"    </a>",
"    ]. In addition, they result in vasomotor symptoms and may lead to cervical stenosis (an antiestrogenic effect) or profuse vaginal hemorrhage (due to GnRHa-induced estrogen flare) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32601/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. The exception to this is for temporary cessation of menses in patients with severe anemia that may preclude surgery, or in whom intravenous iron therapy is contraindicated.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/0/26629?source=see_link\">",
"     Danazol",
"    </a>",
"    , another antiestrogenic agent, is not recommended since a randomized trial found that it did not reduce operative duration or fluid deficit and the adverse effects are poorly tolerated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32601/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Vasopressin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vasopressin intracervical injection is an option for decreasing blood loss during hysteroscopic myomectomy. Injection of vasopressin into the cervical stroma was found to decrease blood loss and absorption of distension fluid during hysteroscopic myomectomy or endometrial resection in one randomized trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32601/abstract/21\">",
"     21",
"    </a>",
"    ]. Although generally well tolerated, vasopressin injection must be performed with caution (by aspirating and confirming the absence of blood prior to each injection), since intravascular injection or absorption has been associated with profound hypertension, bradycardia, and intraoperative mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32601/abstract/22\">",
"     22",
"    </a>",
"    ]. There are few data that evaluate the risks versus benefits of the use of vasopressin for hysteroscopic myomectomy.",
"   </p>",
"   <p>",
"    We routinely use vasopressin prior to hysteroscopic myomectomy; we mix 20 units in 100 mL of normal saline, and inject into the cervical stroma in 5 mL aliquots at the 12, 3, 6, and 9 o'clock positions around the cervix. It can be given every 30 to 45 minutes, if bleeding is encountered or the procedure is prolonged. An additional benefit of vasopressin is that it facilitates cervical dilation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32601/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/17/9498?source=see_link&amp;anchor=H32#H32\">",
"     \"Overview of hysteroscopy\", section on 'Cervical stenosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Cervical preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cervical dilation can be facilitated with use of preoperative",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/41/662?source=see_link\">",
"     misoprostol",
"    </a>",
"    or laminaria. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/17/9498?source=see_link&amp;anchor=H20#H20\">",
"     \"Overview of hysteroscopy\", section on 'Cervical preparation and dilation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hysteroscopic myomectomy is performed under general or regional anesthesia. In addition, a paracervical block is sometimes performed to provide postoperative analgesia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/17/9498?source=see_link&amp;anchor=H23#H23\">",
"     \"Overview of hysteroscopy\", section on 'Anesthesia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     INSTRUMENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advances in operative technology have greatly improved the performance of hysteroscopic myomectomy since it was first performed in 1976 by Neuwirth and Amin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32601/abstract/24\">",
"     24",
"    </a>",
"    ]. Surgical innovations have improved visualization and decreased risk of fluid-related complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The wire loop with a monopolar or bipolar resectoscope is the most commonly used instrument for hysteroscopic myomectomy (",
"    <a class=\"graphic graphic_picture graphicRef55853 \" href=\"mobipreview.htm?14/35/14901\">",
"     picture 1",
"    </a>",
"    ). Most gynecologists are familiar with this technique and the equipment is cost-effective and widely available. If a monopolar device is used, a non-electrolytic solution is used (eg, 1.5 percent glycine). If a bipolar device is used, the fluid medium is isotonic saline or Ringer's lactate solution [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32601/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/26/22951?source=see_link&amp;anchor=H4#H4\">",
"     \"Hysteroscopy: Managing fluid and gas distending media\", section on 'Fluid media'",
"    </a>",
"    .) As an adjunct to this technique, hysteroscopic scissors can be used for small pedunculated fibroids or fragments that remain attached to the uterine wall and are not easily removed with the loop.",
"   </p>",
"   <p>",
"    New technologies, such as vaporization electrodes and hysteroscopic morcellators, have been introduced. The goal of these techniques is to make resection of fibroids easier. However, these devices are expensive and additional training is required. Vaporization electrodes (eg, VaporTrode&reg;, Force FX&trade;) operate at a higher power density (120 to 220 watts versus 60 to 120 watts with a monopolar resectoscope) and vaporize the tissue. This eliminates accumulation of tissue fragments that can occlude the view; however, it also prohibits evaluation of the tissue for pathology. In addition, vaporization may lead to the formation of bubbles in the distension fluid, thereby interfering with visualization.",
"   </p>",
"   <p>",
"    The vaporization technique should be avoided at the cornua and isthmus, since these anatomic regions are thinner and at increased risk of perforation, bowel burns, and intraperitoneal injuries. With the higher power settings used, two dispersive pads should be placed to ground the patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32601/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another option for this procedure is a hysteroscopic morcellator (Intra Uterine Morcellator), which has a rotary blade for resection and suction tubing to remove tissue fragments. Comparative studies have reported that myomectomy duration was 8 to 26 minutes shorter with the Intra Uterine Morcellator versus a resectoscope [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32601/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. The disadvantage for the hysteroscopic morcellators is that they cannot cauterize bleeding vessels. The hysteroscopic morcellator is also not designed to treat deeper myomas, and thus, is limited to women with hysteroscopic type 0 leiomyomas. Since myomas that appear to be type 0 upon preoperative evaluation may \"sink\" deeper into the myometrium during surgery and may not be retrieved with a morcellating device, the optimal situation is for a surgeon to have access to both the wire loop and morcellator.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Tissue removal and fluid control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of a hysteroscope with a continuous flow operative sheath helps to clear blood from the uterine cavity and thus improves visualization. In addition, some operative sheaths aspirate pieces of tissue from the uterine cavity to remove debris or retrieve specimens for pathologic evaluation (eg, Chip E-Vac, hysteroscopic morcellator). This allows removal of large debris while maintaining clear visualization.",
"   </p>",
"   <p>",
"    Hysteroscopic myomectomy may be associated with a risk of excessive absorption of distending fluid. Continuous fluid monitoring is necessary throughout the procedure. Automated fluid pump and monitoring systems are preferable to manual techniques [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32601/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/26/22951?source=see_link&amp;anchor=H7#H7\">",
"     \"Hysteroscopy: Managing fluid and gas distending media\", section on 'Inflow and monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     PROCEDURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Positioning, sterile preparation, and cervical dilation are performed in the standard fashion for hysteroscopy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/17/9498?source=see_link&amp;anchor=H24#H24\">",
"     \"Overview of hysteroscopy\", section on 'Procedure'",
"    </a>",
"    .) Close attention to the distension fluid deficit is critical to avoid complications of excessive fluid absorption. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/26/22951?source=see_link\">",
"     \"Hysteroscopy: Managing fluid and gas distending media\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Wire loop technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;This section will describe the wire loop resectoscope technique, which is the most commonly used for hysteroscopic myomectomy. This technique works well for most Intracavitary leiomyomas, those that protrude entirely or more than 50 percent of their mass into the uterine cavity (type 0 or 1) (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Myometrial penetration'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Insert the resectoscope through the cervix.",
"     </li>",
"     <li>",
"      After distension with fluid, inspect the uterine cavity. Note the size and location of the fibroids and whether they are sessile or pedunculated.",
"     </li>",
"     <li>",
"      We set a monopolar resectoscope to a cutting current of 60 to 120 watts; fibroids that are calcified may require a current up to 120 watts. Bipolar technology uses the default setting for both cutting and hemostasis. The wire loop should easily pass through the tissue. If it does not, the power setting is increased to prevent tissue adherence to the wire loop.",
"     </li>",
"     <li>",
"      Begin incising at the most cephalad surface of the myoma (",
"      <a class=\"graphic graphic_figure graphicRef58947 \" href=\"mobipreview.htm?38/20/39234\">",
"       figure 2",
"      </a>",
"      )&nbsp;(",
"      <a class=\"graphic graphic_picture graphicRef61871 \" href=\"mobipreview.htm?15/8/15503\">",
"       picture 2",
"      </a>",
"      ). For a pedunculated fibroid, the loop electrode can be used to cut directly through the base.",
"     </li>",
"     <li>",
"      Bring the resectoscope loop towards the surgeon using the spring mechanism of the loop alone or by moving the entire resectoscope towards the surgeon. To avoid injury, it is important to keep the loop in view at all times and activate the loop only when moving it towards the operator.",
"     </li>",
"     <li>",
"      Repeat this motion until the fibroid has been resected to the level of the surrounding endometrium.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Tissue obtained should be sent for pathologic evaluation. The surgically disrupted area will become covered with newly proliferated endometrium postoperatively.",
"   </p>",
"   <p>",
"    During hysteroscopic wire loop resection, the edges of the fibroid tend to fall inward as the middle is resected, thus increasing the panoramic view. It is more efficient to continue resection until fibroid fragments, or \"chips,\" preclude further visualization. At that point, carefully remove the chips (",
"    <a class=\"graphic graphic_picture graphicRef53091 \" href=\"mobipreview.htm?0/59/951\">",
"     picture 3",
"    </a>",
"    ). This can be accomplished using the inactivated wire loop or blindly with a",
"    <span class=\"nowrap\">",
"     polyp/myoma",
"    </span>",
"    forceps or suction curette; another option is to remove the inner sheath of the resectoscope to facilitate the egress of tissue chips. As noted in a preceding section, some surgical systems evacuate chips (Chip E-Vac, hysteroscopic morcellator) (see",
"    <a class=\"local\" href=\"#H21\">",
"     'Tissue removal and fluid control'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    Occasionally, as the fibroid is cut, the previously round myoma becomes more irregularly shaped, and can be grasped bluntly and avulsed with",
"    <span class=\"nowrap\">",
"     polyp/myoma",
"    </span>",
"    forceps. If this is done, hysteroscopic reinspection is imperative to ensure complete resection and hemostasis. Excessive traction blindly with the avulsing technique should be avoided to decrease the risk of uterine eversion, perforation, or injury to surrounding intraabdominal viscera.",
"   </p>",
"   <p>",
"    In the event of heavy perioperative bleeding, the endometrium should be reinspected with the hysteroscope. Small areas of bleeding can be desiccated with the resectoscope using coagulating current. When using a monopolar system, set the coagulating current at 60 to 80 watts. With bipolar technology, the coagulating current is set to the default setting. Additional measures are described below (see",
"    <a class=\"local\" href=\"#H38\">",
"     'Excessive perioperative bleeding'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Techniques for challenging resections",
"    </span>",
"    &nbsp;&mdash;&nbsp;When a leiomyoma is large (&gt;3 cm), sessile, or penetrates into the myometrium, advanced hysteroscopy skills are necessary to differentiate the fibroid from the myometrium and apply techniques to achieve complete fibroid resection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32601/abstract/30\">",
"     30",
"    </a>",
"    ]. Excessive resection of the myometrium will increase blood loss, fluid absorption, and myometrial scar tissue, and potentially result in uterine perforation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Distinguishing myoma versus myometrium",
"    </span>",
"    &nbsp;&mdash;&nbsp;To distinguish the border between the leiomyoma and surrounding myometrium, a surgeon should recognize differences in texture and appearance between the two types of tissue. The fibroid is firm, with a whorled appearance, while the myometrium is soft and the muscular fascicles are apparent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Enucleating a myoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Techniques for enucleating the fibroid from its pseudocapsule include placing the wire loop electrode strategically behind the myoma to elevate and separate the myoma (",
"    <a class=\"graphic graphic_picture graphicRef66817 \" href=\"mobipreview.htm?17/63/18416\">",
"     picture 4",
"    </a>",
"    ). Initially, the inactive electrode is used to elevate the leiomyoma out of the pseudocapsule, followed by using the activated electrode to incise the myoma and facilitate its retrieval. Another technique is to use the inactive loop to partially enucleate the fibroid with mechanical dissection and then deflate the uterine cavity to cause further protrusion of the myoma (see",
"    <a class=\"local\" href=\"#H27\">",
"     'Use of uterine contractions'",
"    </a>",
"    below). The wire loop technique, described in a preceding section, is then resumed to achieve complete resection (see",
"    <a class=\"local\" href=\"#H23\">",
"     'Wire loop technique'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Use of uterine contractions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Deflation of the uterine cavity refers to removing the operative hysteroscope and waiting for several minutes to permit myometrial contractions to cause extrusion of the myoma. When the hysteroscope is replaced, the surgeon will commonly see more of the myoma extruding into the cavity. Facilitation of uterine contractions with administration of a prostaglandin has been proposed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32601/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]; a series of 13 patients reported successful use of carboprost (125 mcg in 5 mL of saline, injected intracervically) for this purpose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32601/abstract/33\">",
"     33",
"    </a>",
"    ]. However, profound diarrhea and difficult uterine distention may be associated with carboprost.",
"   </p>",
"   <p>",
"    Uterine massage via bimanual examination or other techniques has also been described to help to extrude the remaining portion of a fibroid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32601/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Sonographic guidance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of intraoperative pelvic ultrasonography to delimit the endometrial, myometrial, and serosal boundaries can be useful, in our experience. The only study to evaluate this approach was a retrospective cohort study of 126 patients that reported that complete fibroid resection was more likely with sonographic versus laparoscopic guidance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32601/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Two-step procedures",
"    </span>",
"    &nbsp;&mdash;&nbsp;A two-step procedure is occasionally necessary for fibroids that are multiple, large, broad-based, or penetrate deeply within the myometrium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32601/abstract/37\">",
"     37",
"    </a>",
"    ]. The most common reason for this is that the initial procedure was halted when the maximal fluid absorption was reached. Such patients should be seen for a follow-up visit two to four months after the initial procedure to assess whether fibroid-related symptoms persist. If so, evaluation of the uterine cavity is repeated: the size, number, and location of the leiomyoma(s). With this information, the surgeon can offer appropriate management, whether hysteroscopic myomectomy or another treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     CONCOMITANT PROCEDURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Endometrial polypectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Removal of a coexisting endometrial polyp is standard practice at the time of hysteroscopic myomectomy. There are no data regarding the outcomes of such concurrent procedures. In our experience, removing both types of lesions during the same procedure does not increase operative duration or complications. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/10/7336?source=see_link\">",
"     \"Endometrial polyps\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Endometrial ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;In women who have abnormal uterine bleeding and do not plan a subsequent pregnancy, some surgeons perform a concomitant myomectomy and endometrial ablation or resection. It is uncertain whether this procedure is more effective at improving uterine bleeding symptoms than myomectomy alone.",
"   </p>",
"   <p>",
"    This topic is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/7/31866?source=see_link&amp;anchor=H30#H30\">",
"     \"An overview of endometrial ablation\", section on 'Concomitant procedures'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Hysteroscopic sterilization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who desire hysteroscopic sterilization and who have symptomatic intracavitary fibroids will need hysteroscopic myomectomy. Hysteroscopic sterilization and myomectomy can be done concurrently, however, bleeding, debris,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    endometrial edema from the myomectomy may also obscure the ostia. Patients interested in concomitant hysteroscopic sterilization and myomectomy should be scheduled for the procedure within one week after menses to decrease the difficulty in visualizing tubal ostia. There are no data regarding combining these two procedures. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/23/12665?source=see_link&amp;anchor=H7#H7\">",
"     \"Hysteroscopic sterilization\", section on 'Contraindications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     FOLLOW-UP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients experience postoperative cramping or light bleeding and some complain of vaginal discomfort.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     Acetaminophen",
"    </a>",
"    or nonsteroidal antiinflammatory drugs are usually adequate for postoperative pain control, if necessary. The patient may resume most normal activities within 24 hours and should follow standard postoperative instructions for gynecologic procedures. (See",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/27/28083?source=see_link\">",
"     \"Patient information: Care after gynecologic surgery (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We see patients for a follow-up visit four to six weeks postoperatively to assess for further complications and review pathology results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Series of 200 or more hysteroscopic myomectomy procedures report a complication rate of 0.8 to 2.6 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32601/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. In a retrospective series of 235 procedures, the complication rate was lower for procedures involving single versus multiple fibroids (1.4 versus 6.7 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32601/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Few large studies of hysteroscopic complications report specific complications for hysteroscopic myomectomy. General complications of hysteroscopy are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/17/9498?source=see_link&amp;anchor=H37#H37\">",
"     \"Overview of hysteroscopy\", section on 'Complications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Uterine perforation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extensive resection increases the risk of uterine perforation, but this complication is uncommon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32601/abstract/16\">",
"     16",
"    </a>",
"    ]. There are no data to suggest that laparoscopic guidance decreases the frequency of uterine perforation. Uterine perforation associated with hysteroscopy can be diagnosed by direct visualization of the defect, or suspected if visualization is obscured by blood. If electrosurgical energy, morcellation, or suction curettage were utilized during the procedure and perforation is suspected, the potential for visceral injury (eg, bowel, bladder) is increased. In such patients, immediate abdominal exploration should be performed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/19/4408?source=see_link&amp;anchor=H22#H22\">",
"     \"Uterine perforation during gynecologic procedures\", section on 'Criteria for surgical management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Excessive fluid absorption",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extensive endometrial or myometrial resection increases the risk of absorption of distension fluid, potentially resulting in hyponatremia or volume overload. A common reason for termination of a technically difficult procedure is excessive absorption of distension fluid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32601/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diagnosis and management of excessive fluid absorption are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/26/22951?source=see_link\">",
"     \"Hysteroscopy: Managing fluid and gas distending media\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/41/8858?source=see_link\">",
"     \"Hyponatremia following transurethral resection or hysteroscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Excessive perioperative bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Excessive bleeding was reported in 4 of 235 women in a retrospective series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32601/abstract/38\">",
"     38",
"    </a>",
"    ]; 4 of 94 women required perioperative blood transfusion in another series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32601/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If a patient has persistent bleeding, a size 16 French Foley catheter with a 30 mL balloon can be inserted into the uterine cavity and distended with 30 mL of sterile water. Over four to six hours, the catheter balloon is gradually deflated until empty and then removed while the bleeding is monitored. With the balloon removed, if bleeding is minimal, the patient can be discharged from the surgical unit. In one series of 216 resectoscope procedures, four women (1.9 percent) developed postoperative uterine bleeding and were successfully treated with this procedure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32601/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/17/9498?source=see_link&amp;anchor=H43#H43\">",
"     \"Overview of hysteroscopy\", section on 'Hemorrhage'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the patient continues to bleed briskly with the Foley bulb in place, the initial step is to administer intracervical vasopressin&nbsp;(see",
"    <a class=\"local\" href=\"#H16\">",
"     'Vasopressin'",
"    </a>",
"    above). If excessive bleeding persists, the patient is examined using a speculum and hysteroscope to assess for a cervical laceration or uterine perforation; if present, appropriate measures are taken to control bleeding (see",
"    <a class=\"local\" href=\"#H36\">",
"     'Uterine perforation'",
"    </a>",
"    above). If bleeding is significantly reduced, the patient is monitored in the operating room for 20 minutes to make sure that the bleeding does not recur. If bleeding persists after injection of vasopressin, the patient should be evaluated for anemia and coagulopathy, and treated if appropriate. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/18/43305?source=see_link&amp;anchor=H23#H23\">",
"     \"Management of hemorrhage in gynecologic surgery\", section on 'Medical stabilization'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h2\">",
"     Intrauterine adhesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Formation of intrauterine adhesions can interfere with fertility or menstruation. In studies in which women had a second look hysteroscopy after the initial hysteroscopic myomectomy report, the rates of this complication varied widely, from 0 to 46 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32601/abstract/15,38,41\">",
"     15,38,41",
"    </a>",
"    ]. The rate appears to be higher if more than one fibroid is resected (in one study, 31 percent for single versus 46 percent for multiple fibroids) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32601/abstract/15\">",
"     15",
"    </a>",
"    ]. Evaluation and treatment for intrauterine adhesions are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/31/26101?source=see_link\">",
"     \"Intrauterine adhesions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection is uncommon; it was reported in 2 of 128 women in one series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32601/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Outcomes after hysteroscopic surgery have been difficult to compare due to the lack of consistency across studies regarding the type of myoma treated, menopausal status, objective measurement of blood loss, complication rates, duration of follow-up, and rates of subsequent reoperation or pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32601/abstract/42\">",
"     42",
"    </a>",
"    ]. However, many studies and surgeons report high patient satisfaction, resolution of abnormal uterine bleeding, and a low rate of complications [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32601/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     Complete myoma resection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complete resection of a fibroid depends upon the extent of myometrial penetration, as noted in a preceding section (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Leiomyoma characteristics'",
"    </a>",
"    above). The rate of incomplete myoma resection ranges from 5 to 17 percent in retrospective series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32601/abstract/11,38\">",
"     11,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Incomplete myoma resection does not commit a patient to reoperation. In a series of 41 women with incomplete hysteroscopic resection of fibroids, only 44 percent underwent further fibroid-related surgery within three years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32601/abstract/11\">",
"     11",
"    </a>",
"    ]. In addition, in another series, at three-month follow-up, saline infusion sonohysterography revealed that incompletely resected fibroids had regressed in 21 of 38 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32601/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h2\">",
"     Recurrence of leiomyomas or bleeding symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recurrence rate of fibroids",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    abnormal uterine bleeding was approximately 20 percent in most studies in which women were followed for three or more years after hysteroscopic myomectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32601/abstract/14,40,44\">",
"     14,40,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Across all studies, 3 to 21 percent of women underwent subsequent surgery for fibroid-related complaints. In one study, the risk was highest in women with fibroids &gt;3 cm or when two or more fibroids were present [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32601/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h2\">",
"     Reproductive outcomes",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h3\">",
"     Infertility and recurrent pregnancy loss",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with cavity-distorting fibroids who undergo myomectomy are more likely to conceive a pregnancy; however, the effect on the risk of miscarriage is uncertain.",
"   </p>",
"   <p>",
"    In addition, observational studies have reported that the presence of intracavitary leiomyomas decreases pregnancy rates in women undergoing in vitro fertilization. Thus, many IVF units advise women with these lesions to undergo myomectomy.",
"   </p>",
"   <p>",
"    The effects of leiomyomas on reproductive function are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/60/30662?source=see_link&amp;anchor=H4#H4\">",
"     \"Reproductive issues in women with uterine leiomyomas (fibroids)\", section on 'Infertility and miscarriage'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h3\">",
"     Obstetric issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is not known whether hysteroscopic myomectomy affects placentation in subsequent pregnancies. In addition, there have been no case reports of uterine rupture after hysteroscopic myomectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32601/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?20/20/20804?source=see_link\">",
"       \"Patient information: Uterine fibroids (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hysteroscopic myomectomy is performed for intracavitary fibroids, ie, submucosal and some intramural leiomyomas for which most of the fibroid protrudes into the uterine cavity. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Patient selection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common indications for hysteroscopic myomectomy are abnormal uterine bleeding, recurrent pregnancy loss, and infertility. Hysteroscopic myomectomy is contraindicated in women in whom hysteroscopic surgery is contraindicated (eg, active pelvic infection, intrauterine pregnancy). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Indications'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Contraindications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women planning hysteroscopic myomectomy, we suggest preoperative evaluation of the uterus with saline infusion sonography (SIS). Use of both diagnostic hysteroscopy and transvaginal sonography is a reasonable option where SIS is not available. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Evaluation of the uterus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The following recommendations are for women with fibroid-associated symptoms who desire surgical treatment:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We suggest not performing hysteroscopic myomectomy in women with intracavitary fibroids that extend 50 percent or more into the myometrium (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Removal of fibroids with deep myometrial involvement requires advanced hysteroscopic skills or myomectomy using laparotomy or laparoscopy. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Myometrial penetration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with intracavitary fibroids in combination with three or more intramural or subserosal fibroids with a total volume of &gt;3 cm who have fibroid-associated bulk symptoms (abdominal or pelvic pressure or pain, urinary symptoms, constipation), we suggest myomectomy using laparotomy or laparoscopy rather than hysteroscopy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Isolated removal of intracavitary fibroids is reasonable in some women, such as those with menstrual aberrations only, recurrent miscarriage or fibroid-associated leukorrhea. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Presence of other leiomyomas or adenomyosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We suggest against use of gonadotropin releasing hormone agonists prior to hysteroscopic myomectomy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Use of these agents is reasonable in women with large fibroids (&gt;3 cm) who are willing to tolerate the vasomotor symptoms and by surgeons who find an operative benefit. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'GnRH agonists'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Potential complications of hysteroscopic myomectomy include: uterine perforation, excessive absorption of distension fluid with resultant hyponatremia or volume overload, excessive perioperative bleeding, intrauterine adhesions, and infection. (See",
"      <a class=\"local\" href=\"#H35\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Following hysteroscopic myomectomy, the recurrence rate of fibroids",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      abnormal uterine bleeding is approximately 20 percent. (See",
"      <a class=\"local\" href=\"#H43\">",
"       'Recurrence of leiomyomas or bleeding symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women with cavity-distorting fibroids who undergo myomectomy are more likely to conceive a pregnancy; however, the effect on the risk of miscarriage is uncertain. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/60/30662?source=see_link&amp;anchor=H4#H4\">",
"       \"Reproductive issues in women with uterine leiomyomas (fibroids)\", section on 'Infertility and miscarriage'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32601/abstract/1\">",
"      Buttram VC Jr, Reiter RC. Uterine leiomyomata: etiology, symptomatology, and management. Fertil Steril 1981; 36:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32601/abstract/2\">",
"      Serden SP, Brooks PG. Treatment of abnormal uterine bleeding with the gynecologic resectoscope. J Reprod Med 1991; 36:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32601/abstract/3\">",
"      Fraser IS, Critchley HO, Munro MG, et al. A process designed to lead to international agreement on terminologies and definitions used to describe abnormalities of menstrual bleeding. Fertil Steril 2007; 87:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32601/abstract/4\">",
"      Wegienka G, Baird DD, Hertz-Picciotto I, et al. Self-reported heavy bleeding associated with uterine leiomyomata. Obstet Gynecol 2003; 101:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32601/abstract/5\">",
"      Ben-Baruch G, Schiff E, Menashe Y, Menczer J. Immediate and late outcome of vaginal myomectomy for prolapsed pedunculated submucous myoma. Obstet Gynecol 1988; 72:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32601/abstract/6\">",
"      Di Spiezio Sardo A, Mazzon I, Bramante S, et al. Hysteroscopic myomectomy: a comprehensive review of surgical techniques. Hum Reprod Update 2008; 14:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32601/abstract/7\">",
"      Lefebvre G, Vilos G, Allaire C, et al. The management of uterine leiomyomas. J Obstet Gynaecol Can 2003; 25:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32601/abstract/8\">",
"      Akrivis Ch, Varras M, Bellou A, et al. Primary postpartum haemorrhage due to a large submucosal nonpedunculated uterine leiomyoma: a case report and review of the literature. Clin Exp Obstet Gynecol 2003; 30:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32601/abstract/9\">",
"      Mason TC, Adair J, Lee YC. Postpartum pyomyoma. J Natl Med Assoc 2005; 97:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32601/abstract/10\">",
"      Wamsteker K, Emanuel MH, de Kruif JH. Transcervical hysteroscopic resection of submucous fibroids for abnormal uterine bleeding: results regarding the degree of intramural extension. Obstet Gynecol 1993; 82:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32601/abstract/11\">",
"      Van Dongen H, Emanuel MH, Smeets MJ, et al. Follow-up after incomplete hysteroscopic removal of uterine fibroids. Acta Obstet Gynecol Scand 2006; 85:1463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32601/abstract/12\">",
"      Emanuel MH, Hart A, Wamsteker K, Lammes F. An analysis of fluid loss during transcervical resection of submucous myomas. Fertil Steril 1997; 68:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32601/abstract/13\">",
"      Lasmar RB, Barrozo PR, Dias R, Oliveira MA. Submucous myomas: a new presurgical classification to evaluate the viability of hysteroscopic surgical treatment--preliminary report. J Minim Invasive Gynecol 2005; 12:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32601/abstract/14\">",
"      Hart R, Moln&aacute;r BG, Magos A. Long term follow up of hysteroscopic myomectomy assessed by survival analysis. Br J Obstet Gynaecol 1999; 106:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32601/abstract/15\">",
"      Taskin O, Sadik S, Onoglu A, et al. Role of endometrial suppression on the frequency of intrauterine adhesions after resectoscopic surgery. J Am Assoc Gynecol Laparosc 2000; 7:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32601/abstract/16\">",
"      Propst AM, Liberman RF, Harlow BL, Ginsburg ES. Complications of hysteroscopic surgery: predicting patients at risk. Obstet Gynecol 2000; 96:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32601/abstract/17\">",
"      Perino A, Chianchiano N, Petronio M, Cittadini E. Role of leuprolide acetate depot in hysteroscopic surgery: a controlled study. Fertil Steril 1993; 59:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32601/abstract/18\">",
"      Mencaglia L, Tantini C. GnRH agonist analogs and hysteroscopic resection of myomas. Int J Gynaecol Obstet 1993; 43:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32601/abstract/19\">",
"      Campo S, Campo V, Gambadauro P. Short-term and long-term results of resectoscopic myomectomy with and without pretreatment with GnRH analogs in premenopausal women. Acta Obstet Gynecol Scand 2005; 84:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32601/abstract/20\">",
"      Indman PD. Hysteroscopic treatment of menorrhagia associated with uterine leiomyomas. Obstet Gynecol 1993; 81:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32601/abstract/21\">",
"      Phillips DR, Nathanson HG, Milim SJ, et al. The effect of dilute vasopressin solution on blood loss during operative hysteroscopy: a randomized controlled trial. Obstet Gynecol 1996; 88:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32601/abstract/22\">",
"      Hobo R, Netsu S, Koyasu Y, Tsutsumi O. Bradycardia and cardiac arrest caused by intramyometrial injection of vasopressin during a laparoscopically assisted myomectomy. Obstet Gynecol 2009; 113:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32601/abstract/23\">",
"      Phillips DR, Nathanson HG, Milim SJ, Haselkorn JS. The effect of dilute vasopressin solution on the force needed for cervical dilatation: a randomized controlled trial. Obstet Gynecol 1997; 89:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32601/abstract/24\">",
"      Neuwirth RS. A new technique for and additional experience with hysteroscopic resection of submucous fibroids. Am J Obstet Gynecol 1978; 131:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32601/abstract/25\">",
"      Varma R, Soneja H, Clark TJ, Gupta JK. Hysteroscopic myomectomy for menorrhagia using Versascope bipolar system: efficacy and prognostic factors at a minimum of one year follow up. Eur J Obstet Gynecol Reprod Biol 2009; 142:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32601/abstract/26\">",
"      Munro MG. Capacitive coupling: a comparison of measurements in four uterine resectoscopes. J Am Assoc Gynecol Laparosc 2004; 11:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32601/abstract/27\">",
"      van Dongen H, Emanuel MH, Wolterbeek R, et al. Hysteroscopic morcellator for removal of intrauterine polyps and myomas: a randomized controlled pilot study among residents in training. J Minim Invasive Gynecol 2008; 15:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32601/abstract/28\">",
"      Emanuel MH, Wamsteker K. The Intra Uterine Morcellator: a new hysteroscopic operating technique to remove intrauterine polyps and myomas. J Minim Invasive Gynecol 2005; 12:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32601/abstract/29\">",
"      Loffer FD, Bradley LD, Brill AI, et al. Hysteroscopic Fluid Monitoring Guidelines. J Am Assoc Gynecol Laparosc 2000; 7:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32601/abstract/30\">",
"      Betjes HE, Hanstede MM, Emanuel MH, Stewart EA. Hysteroscopic myomectomy and case volume hysteroscopic myomectomy performed by high- and low-volume surgeons. J Reprod Med 2009; 54:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32601/abstract/31\">",
"      Murakami T, Tamura M, Ozawa Y, et al. Safe techniques in surgery for hysteroscopic myomectomy. J Obstet Gynaecol Res 2005; 31:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32601/abstract/32\">",
"      Murakami T, Tachibana M, Hoshiai T, et al. Successful strategy for the hysteroscopic myomectomy of a submucous myoma arising from the uterine fundus. Fertil Steril 2006; 86:1513.e19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32601/abstract/33\">",
"      Indman PD. Use of carboprost to facilitate hysteroscopic resection of submucous myomas. J Am Assoc Gynecol Laparosc 2004; 11:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32601/abstract/34\">",
"      Vlahos NF. Hysteroscopic resection of a large submucosal fibroid using intermittent bimanual uterine massage and a bipolar resectoscope: a case report. J Reprod Med 2005; 50:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32601/abstract/35\">",
"      Hallez JP. Single-stage total hysteroscopic myomectomies: indications, techniques, and results. Fertil Steril 1995; 63:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32601/abstract/36\">",
"      Coccia ME, Becattini C, Bracco GL, et al. Intraoperative ultrasound guidance for operative hysteroscopy. A prospective study. J Reprod Med 2000; 45:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32601/abstract/37\">",
"      Marziani R, Mossa B, Ebano V, et al. Transcervical hysteroscopic myomectomy: long-term effects on abnormal uterine bleeding. Clin Exp Obstet Gynecol 2005; 32:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32601/abstract/38\">",
"      Polena V, Mergui JL, Perrot N, et al. Long-term results of hysteroscopic myomectomy in 235 patients. Eur J Obstet Gynecol Reprod Biol 2007; 130:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32601/abstract/39\">",
"      Jansen FW, Vredevoogd CB, van Ulzen K, et al. Complications of hysteroscopy: a prospective, multicenter study. Obstet Gynecol 2000; 96:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32601/abstract/40\">",
"      Derman SG, Rehnstrom J, Neuwirth RS. The long-term effectiveness of hysteroscopic treatment of menorrhagia and leiomyomas. Obstet Gynecol 1991; 77:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32601/abstract/41\">",
"      Touboul C, Fernandez H, Deffieux X, et al. Uterine synechiae after bipolar hysteroscopic resection of submucosal myomas in patients with infertility. Fertil Steril 2009; 92:1690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32601/abstract/42\">",
"      Myers ER, Barber MD, Gustilo-Ashby T, et al. Management of uterine leiomyomata: what do we really know? Obstet Gynecol 2002; 100:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32601/abstract/43\">",
"      Dueholm, M, Forman, A, Ingerslev, J. Regression of residual tissue after incomplete resection of submucous myomas. Gynaecol Endosc 1998; 7:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32601/abstract/44\">",
"      Vercellini P, Z&agrave;ina B, Yaylayan L, et al. Hysteroscopic myomectomy: long-term effects on menstrual pattern and fertility. Obstet Gynecol 1999; 94:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32601/abstract/45\">",
"      Ubaldi F, Tournaye H, Camus M, et al. Fertility after hysteroscopic myomectomy. Hum Reprod Update 1995; 1:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32601/abstract/46\">",
"      Kelly BA, Bright P, Mackenzie IZ. Does the surgical approach used for myomectomy influence the morbidity in subsequent pregnancy? J Obstet Gynaecol 2008; 28:77.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3314 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-60.18.131.125-8F74BD76B3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_53_32601=[""].join("\n");
var outline_f31_53_32601=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H48\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATIENT SELECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Leiomyoma characteristics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Myometrial penetration",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Leiomyoma size",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Presence of other leiomyomas or adenomyosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PREOPERATIVE EVALUATION AND PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Informed consent",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Evaluation of the uterus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Preoperative medications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Prophylactic antibiotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - GnRH agonists",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Vasopressin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Cervical preparation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Anesthesia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      INSTRUMENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Resection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Tissue removal and fluid control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Wire loop technique",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Techniques for challenging resections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Distinguishing myoma versus myometrium",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Enucleating a myoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Use of uterine contractions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Sonographic guidance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Two-step procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      CONCOMITANT PROCEDURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Endometrial polypectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Endometrial ablation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Hysteroscopic sterilization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      FOLLOW-UP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Uterine perforation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Excessive fluid absorption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Excessive perioperative bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      Intrauterine adhesions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      Complete myoma resection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      Recurrence of leiomyomas or bleeding symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      Reproductive outcomes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      - Infertility and recurrent pregnancy loss",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      - Obstetric issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/3314\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3314|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?30/16/30978\" title=\"figure 1\">",
"      Fibroid anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?38/20/39234\" title=\"figure 2\">",
"      Myomectomy with hysteroscope",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3314|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?14/35/14901\" title=\"picture 1\">",
"      Resectoscope instruments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?15/8/15503\" title=\"picture 2\">",
"      Hysterosc myomectomy loop",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?0/59/951\" title=\"picture 3\">",
"      Hysterosc myomectomy chips",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?17/63/18416\" title=\"picture 4\">",
"      Fibroid pseudocapsule",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3314|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?18/38/19052\" title=\"table 1\">",
"      Indications endometrial evaluat",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/3/12346?source=related_link\">",
"      Abdominal myomectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/7/31866?source=related_link\">",
"      An overview of endometrial ablation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/36/585?source=related_link\">",
"      Antimicrobial prophylaxis for bacterial endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/41/20122?source=related_link\">",
"      Chronic menorrhagia or anovulatory uterine bleeding",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/10/7336?source=related_link\">",
"      Endometrial polyps",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/17/6426?source=related_link\">",
"      Epidemiology, clinical manifestations, diagnosis, and natural history of uterine leiomyomas (fibroids)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/53/38744?source=related_link\">",
"      Evaluation of the endometrium for malignant or premalignant disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/41/8858?source=related_link\">",
"      Hyponatremia following transurethral resection or hysteroscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/23/12665?source=related_link\">",
"      Hysteroscopic sterilization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/26/22951?source=related_link\">",
"      Hysteroscopy: Managing fluid and gas distending media",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/31/26101?source=related_link\">",
"      Intrauterine adhesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/18/43305?source=related_link\">",
"      Management of hemorrhage in gynecologic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/17/9498?source=related_link\">",
"      Overview of hysteroscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/55/39800?source=related_link\">",
"      Overview of preoperative evaluation and preparation for gynecologic surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/48/41735?source=related_link\">",
"      Overview of the principles of medical consultation and perioperative medicine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/14/18666?source=related_link\">",
"      Overview of treatment of uterine leiomyomas (fibroids)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/27/28083?source=related_link\">",
"      Patient information: Care after gynecologic surgery (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?20/20/20804?source=related_link\">",
"      Patient information: Uterine fibroids (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/24/16775?source=related_link\">",
"      Prolapsed uterine leiomyoma (fibroid)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/60/30662?source=related_link\">",
"      Reproductive issues in women with uterine leiomyomas (fibroids)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/35/27191?source=related_link\">",
"      Uterine adenomyosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/19/4408?source=related_link\">",
"      Uterine perforation during gynecologic procedures",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_53_32602="Immunizations during pregnancy";
var content_f31_53_32602=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Immunizations during pregnancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/53/32602/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/53/32602/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/53/32602/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/53/32602/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/53/32602/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?31/53/32602/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?31/53/32602/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?31/53/32602/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Maternal immunization protects both the mother and fetus from the morbidity of certain infections. It can also provide the infant passive protection against infections acquired independently after birth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/1\">",
"     1",
"    </a>",
"    ]. Ideally, immunizations are given prior to conception, but administration during pregnancy is indicated in some situations.",
"   </p>",
"   <p>",
"    Nonimmune women are immunized during pregnancy when there is a high risk of exposure to an infection, the infection is hazardous to mother or fetus, and the immunizing agent is unlikely to cause harm. Despite maternal immunological adaptations to pregnancy, immunization of pregnant women appears to be as effective as in nonpregnant women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The Infectious Diseases Society of America has published general guidelines for immunization of pregnant women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Providers should be aware of immunizations routinely recommended for all pregnant women (tetanus, diphtheria, influenza) (see",
"      <a class=\"local\" href=\"#H16\">",
"       'Routine immunizations'",
"      </a>",
"      below).",
"     </li>",
"     <li>",
"      Providers should administer appropriate vaccines to pregnant women with medical or exposure indications that put them at risk for vaccine preventable infections (see",
"      <a class=\"local\" href=\"#H20\">",
"       'Selective immunization of high risk groups'",
"      </a>",
"      below).",
"     </li>",
"     <li>",
"      Following delivery, postpartum women should receive all recommended vaccines that could not be or were not administered during pregnancy (eg,",
"      <span class=\"nowrap\">",
"       measles/mumps/rubella,",
"      </span>",
"      varicella, Tetanus toxoids diphtheria acellular pertussis vaccine [Tdap]) (see",
"      <a class=\"local\" href=\"#H35\">",
"       'Postpartum immunization'",
"      </a>",
"      below).",
"     </li>",
"     <li>",
"      Providers should be aware of and follow contraindications and precautions for immunization of pregnant women.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Obstetrician-gynecologists are often the primary clinician for women of child-bearing age; as such, they are in a good position to screen for immunization status and to provide appropriate vaccinations. However, financial factors (eg, inadequate reimbursement, cost of storing vaccines) and knowledge about vaccine counseling, safety, and administration appear to be barriers to vaccine administration in",
"    <span class=\"nowrap\">",
"     OB/GYN",
"    </span>",
"    offices [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The specific immunization guidelines in this review are based upon recommendations for residents of the United States by the Advisory Committee on Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/6\">",
"     6",
"    </a>",
"    ]. ACIP statements are published in the Morbidity and Mortality Weekly Report (MMWR) and may be obtained from the CDC's Immunization Hotline (1-800-232-2522) or downloaded from the CDC's website (",
"    <a class=\"external\" href=\"file://www.cdc.gov/vaccines/recs/schedules/adult-schedule.htm\">",
"     www.cdc.gov/vaccines/recs/schedules/adult-schedule.htm",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TYPES OF IMMUNIZATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Toxoids, inactivated vaccines, immune globulin preparations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Toxoids, inactivated virus vaccines, immune globulin preparations, and live viral and bacterial vaccines can augment an individual's immune status. All but the live viral or bacterial vaccines are generally considered safe for administration to pregnant women, since there is no evidence that they have harmful effects on the fetus or pregnancy. Nevertheless, if prompt administration is not medically indicated, it is preferable to delay administration of these agents until the second trimester since the possibility of risk to fetal development cannot be definitively excluded. Waiting until the second trimester also helps to avoid spurious associations in the patient's mind between immunization and common adverse first trimester events (eg, miscarriage, birth defects). However, some vaccines, such as inactivated influenza vaccines, are medically indicated regardless of gestational age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Live vaccines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Live vaccines have the potential for infecting the fetus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/7\">",
"     7",
"    </a>",
"    ]. Harmful effects have not been reported in newborns of mothers who received live vaccines during pregnancy, although subclinical infection has been documented. Because a risk of fetal damage cannot be definitively excluded, use of live vaccines is",
"    <strong>",
"     strongly discouraged",
"    </strong>",
"    during pregnancy unless the gravida is at substantial risk of exposure to a natural infection associated with serious morbidity or mortality. The risk-benefit ratio of administering live vaccines should be weighed individually for such patients in consultation with an infectious disease expert.",
"   </p>",
"   <p>",
"    If a live virus vaccine is inadvertently given to a pregnant woman, or if a woman becomes pregnant within four weeks after vaccination, she should be counseled about the potential effects on the fetus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/8\">",
"     8",
"    </a>",
"    ]. Termination of pregnancy is not warranted for this indication, given the absence of documented harm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     IMMUNIZATIONS THAT SHOULD BE GIVEN PRIOR TO CONCEPTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several infections with serious consequences for the mother or fetus can be prevented by preconception vaccination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     ACIP recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immunization recommendations in the United States developed by the ACIP of CDC are shown in the tables (",
"    <a class=\"graphic graphic_figure graphicRef82634 \" href=\"mobipreview.htm?36/52/37701\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef62130 \" href=\"mobipreview.htm?41/17/42263\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Before administering any vaccine, reasonable practices include asking the woman if she is pregnant or could become pregnant in the next four weeks and counseling her about the potential risks of vaccination during pregnancy or just before conception. Routine pregnancy testing of women of childbearing age before administering a vaccine, even a live-virus vaccine, is not necessary as long as pregnancy can reasonably be excluded by history. Pregnancy should be avoided for at least four weeks after immunization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Human papillomavirus",
"    </span>",
"    &nbsp;&mdash;&nbsp;The quadrivalent HPV vaccine does not contain live virus and has been classified as a category B drug by the Food and Drug Administration (FDA). However, use in pregnancy is",
"    <strong>",
"     not",
"    </strong>",
"    recommended, given that safety in this setting has not been thoroughly evaluated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/10-13\">",
"     10-13",
"    </a>",
"    ]. If a woman is found to be pregnant after initiating the vaccination series, the remainder of the three-dose regimen should be delayed until after completion of the pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/14\">",
"     14",
"    </a>",
"    ]. A detailed discussion of HPV vaccines can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/17/19738?source=see_link\">",
"     \"Recommendations for the use of human papillomavirus vaccines\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following data represent the limited available evidence on reproductive outcomes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reproduction studies in female rats at doses up to 300 times the human dose (on a",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      basis) did not show evidence of impaired fertility or fetal harm [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In five phase III clinical trials, the incidence of congenital anomalies was not significantly increased in vaccine exposed pregnancies compared with an unexposed group (40 anomalies in 2008 exposed pregnancies [2 percent] versus 30 anomalies in 2029 unexposed controls [1.5 percent], p = 0.2) and there was no consistent pattern of abnormalities [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/13\">",
"       13",
"      </a>",
"      ]. There was also no difference between groups in the rate of miscarriage or stillbirth.",
"     </li>",
"     <li>",
"      Five infants with congenital anomalies have born to women who received vaccine within 30 days of the estimated onset of pregnancy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/11,13\">",
"       11,13",
"      </a>",
"      ]. The opinion of an expert panel was that the five congenital abnormalities (one pyloric stenosis with ankyloglossia, one congenital hydronephrosis, one congenital megacolon, one club foot, and one hip dysplasia) were unrelated to vaccine exposure. The incidence of miscarriage was not increased women who received vaccine within 30 days of the estimated onset of pregnancy.",
"     </li>",
"     <li>",
"      Merck maintains a Pregnancy Registry to monitor fetal outcomes of pregnant women exposed to Gardasil (telephone 1-800-986-8999). As of May 31, 2008, there were 517 evaluable reports for women exposed to the vaccine in the month before the onset of their last menstrual period or during pregnancy and entered into the registry before the outcome of pregnancy was known [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/12\">",
"       12",
"      </a>",
"      ]. The rates of miscarriage and congenital anomalies in these pregnancies were equivalent to the rates in unexposed women (miscarriage rate 6.9 per 100 exposed women, major birth defects 2.2 per 100 exposed liveborns). The 10 infants with anomalies all had a different anomaly.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Special considerations for women planning a pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following immunizations are particularly important for susceptible women of childbearing age who may become pregnant since (1) these immunizations are contraindicated during pregnancy, and (2) infection occurring in nonimmune pregnant women can adversely affect pregnancy outcome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Measles, mumps, rubella",
"    </span>",
"    &nbsp;&mdash;&nbsp;Measles during pregnancy is associated with an increased rate of preterm birth and, possibly, miscarriage [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. There is no definite evidence of a higher rate of birth defects among offspring of infected gravida [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mumps in the first trimester may be associated with fetal death. Embryopathy does not appear to be increased, although an association with endocardial fibroelastosis has been observed in some studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rubella is associated with an increased risk of miscarriage and fetal death. In addition, congenital rubella syndrome (eg, deafness, visual problems, cardiac defects, bone lesions, and neurologic abnormalities including intellectual disability) has been estimated to occur in 20 to 85 percent of infants of women with rubella before 20 weeks of gestation, with the highest risk in those infected in the first month of pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/16\">",
"     16",
"    </a>",
"    ]. As a result of successful implementation of rubella vaccination programs, rubella is no longer endemic in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/19\">",
"     19",
"    </a>",
"    ]. However, it occurs in other parts of the world and thus it is occasionally diagnosed in recent immigrants from those areas. Women with religious objections to vaccination are another population at risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/60/6087?source=see_link\">",
"     \"Rubella in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The measles, mumps, rubella (MMR) vaccine, a live-attenuated vaccine, should be given to women who are not pregnant and who do not have evidence of immunity to rubella [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/14\">",
"     14",
"    </a>",
"    ]. Women from resource poor countries are particularly likely to have not received routine childhood immunization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The test of choice for determining rubella immunity is an IgG antibody titer; an IgM antibody titer should not be obtained unless there is suspicion of",
"    <span class=\"nowrap\">",
"     recent/acute",
"    </span>",
"    infection. Additional laboratory evidence to document measles and mumps immunity or nonimmunity is not required before vaccine administration. Once rubella immunity has been documented, it is not necessary to repeat rubella serology with each pregnancy.",
"   </p>",
"   <p>",
"    As discussed above, before administering the vaccine, the woman should be asked if she is pregnant or could become pregnant in the next four weeks and she should be counseled about the potential risks of vaccination during pregnancy or just before conception. Routine pregnancy testing before vaccination is not recommended if absence of pregnancy is reasonably certain by history.",
"   </p>",
"   <p>",
"    Vaccinated women are advised to avoid conception for 28 days after administration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/14\">",
"     14",
"    </a>",
"    ]. The vaccine can be given safely to postpartum women who are breastfeeding. Although rubella virus is excreted into breast milk, only seroconversion without serious infection has been reported in breastfeeding infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/22\">",
"     22",
"    </a>",
"    ]. The children of pregnant women can also be vaccinated without risk to the mother or fetus, since infection is not transmitted from recently immunized individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    No congenital rubella syndrome-like defects have been observed in the offspring of women vaccinated just before or inadvertently during pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. Termination of pregnancy should",
"    <strong>",
"     NOT",
"    </strong>",
"    be recommended solely on the basis of a theoretical risk of embryopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/16,26\">",
"     16,26",
"    </a>",
"    ]. The Vaccine in Pregnancy Registry, which was active from 1971 to 1989, did not report any evidence of congenital rubella syndrome in the offspring of 226 women who received the RA",
"    <span class=\"nowrap\">",
"     27/3",
"    </span>",
"    rubella vaccine and continued their pregnancy to term [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Varicella",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary varicella infection during the first 20 weeks of gestation causes congenital varicella syndrome (eg, limb hypoplasia, microcephaly, dermal scarring, ocular defects) in 2 percent of fetuses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/27\">",
"     27",
"    </a>",
"    ]. Nine cases of congenital varicella syndrome have been reported in women who developed varicella between 20 and 28 weeks of gestation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. Maternal infection from five days before to two days after delivery results in neonatal disease in 17 to 30 percent of offspring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/30\">",
"     30",
"    </a>",
"    ]. In utero exposure to maternal varicella may also result in herpes zoster in infancy or early childhood [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/31\">",
"     31",
"    </a>",
"    ]. In addition, maternal disease is uncomfortable and can be associated with severe maternal complications. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/28/33225?source=see_link\">",
"     \"Varicella-zoster virus infection in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As with other live vaccines,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    should",
"    <strong>",
"     NOT",
"    </strong>",
"    be administered to pregnant women and the ACIP recommends that pregnancy be avoided for one month following each dose of vaccine (the manufacturer recommends three months) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/14\">",
"     14",
"    </a>",
"    ]. As discussed above, before administering the vaccine, the woman should be asked if she is pregnant or could become pregnant in the next four weeks and she should be counseled about the potential risks of vaccination during pregnancy or just before conception. Routine pregnancy testing before vaccination is not necessary if pregnancy can be reasonably excluded by history.",
"   </p>",
"   <p>",
"    Nonpregnant women without evidence of immunity who do not plan to become pregnant within the next month are candidates for immunization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/14\">",
"     14",
"    </a>",
"    ]. Evidence of immunity to varicella in this population includes any of the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/30\">",
"     30",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Documentation of age appropriate vaccination",
"     </li>",
"     <li>",
"      History of varicella based on diagnosis or verification of varicella by a health-care provider",
"     </li>",
"     <li>",
"      History of herpes zoster based on health-care provider diagnosis",
"     </li>",
"     <li>",
"      Laboratory evidence of immunity or laboratory confirmation of disease; or",
"     </li>",
"     <li>",
"      Birth in the United States before 1980, EXCEPT in pregnant women, health care personnel, or immunocompromised persons",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/26/37289?source=see_link\">",
"     \"Prevention of varicella-zoster virus infection: Chickenpox\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A VARIVAX registry has been created to track pregnancy outcomes when vaccination occurred within three months of or during pregnancy (1-800-986-8999). After 10 years, no cases of congenital varicella syndrome had been identified among the offspring of varicella negative women immunized during the first or second trimester (n = 82), third trimester or within one month of the last menstrual period (LMP) before conception, or more than one month before this LMP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. While reassuring, these data are too limited to assure safety of vaccine administration during pregnancy. However, pregnancy termination solely because of varicella vaccination during the gestation is unwarranted [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/6,30\">",
"     6,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are minimal data regarding the safety of breastfeeding after vaccination. A study of 12 nursing mothers given",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    postpartum did not detect varicella DNA in samples of postvaccination breast milk and none of their infants seroconverted or had evidence of varicella virus DNA [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/34\">",
"     34",
"    </a>",
"    ]. Varicella vaccine may be considered for a nursing mother, extrapolating from this study and the observation that no harm has been demonstrated from other live attenuated vaccines given to lactating women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recently vaccinated healthy individuals rarely transmit the vaccine virus to close, susceptible contacts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/6,35-37\">",
"     6,35-37",
"    </a>",
"    ]. The risk for transmission is higher when vaccinees are immunocompromised and develop a varicella-like rash. Routine immunization of the children of pregnant susceptible women is not contraindicated. In such circumstances, the potential risk of transmission of vaccine virus is probably smaller than the risks from transmission of natural virus from unimmunized children who develop chickenpox. The benefits and risks of varicella immunization of children of pregnant women should be discussed with patients on a case-by-case basis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     MMRV vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;A combination measles, mumps, rubella, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    (MMRV,",
"    <span class=\"nowrap\">",
"     Oka/Merck,",
"    </span>",
"    ProQuad) became available in 2005. It is indicated for simultaneous immunization against measles, mumps, rubella, and varicella among children 12 months to 12 years of age and is used in place of trivalent MMR vaccine and monovalent varicella vaccine. Although not intended for adults, the issues described above for MMR and varicella immunization apply to this vaccine if administered to an adult since it is composed of live, attenuated virus. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/30/14822?source=see_link\">",
"     \"Measles-mumps-rubella vaccination in high risk adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Zoster",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/4/5190?source=see_link\">",
"     Zoster vaccine",
"    </a>",
"    (Zostavax) is a live vaccine approved for prevention of shingles and postherpetic neuralgia in adults over 60 years of age. Because it is a live vaccine, it should",
"    <strong>",
"     NOT",
"    </strong>",
"    be administered to pregnant females, but this would be unlikely, given that it is not indicated for women of childbearing age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. There is no safety information from animal reproduction studies or case reports of inadvertent administration in pregnant or nursing women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     IMMUNIZATION ISSUES DURING PREGNANCY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     General principles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ideally, women should be vaccinated against preventable diseases in their environment before pregnancy according to the recommended adult immunization schedule (",
"    <a class=\"graphic graphic_figure graphicRef82634 \" href=\"mobipreview.htm?36/52/37701\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef62130 \" href=\"mobipreview.htm?41/17/42263\">",
"     figure 2",
"    </a>",
"    ) (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Immunizations that should be given prior to conception'",
"    </a>",
"    above). When immunization is performed during pregnancy, the benefits to both mother and fetus should outweigh the risks. There is no evidence of harm to pregnant women or fetuses from administration of inactivated vaccines. However, live vaccines that are considered safe in children and adults may be harmful to a developing fetus (see",
"    <a class=\"local\" href=\"#H4\">",
"     'Live vaccines'",
"    </a>",
"    above). They should be avoided during pregnancy unless there is danger of imminent exposure to diseases such as yellow fever or poliomyelitis (see below).",
"   </p>",
"   <p>",
"    In addition, pregnant women should minimize their risk of exposure to infections to which they are susceptible by avoiding travel to high risk locations (eg, areas where yellow fever is prevalent), assuring that household members are immunized according to standard immunization schedules, and maintaining good hygienic practices (eg, using clean water and cooking shellfish to minimize risks of hepatitis A, cholera, and typhoid in endemic areas).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Lack of autism association with immunizations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some authors have attributed regressive autism to childhood vaccine exposure (particularly measles vaccine and thimerosal (a mercury preservative used in vaccines)). However, the overwhelming majority of epidemiologic evidence does not support an association between immunizations and autism. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/14/26857?source=see_link\">",
"     \"Autism and chronic disease: Little evidence for vaccines as a contributing factor\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/36/21066?source=see_link\">",
"     \"Autism and chronic disease: Little evidence for thimerosal as a contributing factor\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although some vaccines given to adults contain thimerosal, there is no evidence that thimerosal-containing vaccines cause adverse effects in offspring of women who received these vaccines during pregnancy. The Advisory Committee on Immunization Practices (ACIP) does not recommend avoidance of thimerosal-containing vaccines for any group, including pregnant women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/6\">",
"     6",
"    </a>",
"    ]. A list of vaccines by brand name and with their thimerosal content is available from the US Food and Drug Administration (FDA) at",
"    <a class=\"external\" href=\"file://www.fda.gov/biologicsbloodvaccines/safetyavailability/vaccinesafety/ucm096228.htm\">",
"     file://www.fda.gov/biologicsbloodvaccines/safetyavailability/vaccinesafety/ucm096228.htm",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Routine immunizations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The only vaccines recommended for routine use during pregnancy are primary or booster doses of adult type tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap), and inactivated influenza vaccines (seasonal and H1N1) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/3\">",
"     3",
"    </a>",
"    ]. Immunizations during pregnancy are typically delayed until the second or third trimester, when possible, to minimize concerns about teratogenicity or miscarriage resulting from the vaccine or toxoid. However, routine immunizations, such as tetanus and influenza immunizations, may be given during the first trimester because of special risks to the unimmunized pregnant woman, fetus, or newborn.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Tetanus, diphtheria, pertussis (Tdap)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonatal tetanus is rare in countries where universal immunization of",
"    <span class=\"nowrap\">",
"     children/adults",
"    </span>",
"    with tetanus toxoid is routine. However, in some developing countries, it is one of the leading causes of neonatal death due to unclean cord cutting and care practices, unhygienic deliveries, and lack of maternal tetanus immunization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. This preventable disease can be eliminated by giving tetanus toxoid to pregnant women who have not been vaccinated or who are inadequately vaccinated, thereby passively immunizing the fetus and neonate [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. Where appropriate, promotion of aseptic obstetrical practices, including those involving postnatal umbilical cord care, is also effective in reducing neonatal tetanus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prevalence of pertussis in the United States has been increasing, in part because pertussis immunity after vaccination or disease wanes over time. Adults who develop pertussis can transmit the disease to susceptible infants in the household, which is a concern because infants under three months of age are at highest risk of morbidity and mortality from this disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/45\">",
"     45",
"    </a>",
"    ]. Over 50 percent of infants with pertussis contract the disease from family members, mostly from their mothers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. Vaccination of the mother and other household contacts protects them and thus can significantly decrease the risk of infant exposure. Placental transfer of maternal antibodies may also provide a degree of passive protection of the infant against pertussis for two to six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/48\">",
"     48",
"    </a>",
"    ]. However, in one study of 105 predominantly Hispanic pregnant women who had been vaccinated against pertussis within two years prior to delivery, the levels of anti-pertussis antibodies in cord blood at delivery were overall low, such that only 40 percent of infants would be expected to have detectable antibody levels at two months of age based on half-life calculations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/49\">",
"     49",
"    </a>",
"    ]. These findings suggest that vaccination during the third trimester and reimmunization in subsequent pregnancies may be necessary to ensure adequate antibody levels in the infant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/50\">",
"     50",
"    </a>",
"    ]. Although in theory passive protection might interfere with the infant's immune response to infant doses of vaccines for protection against tetanus, diphtheria, or pertussis, this risk is thought to be very low [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Available vaccines that protect against tetanus, diphtheria, and pertussis include the tetanus and diphtheria toxoid vaccine (Td) and the tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap). The ACIP recommendations for the use of these vaccines in pregnant women to prevent tetanus, diphtheria, and pertussis are described below, and supported by the American College of Obstetricians and Gynecologists [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/52\">",
"     52",
"    </a>",
"    ]. In 2013, the ACIP recommended that all pregnant women receive vaccination against pertussis with Tdap during each pregnancy, optimally between 27 and 36 weeks of gestation, regardless of prior vaccination status, to better protect their infant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/53\">",
"     53",
"    </a>",
"    ]. A review of 132 reports of Tdap administered to pregnant women to the Vaccine Adverse Event Reporting System (VAERS) from 2005 to 2010 did not identify any increase in adverse maternal, infant, or pregnancy outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/54\">",
"     54",
"    </a>",
"    ]. Available data have not shown an increased risk of adverse events after two doses of Tdap; data for more than two doses are limited but also reassuring.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       No, incomplete, or unknown immunization against tetanus and diphtheria",
"      </strong>",
"      &mdash; Pregnant women who have not received three doses of a vaccine containing tetanus and diphtheria toxoids (Td) should undertake or complete the series of three vaccinations. The preferred schedule in pregnant women is at time 0, 4 weeks later, and at 6 to 12 months after the initial dose.",
"      <br/>",
"      <br/>",
"      In order to also provide protection against pertussis, a dose of Tdap should",
"      <strong>",
"       replace",
"      </strong>",
"      one of the Td doses, preferably the dose due when the woman is between 20 weeks of gestation and delivery. Administration after 20 weeks minimizes any theoretical risks to the fetus during early development while still providing protection to the mother and passive protection to the infant after birth. &nbsp;",
"     </li>",
"     <li>",
"      <strong>",
"       Td immunization complete and up to date &mdash;",
"      </strong>",
"      Pregnant women who have been immunized with a full three-dose series of Td vaccine should receive a single dose of Tdap at 27 to 36 weeks of gestation, to address waning immunity against pertussis. Tdap is indicated in each pregnancy, even if the woman has a previous history of pertussis or vaccination. Alternatively, if Tdap is not administered during pregnancy, it should be administered immediately postpartum to provide protection to the infant indirectly or, if breastfeeding, through transfer of maternal antibodies in breast milk; however, the maternal immune response may not be sufficiently rapid to protect the infant until two weeks post-immunization [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       More than 5 or 10 years since last Td booster",
"      </strong>",
"      &mdash; As above, a Tdap vaccine is recommended for all pregnant women regardless of prior immunization history. This will also serve as a booster vaccination against tetanus and diphtheria for those women in whom 5 or 10 years has elapsed since the last Td booster. If the Tdap cannot be given, a Td booster vaccination during pregnancy is recommended if &ge;10 years have elapsed since a previous Td booster (administer during the second or third trimester) or if booster protection is needed for wound management &ge;5 years since the previous booster (administer when needed).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional information on Tdap and Td can be found separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/22/39271?source=see_link\">",
"     \"Treatment and prevention of Bordetella pertussis infection in adolescents and adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/54/7014?source=see_link\">",
"     \"Tetanus-diphtheria toxoid vaccination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Influenza",
"    </span>",
"    &nbsp;&mdash;&nbsp;Influenza is particularly morbid in pregnant women, as it increases the risk of serious medical and pregnancy complications and hospitalization. Vaccination of pregnant women with the intramuscular inactivated virus vaccine is recommended to reduce the risk of these complications, as well as to provide passive protection to the neonate. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35224?source=see_link\">",
"     \"Influenza and pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H624273493\">",
"    <span class=\"h4\">",
"     Inactivated vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaccination of pregnant women plays the key role in prevention of seasonal influenza virus. During the 2009 influenza A (H1N1) pandemic in Norway, vaccination during pregnancy substantially reduced the risk of an influenza diagnosis (adjusted hazard ratio 0.30; 95% CI 0.25-0.34) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/56\">",
"     56",
"    </a>",
"    ]. Multiple studies have evaluated the safety of the inactivated virus (parenteral) influenza vaccine during pregnancy, including vaccines against the pandemic H1N1 influenza virus, and none demonstrated an increased risk of either maternal complications or adverse fetal outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/56-64\">",
"     56-64",
"    </a>",
"    ]. Inactivated virus (intramuscular) influenza vaccination is not a contraindication to breastfeeding. Other studies have shown the cost-effectiveness of universal vaccination in the setting of pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The vaccine is made from inactivated influenza viruses likely to circulate in the upcoming winter. After 2010, the influenza vaccine included antigens from the 2009-2010 pandemic H1N1 influenza virus in addition to seasonal influenza viruses. Ideally, vaccination should be administered intramuscularly from October to mid-November (prior to the influenza season) to",
"    <strong>",
"     ALL",
"    </strong>",
"    women who will be pregnant during the influenza season, regardless of their stage of pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. Vaccination after this period can still be beneficial because peak influenza activity usually occurs in January or February, but may occur as late as May. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35224?source=see_link\">",
"     \"Influenza and pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the United States, rates of influenza vaccination during pregnancy are less than 50 percent overall but higher in women whose providers specifically recommend and provide it [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. This finding highlights the importance of provider involvement to increase influenza vaccination of pregnant women.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H624273469\">",
"    <span class=\"h4\">",
"     LAIV",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to the intramuscular inactivated vaccine, the intranasal vaccine (LAIV, FluMist) is a live, attenuated influenza vaccine and should",
"    <strong>",
"     not",
"    </strong>",
"    be used in pregnant women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. Pregnant women do not need to avoid contact with persons immunized with LAIV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/66\">",
"     66",
"    </a>",
"    ]. Postpartum women can receive LAIV, although there is a possibility that a mother recently vaccinated with LAIV can infect her neonate by shedding the vaccine virus, given the close contact between mothers and newborns [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/72\">",
"     72",
"    </a>",
"    ]. There is no information regarding excretion in breast milk, but LAIV is not contraindicated in breastfeeding women.",
"   </p>",
"   <p>",
"    Among pregnant women who received LAIV, no unusual patterns of pregnancy complications or adverse fetal outcomes were observed in the database of the Vaccine Adverse Event Reporting System [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Selective immunization of high risk groups",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some pregnant women are at high risk for acquiring an infection because of their occupation, habits, travel plans, or the area in which they reside. These women should be immunized if an appropriate agent is available, the medication is not known to be harmful, and infection could result in significant harm to mother or baby. In fact, there are no immunizing agents that are more dangerous to the pregnant woman or her fetus than the disease they are designed to prevent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Hepatitis B",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/36/27207?source=see_link\">",
"     Hepatitis B vaccine",
"    </a>",
"    is a recombinant vaccine with no known harm to the fetus or newborn. Although childhood immunization is now routine, many adults have never been immunized. Hepatitis B vaccine should be given during pregnancy in the following settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pregnant women who are completing an immunization series begun prior to conception.",
"     </li>",
"     <li>",
"      Unimmunized pregnant women negative for hepatitis B surface antigen who are at high risk for acquiring hepatitis B (HBV) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/73\">",
"       73",
"      </a>",
"      ]. Indications for HBV vaccination, including a description of high risk groups, are discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/60/31690?source=see_link&amp;anchor=H8#H8\">",
"       \"Hepatitis B virus vaccination\", section on 'Other high-risk groups'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In order to complete the immunization series during pregnancy, one study administered",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/36/27207?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    on an accelerated schedule (at 0, 1, and 4 months instead of 0, 1, and 6 months) to pregnant women under 25 weeks of gestation at high risk of acquiring hepatitis (sexually transmitted disease, current injection drug use) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/74\">",
"     74",
"    </a>",
"    ]. Eighty-four percent of the patients received the full series and 90 percent seroconverted after the third dose, with no increase in adverse effects.",
"   </p>",
"   <p>",
"    Prevaccination screening for hepatitis B antibody is not necessary, although screening for hepatitis B surface antigen is a routine prenatal laboratory test because vertical transmission of HBV can usually be prevented by appropriate intervention (passive and active immunization of offspring at birth). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/63/37881?source=see_link\">",
"     \"Hepatitis viruses and the newborn: Clinical manifestations and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A combined hepatitis A virus recombinant",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/36/27207?source=see_link\">",
"     hepatitis B virus vaccine",
"    </a>",
"    is also available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Hepatitis A",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hepatitis A is a common cause of acute hepatitis associated with significant morbidity and occasional mortality. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/26/7591?source=see_link\">",
"     \"Overview of hepatitis A virus infection in adults\"",
"    </a>",
"    .) Acute maternal hepatitis A may be associated with preterm delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/75\">",
"     75",
"    </a>",
"    ]. In utero infection has been reported manifesting as meconium peritonitis, fetal ascites, and polyhydramnios [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/76,77\">",
"     76,77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two inactivated hepatitis A vaccines, and a combined hepatitis A virus recombinant",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/36/27207?source=see_link\">",
"     hepatitis B virus vaccine",
"    </a>",
"    , are available for preexposure prophylaxis. &nbsp;Susceptible pregnant women at increased risk for hepatitis A infection are candidates for vaccination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/73\">",
"     73",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/30/44518?source=see_link\">",
"     Hepatitis A virus vaccine",
"    </a>",
"    and passive immunization with immune globulin are indicated for postexposure prophylaxis during pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/38/1641?source=see_link\">",
"     \"Hepatitis A virus vaccination and postexposure prophylaxis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Pneumococcus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumococcal vaccine is recommended for pregnant women with conditions that increase the risk of invasive pneumococcal disease (",
"    <a class=\"graphic graphic_table graphicRef86782 \" href=\"mobipreview.htm?11/48/12046\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/12/21705?source=see_link\">",
"     \"Pneumococcal vaccination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There is little information on the safety of pneumococcal vaccine during the first trimester of pregnancy; adverse events have not been reported after inadvertent administration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/78\">",
"     78",
"    </a>",
"    ]. It appears safe when given in the second and third trimesters and has been used at this time to try to provide passive immunization to the newborn [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/79\">",
"     79",
"    </a>",
"    ]; however, a reduction in neonatal infection has not been demonstrated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/80\">",
"     80",
"    </a>",
"    ]. Ideally, the vaccine should be given prior to conception, but the indications for administration are not altered by pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Yellow fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;Yellow fever is a mosquito-borne viral hemorrhagic fever, characterized by hepatic, renal, and myocardial injury, hemorrhage, and a high case-fatality rate. The disease occurs in tropical regions of South America and sub-Saharan Africa. Pregnant women should avoid travel to these areas since they are at risk for acquisition of infection. If travel is not avoidable and the risk of yellow fever is high, immunization with a live attenuated virus vaccine may be considered, but should only be administered in consultation with an infectious disease specialist.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/13/14550?source=see_link\">",
"     Yellow fever vaccine",
"    </a>",
"    can cause serious, including fatal, adverse effects in the mother. In cases where the risk of disease is low but vaccination is an international travel requirement, a waiver may be sought. Pregnant women who travel to areas endemic for yellow fever without having undergone vaccination should take precautions to reduce the risk of mosquito exposure, including staying in urban settings, avoiding the outdoors at dawn or dusk, wearing protective clothing outside, and using insect repellant containing DEET on exposed surfaces. The Centers for Disease Control and Prevention (CDC) and Environmental Protection Agency recommendations for DEET use in pregnant and lactating women do not differ from those for nonpregnant adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/81\">",
"     81",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/21/15705?source=see_link\">",
"     \"Yellow fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Healthy people rarely fail to develop neutralizing antibodies following vaccination, but there are conflicting data about the immune response of pregnant women to yellow fever vaccination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/82,83\">",
"     82,83",
"    </a>",
"    ]. Serologic testing to document an immune response to the vaccine should be considered, if available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/84\">",
"     84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Subclinical congenital yellow fever and an increased risk for miscarriage have been reported in women vaccinated for yellow fever during pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/85,86\">",
"     85,86",
"    </a>",
"    ]. However, in larger series, there has been no increase in adverse pregnancy outcome among women with complete follow-up after vaccination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/83,87-89\">",
"     83,87-89",
"    </a>",
"    ]. Fetal infection after vaccination occurs at a low rate, but has not been associated with an increased risk of major congenital anomalies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/88,89\">",
"     88,89",
"    </a>",
"    ]. In a series of 304 babies exposed to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/13/14550?source=see_link\">",
"     yellow fever vaccine",
"    </a>",
"    during the prenatal period, dysmorphological examinations revealed major malformations in 3.3 percent, a rate similar to that in the reference population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/89\">",
"     89",
"    </a>",
"    ]. A study of 441 women inadvertently vaccinated early in their pregnancy did not find an increased risk for fetal death",
"    <span class=\"nowrap\">",
"     (7.4/1000",
"    </span>",
"    in vaccinated women versus",
"    <span class=\"nowrap\">",
"     18.5/1000",
"    </span>",
"    in unvaccinated women in the general population) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women should avoid pregnancy for one month after receiving vaccination for yellow fever.",
"   </p>",
"   <p>",
"    Breastfeeding is a precaution against",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/13/14550?source=see_link\">",
"     yellow fever vaccine",
"    </a>",
"    administration. Two serious adverse events have been reported in exclusively breastfed infants whose mothers were vaccinated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/84,90\">",
"     84,90",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Poliovirus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Poliomyelitis, a systemic viral infection with varying manifestations ranging from asymptomatic disease to paralysis, has been eradicated from the Americas and most other developed countries in the world. However, polio transmission continues in some developing countries, including Afghanistan, India, Pakistan, Nigeria, and Niger. An outbreak occurred in Nigeria in 2003 that then spread to neighboring countries; the outbreak accounted for 45 percent of cases reported globally [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pregnant women should avoid travel, if possible, to areas where the disease is present. If travel is not avoidable, they should be immunized. Prior to the 1990s, the recommendation for travelers was to receive the oral polio vaccine (OPV), which is a live-attenuated virus vaccine. However, because of the rare risk for the development of vaccine-associated paralytic poliomyelitis after OPV, only the inactivated polio vaccine (IPV) is available in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/92,93\">",
"     92,93",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/52/17223?source=see_link\">",
"     \"Poliovirus vaccination\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although adverse effects of IPV have not been documented in either the mother or fetus, vaccination is",
"    <strong>",
"     NOT",
"    </strong>",
"    recommended during pregnancy on theoretical grounds [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/93\">",
"     93",
"    </a>",
"    ]. If, however, a pregnant women is at increased risk for exposure to infection, usually because of travel to an area in which polio is endemic or epidemic, IPV can be given.",
"   </p>",
"   <p>",
"    Pregnant women at risk who have been fully immunized in the past should receive a booster dose of IPV. Available data do not indicate the need for more than a single lifetime booster dose of IPV [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/93\">",
"     93",
"    </a>",
"    ]. For those who have not been previously immunized or who received only a partial vaccine series, the schedule of IPV immunizations is based upon the interval prior to travel [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/93\">",
"     93",
"    </a>",
"    ]. The recommended regimens are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/21/2394?source=see_link&amp;anchor=H7672819#H7672819\">",
"     \"Immunizations for travel\", section on 'Poliovirus vaccine'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Haemophilus influenzae",
"    </span>",
"    &nbsp;&mdash;&nbsp;Haemophilus influenzae b conjugate vaccine is recommended for women with prior splenectomy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/9/1177?source=see_link\">",
"     \"Prevention of sepsis in the asplenic patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Meningococcal vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meningococcal vaccination recommendations are not altered by pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/94\">",
"     94",
"    </a>",
"    ]. Both polysaccharide and conjugate vaccines are available. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/32/23050?source=see_link\">",
"     \"Meningococcal vaccines\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Typhoid",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/7/25718?source=see_link\">",
"     typhoid vaccine",
"    </a>",
"    is a capsular polysaccharide vaccine for parenteral use (Typhim Vi, Pasteur",
"    <span class=\"nowrap\">",
"     M&eacute;rieux/Connaught).",
"    </span>",
"    A live attenuated typhoid vaccine (Ty21a) is also available for oral use. Typhoid infection acquired from contaminated food or water is rare; typhoid vaccine is recommended for persons traveling to the developing world and to areas that have typhoid epidemics. Pregnant women should avoid these areas, but may be immunized with the inactive parenteral vaccine if such exposure is unavoidable. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/21/2394?source=see_link\">",
"     \"Immunizations for travel\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Smallpox",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/24/18823?source=see_link\">",
"     smallpox vaccine",
"    </a>",
"    is a live-virus vaccine (vaccinia virus). It is",
"    <strong>",
"     NOT",
"    </strong>",
"    recommended for women who are pregnant (any trimester), women contemplating pregnancy within 28 days, women who are breastfeeding, or close contacts (household member, sex partner) of women who are pregnant or contemplating pregnancy within 28 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/8,95-97\">",
"     8,95-97",
"    </a>",
"    ]. There has been one case report of transmission of vaccinia from a recently vaccinated husband to his nursing wife, followed by mother to child transmission [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/98\">",
"     98",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The vaccinia virus is not teratogenic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/99\">",
"     99",
"    </a>",
"    ]. The major pregnancy-related concern to smallpox immunization is the possibility of fetal vaccinia, which is rare, but potentially lethal. There is no known reliable intrauterine diagnostic test to confirm fetal infection. If a woman becomes pregnant within four weeks of vaccination, she should be counseled about fetal risks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/96\">",
"     96",
"    </a>",
"    ]. The CDC does not recommend routine use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/33/6677?source=see_link\">",
"     vaccinia immune globulin",
"    </a>",
"    (VIG) prophylaxis to reduce the risk of fetal vaccinia in such cases, as the efficacy of this approach has not been proven [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/100,101\">",
"     100,101",
"    </a>",
"    ]. On the other hand, VIG should not be withheld if a pregnant woman develops a condition where VIG is needed. Nonpregnancy related complications are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/7/40057?source=see_link\">",
"     \"Vaccinia virus as the smallpox vaccine\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/61/35797?source=see_link\">",
"     \"The epidemiology, pathogenesis, and clinical manifestations of smallpox\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the event of intentional release of the smallpox virus, pregnant women who have had a definite direct exposure (eg, face-to-face, household, or close-proximity contact with a smallpox patient) should be vaccinated because of the lethality of the disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/97\">",
"     97",
"    </a>",
"    ]. Vaccination should be performed only with consultation from the CDC. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/46/22247?source=see_link\">",
"     \"Identifying and managing casualties of biological terrorism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/24/18823?source=see_link\">",
"     Smallpox vaccination",
"    </a>",
"    during pregnancy has not been clearly associated with prematurity, low birth weight, or congenital malformations. It is not considered an indication for pregnancy termination. The CDC maintains an internet site with information on smallpox vaccination and pregnancy (",
"    <a class=\"external\" href=\"file://www.bt.cdc.gov/agent/smallpox/vaccination/preg-factsheet.asp\">",
"     www.bt.cdc.gov/agent/smallpox/vaccination/preg-factsheet.asp",
"    </a>",
"    ). Pregnant women who are vaccinated should be asked to participate in a voluntary registry of such women (National",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/24/18823?source=see_link\">",
"     Smallpox Vaccine",
"    </a>",
"    in Pregnancy Registry, telephone 404-639-8253).",
"   </p>",
"   <p>",
"    The vaccinia virus can be transmitted in breast milk. Thus, if vaccination is indicated in a nursing mother, she should stop breastfeeding until the vaccination scab sloughs off [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/102\">",
"     102",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Rabies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy is not a contraindication to postexposure prophylaxis if a rabies exposure has occurred [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/8,103\">",
"     8,103",
"    </a>",
"    ]. If the risk of exposure to rabies is substantial, preexposure prophylaxis might also be indicated during pregnancy. The vaccine is made from inactivated virus. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/21/2393?source=see_link\">",
"     \"Rabies immune globulin and vaccine\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Cholera, plague, Japanese encephalitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inactivated vaccines for cholera, plague, and Japanese encephalitis can be given to women who are at substantial risk of disease exposure, and where there are probable benefits of vaccination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11766764\">",
"    <span class=\"h3\">",
"     Anthrax",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anthrax vaccination is not recommended for the general population, but is recommended for individuals with occupations that put them at increased risk of anthrax (eg, laboratory workers and military personnel who are at increased risk of anthrax exposure) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/104\">",
"     104",
"    </a>",
"    ]. Pre-event or pre-exposure anthrax vaccination of pregnant women is not recommended and should be deferred, when indicated, until after pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/104\">",
"     104",
"    </a>",
"    ]. Pregnant women in post-event settings that pose a high risk of exposure to aerosolized B. anthracis spores should receive",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/58/18342?source=see_link\">",
"     anthrax vaccine adsorbed",
"    </a>",
"    (AVA) and 60 days of antimicrobial therapy. In the post-exposure setting, AVA is administered as a three-dose subcutaneous series, with the first dose administered as soon as possible and the second and third doses administered two and four weeks after the first dose.",
"   </p>",
"   <p>",
"    For post-exposure antimicrobial prophylaxis,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    500 mg orally twice daily is the preferred antimicrobial agent.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/10/42152?source=see_link\">",
"     Amoxicillin",
"    </a>",
"    500 mg every eight hours should be used to complete the course of antibiotic therapy if susceptibility testing demonstrates an amoxicillin MIC &le;0.125",
"    <span class=\"nowrap\">",
"     mcg/mL.",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     Doxycycline",
"    </a>",
"    100 mg orally twice daily is an alternative agent, but may have adverse fetal effects (eg, dental staining, depressed bone growth, dental enamel defects), and should therefore only be used in asymptomatic pregnant women when the other antimicrobial agents are contraindicated. Doxycycline is indicated in some cases of life-threatening anthrax infection in pregnant women.",
"   </p>",
"   <p>",
"    A study of 37,140 infants born to women in the military ever vaccinated against anthrax observed that birth defects were slightly more common in first trimester-exposed infants (n = 3465) compared with infants of women vaccinated outside of the first trimester (OR 1.18, 95% CI 0.997-1.41), never-vaccinated (OR 1.20, 95% CI 1.02-1.42) or vaccinated postpartum (OR 1.02, 95% CI 1.01-1.43) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/105\">",
"     105",
"    </a>",
"    ]. Although a causal association is unlikely, the possibility cannot be completely excluded. After review of these data, the ACIP concluded that AVA was safe to administer during pregnancy, but recommended that pregnant women defer vaccination unless exposure to anthrax poses an immediate risk for disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/106\">",
"     106",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another study of 4092 women in the military (3136 of whom had received at least one dose of vaccine) found no difference in pregnancy rate or odds of having a live birth in women receiving at least one dose of vaccine compared to those who had not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/107\">",
"     107",
"    </a>",
"    ]. The study, however, was not powered sufficiently to detect a small but significant effect on birth outcomes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/48/11016?source=see_link&amp;anchor=H16#H16\">",
"     \"Prevention of anthrax\", section on 'Anthrax vaccine in the pre-event/pre-exposure setting'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There are no data on the use of AVA among breastfeeding women. Administration of other inactivated vaccines during breastfeeding is not medically contraindicated so breastfeeding is not considered a contraindication to vaccination, when indicated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/104\">",
"     104",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Tuberculosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of BCG vaccine (Bacillus Calmette Guerin) to prevent tuberculosis is",
"    <strong>",
"     not",
"    </strong>",
"    recommended during pregnancy, although no harmful effects have been shown [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/108\">",
"     108",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/12/40136?source=see_link\">",
"     \"BCG vaccination\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Malaria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaccines that prevent infection by malaria parasites, including a vaccine that specifically targets pregnancy-associated malaria, are in development. At this time, prevention of malaria involves mosquito avoidance and chemoprophylaxis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/13/20695?source=see_link\">",
"     \"Treatment and prevention of malaria in pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     POSTPARTUM IMMUNIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Indications and procedures for vaccination of postpartum women are those described for the general population. Both inactivated and live vaccines (except",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/24/18823?source=see_link\">",
"     smallpox vaccine",
"    </a>",
"    ) may be administered to nursing mothers and breastfeeding does not adversely affect success or safety of vaccination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/6\">",
"     6",
"    </a>",
"    ]. Two vaccines that should be given before discharge to protect mother and newborn are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       MMR",
"      </strong>",
"      &mdash; The measles, mumps, rubella vaccine should be administered to women not immune to rubella (see",
"      <a class=\"local\" href=\"#H5\">",
"       'Immunizations that should be given prior to conception'",
"      </a>",
"      above)&nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/5\">",
"       5",
"      </a>",
"      ]. If a woman tests rubella \"nonimmune,\" but has documentation that she has received two doses of the measles, mumps, rubella vaccine, then revaccination is not advised. However, if she has received only one dose of the vaccine and failed to respond, then revaccination is a reasonable approach. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?14/30/14822?source=see_link\">",
"       \"Measles-mumps-rubella vaccination in high risk adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Varicella",
"      </strong>",
"      &mdash; Varicella vaccination is recommended for women without evidence of immunity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/109\">",
"       109",
"      </a>",
"      ]. The first dose is given while the patient is in the hospital and the second dose is given four to eight weeks later, which typically coincides with the routine postpartum visit. Breastfeeding is not a contraindication to administration.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If not given during pregnancy, Tdap should be given postpartum to women who have never received it [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/6\">",
"     6",
"    </a>",
"    ]. This reduces the risk of maternal pertussis, and thus transmission to the infant, in whom pertussis can be lethal or have significant morbidity. However, the maternal immune response may not be sufficiently rapid to provide indirect protection to the infant until two weeks post-immunization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/55\">",
"     55",
"    </a>",
"    ]. Breastfeeding is not a contraindication to administration (see",
"    <a class=\"local\" href=\"#H17\">",
"     'Tetanus, diphtheria, pertussis (Tdap)'",
"    </a>",
"    above).",
"   </p>",
"   <p>",
"    Rh(D)-negative women should be immunized with anti-D immune globulin, MMR,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"     varicella vaccine",
"    </a>",
"    immediately postpartum, when indicated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A theoretical concern is the possibility that anti-rubella antibodies may be present in sufficient concentration in anti-D immune globulin to inhibit the woman&rsquo;s immune response to the rubella vaccine. However, there is evidence that anti-D immune globulin does not reduce the response to the rubella vaccine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/110-114\">",
"     110-114",
"    </a>",
"    ] and there are no published reports of rubella vaccine failure after administration of anti-D immune globulin. Nevertheless, the CDC suggests that women who have received both anti-D immune globulin and rubella vaccine be serologically tested after vaccination, if feasible, to ensure that seroconversion has occurred [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/6,115\">",
"     6,115",
"    </a>",
"    ]. The ACIP recommends waiting &ge;3 months before evaluating the immune response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/48/24328?source=see_link&amp;anchor=H11#H11\">",
"     \"Assessing the immunologic response to vaccination\", section on 'Interfering factors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     IMMUNE GLOBULINS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immune globulins are given to prevent or reduce the severity of certain diseases in special circumstances. There are no known risks for the fetus from passive immunization of pregnant women with immune globulin preparations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/6\">",
"     6",
"    </a>",
"    ]. Postexposure prophylaxis of hepatitis A and B, measles, rabies, and tetanus is not altered by pregnancy.",
"   </p>",
"   <p>",
"    Production of varicella-zoster immune globulin (VZIG) was discontinued in the United States in 2005. It is currently available as VariZIG under an Investigational New Drug Application Expanded Access protocol and may be obtained by contacting FFF Enterprises at 800-843-7477. You will be asked to provide preliminary information to determine patient eligibility [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/116\">",
"     116",
"    </a>",
"    ]. If the patient is eligible, investigational VZIG will be shipped to your office within 24 hours with an informed consent form, case report forms, Investigator's Brochure, and contact information for Cangene Corporation. The dose is 125",
"    <span class=\"nowrap\">",
"     units/10",
"    </span>",
"    kg of body weight, up to a maximum dose of 625 units (5 vials). The duration of protection is estimated to be three weeks; pregnant women who are again exposed &gt;3 weeks after receiving a dose should receive another full dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/117\">",
"     117",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    VariZIG is a purified human immune globulin preparation made from plasma containing high levels of anti-varicella antibodies (immunoglobulin class G [IgG]) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/6,118\">",
"     6,118",
"    </a>",
"    ]. It is given to pregnant women susceptible to varicella who have a significant contact with a patient with chickenpox or herpes zoster infection. VariZIG can be administered up to ten days after the exposure but should be offered as soon as possible [",
"    <a class=\"abstract\" href=\"mobipreview.htm?31/53/32602/abstract/119\">",
"     119",
"    </a>",
"    ]. The primary goal of therapy is to prevent maternal complications of varicella; there is no evidence that VariZIG prevents viremia, fetal infection, congenital varicella, or neonatal varicella. Administration of VariZIG also might prolong the incubation period for primary varicella from 10 to 21 days to &ge;28 days; thus, a pregnant woman who might be incubating chickenpox should avoid exposing other pregnant patients who have not had chickenpox (eg, should not be seated in the waiting room of an obstetric practice from day 8 to 28 after exposure). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/28/33225?source=see_link&amp;anchor=H24974620#H24974620\">",
"     \"Varicella-zoster virus infection in pregnancy\", section on 'Post-exposure prophylaxis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If administration of VariZIG does not appear possible within 10 days of exposure, then administration of intravenous immune globulin (IVIG 400",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    administered once) should be considered as an alternative. Although licensed IVIG preparations contain anti-varicella antibody titers, the titer of any specific lot of IVIG is uncertain because IVIG is not routinely tested for antivaricella antibodies.",
"   </p>",
"   <p>",
"    If passive immunization is not an option, then clinicians can closely monitor the women for signs and symptoms of varicella and institute treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/7/31856?source=see_link\">",
"     acyclovir",
"    </a>",
"    if illness occurs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     RESOURCES",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      CDC vaccines webpage (",
"      <a class=\"external\" href=\"file://www.cdc.gov/vaccines/default.htm\">",
"       www.cdc.gov/vaccines/default.htm",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Guidelines for vaccinating pregnant women (",
"      <a class=\"external\" href=\"file://www.cdc.gov/vaccines/pubs/preg-guide.htm\">",
"       www.cdc.gov/vaccines/pubs/preg-guide.htm",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Adult immunization schedule (",
"      <a class=\"external\" href=\"file://www.cdc.gov/vaccines/recs/schedules/adult-schedule.htm\">",
"       www.cdc.gov/vaccines/recs/schedules/adult-schedule.htm",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Vaccine administration (",
"      <a class=\"external\" href=\"file://www.cdc.gov/vaccines/recs/vac-admin/default.htm\">",
"       www.cdc.gov/vaccines/recs/vac-admin/default.htm",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Vaccine storage and handling (",
"      <a class=\"external\" href=\"file://www.cdc.gov/vaccines/recs/storage/default.htm\">",
"       www.cdc.gov/vaccines/recs/storage/default.htm",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/39/33395?source=see_link\">",
"       \"Patient information: Avoiding infections in pregnancy (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?7/52/8003?source=see_link\">",
"       \"Patient information: Vaccines and pregnancy (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/61/33746?source=see_link\">",
"       \"Patient information: Tdap vaccine (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/7/17522?source=see_link\">",
"       \"Patient information: Vaccination during pregnancy (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?42/52/43843?source=see_link\">",
"       \"Patient information: Avoiding infections in pregnancy (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nonpregnant women of childbearing age who may become pregnant should receive all clinically indicated immunizations at least one month prior to conception. In the United States, this means immunity (as a result of immunization or disease) to measles, mumps, rubella, tetanus, diphtheria, pertussis, poliomyelitis, and varicella. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'ACIP recommendations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Individuals at high risk for hepatitis A, hepatitis B, pneumococcal, or meningococcal infection should receive these immunizations. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'ACIP recommendations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Before administering any vaccine, reasonable practices include asking the woman if she is pregnant or could become pregnant in the next four weeks and counseling her about the potential risks of vaccination during pregnancy or just before conception. Routine pregnancy testing of women of childbearing age before administering a vaccine, even a live-virus vaccine, is not necessary as long as pregnancy can reasonably be excluded by history. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'ACIP recommendations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Influenza is particularly morbid in pregnant women. During influenza season, we recommend that all pregnant women receive influenza vaccination regardless of trimester of pregnancy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Maternal immunization provides passive protection to the infant in the first few months of life. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Influenza'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pregnant women should minimize their risk of exposure to infections to which they are susceptible by avoiding travel to high risk locations (eg, areas where yellow fever is prevalent), assuring that household members are immunized according to standard immunization schedules (",
"      <a class=\"graphic graphic_figure graphicRef82634 \" href=\"mobipreview.htm?36/52/37701\">",
"       figure 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef62130 \" href=\"mobipreview.htm?41/17/42263\">",
"       figure 2",
"      </a>",
"      ), and maintaining good hygienic practices (eg, using clean and boiled water to minimize risks of hepatitis A, cholera, and typhoid in endemic areas). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Immunization issues during pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When pregnancy occurs within one month of immunization with the live measles, mumps, rubella (MMR) vaccine,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/28/4551?source=see_link\">",
"       varicella vaccine",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?14/13/14550?source=see_link\">",
"       yellow fever vaccine",
"      </a>",
"      , teratogenesis has not been reported. Therefore, termination of pregnancy for this indication is unwarranted. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Special considerations for women planning a pregnancy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H24\">",
"       'Yellow fever'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Live vaccines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is not necessary to delay conception after administration of toxoids, inactivated virus vaccines, or immune globulin preparations. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Toxoids, inactivated vaccines, immune globulin preparations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      MMR and varicella vaccines can be given safely to postpartum women who are breastfeeding and to the children of pregnant women, since the virus is not transmitted through breast milk or casual contact. (See",
"      <a class=\"local\" href=\"#H35\">",
"       'Postpartum immunization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend administration of the tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) to all pregnant women in each pregnancy between 27 and 36 weeks of gestation, even if the woman has a previous history of pertussis or vaccination (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Tdap is given to reduce the risk of maternal pertussis, and thus transmission to the infant, in whom pertussis can be lethal or have significant morbidity. Placental transfer of maternal antibodies may also provide a degree of passive protection of the infant against pertussis for two to six months. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Tetanus, diphtheria, pertussis (Tdap)'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/1\">",
"      Englund JA. The influence of maternal immunization on infant immune responses. J Comp Pathol 2007; 137 Suppl 1:S16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/2\">",
"      Gonik B, Fasano N, Foster S. The obstetrician-gynecologist's role in adult immunization. Am J Obstet Gynecol 2002; 187:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/3\">",
"      Pickering LK, Baker CJ, Freed GL, et al. Immunization programs for infants, children, adolescents, and adults: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2009; 49:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/4\">",
"      Leddy MA, Anderson BL, Power ML, et al. Changes in and current status of obstetrician-gynecologists' knowledge, attitudes, and practice regarding immunization. Obstet Gynecol Surv 2009; 64:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/5\">",
"      Akinsanya-Beysolow I, Wolfe CS. Update: Vaccines for women, adolescence through adulthood. J Womens Health (Larchmt) 2009; 18:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/6\">",
"      National Center for Immunization and Respiratory Diseases. General recommendations on immunization --- recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2011; 60:1.",
"     </a>",
"    </li>",
"    <li>",
"     Preblud SR. Fetal risk associated with rubella vaccination during pregnancy. In: Infectious Diseases in Obstetrics and Gynecology, Third Edition, Monif GG (Ed), IDI Publications, Omaha, NE 1993. p.2-139.",
"    </li>",
"    <li>",
"     www.cdc.gov/vaccines/pubs/preg-guide.htm#1 (Accessed on October 01, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/9\">",
"      Coonrod DV, Jack BW, Boggess KA, et al. The clinical content of preconception care: immunizations as part of preconception care. Am J Obstet Gynecol 2008; 199:S290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/10\">",
"      Committee on Adolescent Health Care, ACOG Working Group on Immunization. ACOG Committee Opinion No. 344: Human papillomavirus vaccination. Obstet Gynecol 2006; 108:699.",
"     </a>",
"    </li>",
"    <li>",
"     Quadrivalent Human Papillomavirus Vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). www.cdc.gov/mmwr/preview/mmwrhtml/rr56e312a1.htm (Accessed on March 20, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/12\">",
"      Dana A, Buchanan KM, Goss MA, et al. Pregnancy outcomes from the pregnancy registry of a human papillomavirus type 6/11/16/18 vaccine. Obstet Gynecol 2009; 114:1170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/13\">",
"      Garland SM, Ault KA, Gall SA, et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine: a combined analysis of five randomized controlled trials. Obstet Gynecol 2009; 114:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/14\">",
"      Centers for Disease Control and Prevention (CDC). FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2010; 59:626.",
"     </a>",
"    </li>",
"    <li>",
"     www.merck.com/product/usa/pi_circulars/g/gardasil/gardasil_pi.pdf (Accessed on October 02, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/16\">",
"      Watson JC, Hadler SC, Dykewicz CA, et al. Measles, mumps, and rubella--vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1998; 47:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/17\">",
"      Siegel M, Fuerst HT. Low birth weight and maternal virus diseases. A prospective study of rubella, measles, mumps, chickenpox, and hepatitis. JAMA 1966; 197:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/18\">",
"      St Geme JW Jr, Noren GR, Adams P Jr. Proposed embryopathic relation between mumps virus and primary endocardial fibroelastosis. N Engl J Med 1966; 275:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/19\">",
"      Centers for Disease Control and Prevention (CDC). Elimination of rubella and congenital rubella syndrome--United States, 1969-2004. MMWR Morb Mortal Wkly Rep 2005; 54:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/20\">",
"      Hahn&eacute; S, Macey J, van Binnendijk R, et al. Rubella outbreak in the Netherlands, 2004-2005: high burden of congenital infection and spread to Canada. Pediatr Infect Dis J 2009; 28:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/21\">",
"      Kakoulidou M, Forsgren M, Lewensohn-Fuchs I, Johansen K. Serum levels of rubella-specific antibodies in Swedish women following three decades of vaccination programmes. Vaccine 2010; 28:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/22\">",
"      Landes RD, Bass JW, Millunchick EW, Oetgen WJ. Neonatal rubella following postpartum maternal immunization. J Pediatr 1980; 97:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/23\">",
"      Centers for Disease Control (CDC). Rubella vaccination during pregnancy--United States, 1971-1988. MMWR Morb Mortal Wkly Rep 1989; 38:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/24\">",
"      Bar-Oz B, Levichek Z, Moretti ME, et al. Pregnancy outcome following rubella vaccination: a prospective controlled study. Am J Med Genet A 2004; 130A:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/25\">",
"      Badilla X, Morice A, Avila-Aguero ML, et al. Fetal risk associated with rubella vaccination during pregnancy. Pediatr Infect Dis J 2007; 26:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/26\">",
"      Centers for Disease Control and Prevention (CDC). Revised ACIP recommendation for avoiding pregnancy after receiving a rubella-containing vaccine. MMWR Morb Mortal Wkly Rep 2001; 50:1117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/27\">",
"      Pastuszak AL, Levy M, Schick B, et al. Outcome after maternal varicella infection in the first 20 weeks of pregnancy. N Engl J Med 1994; 330:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/28\">",
"      Tan MP, Koren G. Chickenpox in pregnancy: revisited. Reprod Toxicol 2006; 21:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/29\">",
"      Bai PV, John TJ. Congenital skin ulcers following varicella in late pregnancy. J Pediatr 1979; 94:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/30\">",
"      Marin M, G&uuml;ris D, Chaves SS, et al. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/31\">",
"      Enders G, Miller E, Cradock-Watson J, et al. Consequences of varicella and herpes zoster in pregnancy: prospective study of 1739 cases. Lancet 1994; 343:1548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/32\">",
"      Shields KE, Galil K, Seward J, et al. Varicella vaccine exposure during pregnancy: data from the first 5 years of the pregnancy registry. Obstet Gynecol 2001; 98:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/33\">",
"      Wilson E, Goss MA, Marin M, et al. Varicella vaccine exposure during pregnancy: data from 10 Years of the pregnancy registry. J Infect Dis 2008; 197 Suppl 2:S178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/34\">",
"      Bohlke K, Galil K, Jackson LA, et al. Postpartum varicella vaccination: is the vaccine virus excreted in breast milk? Obstet Gynecol 2003; 102:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/35\">",
"      Prevention of varicella: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Prevention. MMWR Recomm Rep 1996; 45:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/36\">",
"      Huang W, Hussey M, Michel F. Transmission of varicella to a gravida via close contacts immunized with varicella-zoster vaccine. A case report. J Reprod Med 1999; 44:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/37\">",
"      Salzman MB, Sharrar RG, Steinberg S, LaRussa P. Transmission of varicella-vaccine virus from a healthy 12-month-old child to his pregnant mother. J Pediatr 1997; 131:151.",
"     </a>",
"    </li>",
"    <li>",
"     www.merck.com/product/usa/pi_circulars/z/zostavax/zostavax_pi.pdf (Accessed on October 01, 2007).",
"    </li>",
"    <li>",
"     www.cdc.gov/nip/recs/provisional_recs/zoster-11-20-06.pdf (Accessed on October 01, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/40\">",
"      Whitman C, Belgharbi L, Gasse F, et al. Progress towards the global elimination of neonatal tetanus. World Health Stat Q 1992; 45:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/41\">",
"      Roper MH, Vandelaer JH, Gasse FL. Maternal and neonatal tetanus. Lancet 2007; 370:1947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/42\">",
"      Gupta SD, Keyl PM. Effectiveness of prenatal tetanus toxoid immunization against neonatal tetanus in a rural area in India. Pediatr Infect Dis J 1998; 17:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/43\">",
"      Centers for Disease Control and Prevention (CDC). Progress toward elimination of neonatal tetanus--Egypt, 1988-1994. MMWR Morb Mortal Wkly Rep 1996; 45:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/44\">",
"      Meegan ME, Conroy RM, Lengeny SO, et al. Effect on neonatal tetanus mortality after a culturally-based health promotion programme. Lancet 2001; 358:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/45\">",
"      Gerbie MV, Tan TQ. Pertussis disease in new mothers: effect on young infants and strategies for prevention. Obstet Gynecol 2009; 113:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/46\">",
"      Bisgard KM, Pascual FB, Ehresmann KR, et al. Infant pertussis: who was the source? Pediatr Infect Dis J 2004; 23:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/47\">",
"      Wendelboe AM, Njamkepo E, Bourillon A, et al. Transmission of Bordetella pertussis to young infants. Pediatr Infect Dis J 2007; 26:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/48\">",
"      Gall SA, Myers J, Pichichero M. Maternal immunization with tetanus-diphtheria-pertussis vaccine: effect on maternal and neonatal serum antibody levels. Am J Obstet Gynecol 2011; 204:334.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/49\">",
"      Healy CM, Rench MA, Baker CJ. Importance of timing of maternal combined tetanus, diphtheria, and acellular pertussis (Tdap) immunization and protection of young infants. Clin Infect Dis 2013; 56:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/50\">",
"      Riley LE, Beigi RH. Editorial commentary: maternal pertussis vaccination: protecting neonates from infection. Clin Infect Dis 2013; 56:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/51\">",
"      Mooi FR, de Greeff SC. The case for maternal vaccination against pertussis. Lancet Infect Dis 2007; 7:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/52\">",
"      Committee on Obstetric Practice. ACOG Committee Opinion No. 521: Update on immunization and pregnancy: tetanus, diphtheria, and pertussis vaccination. Obstet Gynecol 2012; 119:690.",
"     </a>",
"    </li>",
"    <li>",
"     Updated Recommendations for Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine (Tdap) in Pregnant Women &mdash; Advisory Committee on Immunization Practices (ACIP), 2012 file://www.cdc.gov/mmwr/preview/mmwrhtml/mm6207a4.htm?s_cid=mm6207a4_e (Accessed on February 21, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/54\">",
"      Zheteyeva YA, Moro PL, Tepper NK, et al. Adverse event reports after tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccines in pregnant women. Am J Obstet Gynecol 2012; 207:59.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/55\">",
"      Halperin BA, Morris A, Mackinnon-Cameron D, et al. Kinetics of the antibody response to tetanus-diphtheria-acellular pertussis vaccine in women of childbearing age and postpartum women. Clin Infect Dis 2011; 53:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/56\">",
"      H&aring;berg SE, Trogstad L, Gunnes N, et al. Risk of fetal death after pandemic influenza virus infection or vaccination. N Engl J Med 2013; 368:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/57\">",
"      Tamma PD, Ault KA, del Rio C, et al. Safety of influenza vaccination during pregnancy. Am J Obstet Gynecol 2009; 201:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/58\">",
"      Moro PL, Broder K, Zheteyeva Y, et al. Adverse events in pregnant women following administration of trivalent inactivated influenza vaccine and live attenuated influenza vaccine in the Vaccine Adverse Event Reporting System, 1990-2009. Am J Obstet Gynecol 2011; 204:146.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/59\">",
"      Moro PL, Broder K, Zheteyeva Y, et al. Adverse events following administration to pregnant women of influenza A (H1N1) 2009 monovalent vaccine reported to the Vaccine Adverse Event Reporting System. Am J Obstet Gynecol 2011; 205:473.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/60\">",
"      Pasternak B, Svanstr&ouml;m H, M&oslash;lgaard-Nielsen D, et al. Vaccination against pandemic A/H1N1 2009 influenza in pregnancy and risk of fetal death: cohort study in Denmark. BMJ 2012; 344:e2794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/61\">",
"      Pasternak B, Svanstr&ouml;m H, M&oslash;lgaard-Nielsen D, et al. Risk of adverse fetal outcomes following administration of a pandemic influenza A(H1N1) vaccine during pregnancy. JAMA 2012; 308:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/62\">",
"      Munoz FM, Greisinger AJ, Wehmanen OA, et al. Safety of influenza vaccination during pregnancy. Am J Obstet Gynecol 2005; 192:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/63\">",
"      Pool V, Iskander J. Safety of influenza vaccination during pregnancy. Am J Obstet Gynecol 2006; 194:1200; author reply 1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/64\">",
"      MacDonald NE, Riley LE, Steinhoff MC. Influenza immunization in pregnancy. Obstet Gynecol 2009; 114:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/65\">",
"      Roberts S, Hollier LM, Sheffield J, et al. Cost-effectiveness of universal influenza vaccination in a pregnant population. Obstet Gynecol 2006; 107:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/66\">",
"      Fiore AE, Shay DK, Broder K, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep 2009; 58:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/67\">",
"      Mak TK, Mangtani P, Leese J, et al. Influenza vaccination in pregnancy: current evidence and selected national policies. Lancet Infect Dis 2008; 8:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/68\">",
"      Centers for Disease Control and Prevention (CDC). Influenza vaccination coverage among pregnant women - 29 States and New York City, 2009-10 season. MMWR Morb Mortal Wkly Rep 2012; 61:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/69\">",
"      Centers for Disease Control and Prevention (CDC). Influenza vaccination coverage among pregnant women: 2011-12 influenza season, United States. MMWR Morb Mortal Wkly Rep 2012; 61:758.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/70\">",
"      Harper SA, Fukuda K, Uyeki TM, et al. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2004; 53:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/71\">",
"      American College of Obstetricians and Gynecologists Committee on Obstetric Practice. ACOG Committee Opinion No. 468: Influenza vaccination during pregnancy. Obstet Gynecol 2010; 116:1006.",
"     </a>",
"    </li>",
"    <li>",
"     Prevention and Control of Influenza with Vaccines",
"Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. file://www.cdc.gov/mmwr/preview/mmwrhtml/rr59e0729a1.htm?s_cid=rr59e0729a1_w .",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/73\">",
"      American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 86: Viral hepatitis in pregnancy. Obstet Gynecol 2007; 110:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/74\">",
"      Sheffield JS, Hickman A, Tang J, et al. Efficacy of an accelerated hepatitis B vaccination program during pregnancy. Obstet Gynecol 2011; 117:1130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/75\">",
"      Elinav E, Ben-Dov IZ, Shapira Y, et al. Acute hepatitis A infection in pregnancy is associated with high rates of gestational complications and preterm labor. Gastroenterology 2006; 130:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/76\">",
"      McDuffie RS Jr, Bader T. Fetal meconium peritonitis after maternal hepatitis A. Am J Obstet Gynecol 1999; 180:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/77\">",
"      Leikin E, Lysikiewicz A, Garry D, Tejani N. Intrauterine transmission of hepatitis A virus. Obstet Gynecol 1996; 88:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/78\">",
"      Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1997; 46:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/79\">",
"      Quiambao BP, Nohynek HM, K&auml;yhty H, et al. Immunogenicity and reactogenicity of 23-valent pneumococcal polysaccharide vaccine among pregnant Filipino women and placental transfer of antibodies. Vaccine 2007; 25:4470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/80\">",
"      Chaithongwongwatthana S, Yamasmit W, Limpongsanurak S, et al. Pneumococcal vaccination during pregnancy for preventing infant infection. Cochrane Database Syst Rev 2012; 7:CD004903.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.cdc.gov/ncidod/dvbid/westnile/qa/insect_repellent.htm (Accessed on January 18, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/82\">",
"      Nasidi A, Monath TP, Vandenberg J, et al. Yellow fever vaccination and pregnancy: a four-year prospective study. Trans R Soc Trop Med Hyg 1993; 87:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/83\">",
"      Suzano CE, Amaral E, Sato HK, et al. The effects of yellow fever immunization (17DD) inadvertently used in early pregnancy during a mass campaign in Brazil. Vaccine 2006; 24:1421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/84\">",
"      Staples JE, Gershman M, Fischer M, Centers for Disease Control and Prevention (CDC). Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2010; 59:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/85\">",
"      Tsai TF, Paul R, Lynberg MC, Letson GW. Congenital yellow fever virus infection after immunization in pregnancy. J Infect Dis 1993; 168:1520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/86\">",
"      Nishioka Sde A, Nunes-Ara&uacute;jo FR, Pires WP, et al. Yellow fever vaccination during pregnancy and spontaneous abortion: a case-control study. Trop Med Int Health 1998; 3:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/87\">",
"      Robert E, Vial T, Schaefer C, et al. Exposure to yellow fever vaccine in early pregnancy. Vaccine 1999; 17:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/88\">",
"      Cetron MS, Marfin AA, Julian KG, et al. Yellow fever vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2002. MMWR Recomm Rep 2002; 51:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/89\">",
"      Cavalcanti DP, Salom&atilde;o MA, Lopez-Camelo J, et al. Early exposure to yellow fever vaccine during pregnancy. Trop Med Int Health 2007; 12:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/90\">",
"      Centers for Disease Control and Prevention (CDC). Transmission of yellow fever vaccine virus through breast-feeding - Brazil, 2009. MMWR Morb Mortal Wkly Rep 2010; 59:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/91\">",
"      Centers for Disease Control and Prevention (CDC). Progress toward poliomyelitis eradication--Nigeria, January 2003-March 2004. MMWR Morb Mortal Wkly Rep 2004; 53:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/92\">",
"      Centers for Disease Control and Prevention (CDC). Recommendations of the Advisory Committee on Immunization Practices: revised recommendations for routine poliomyelitis vaccination. MMWR Morb Mortal Wkly Rep 1999; 48:590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/93\">",
"      Prevots DR, Burr RK, Sutter RW, et al. Poliomyelitis prevention in the United States. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2000; 49:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/94\">",
"      Bilukha OO, Rosenstein N, National Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2005; 54:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/95\">",
"      Centers for Disease Control and Prevention (CDC). Women with smallpox vaccine exposure during pregnancy reported to the National Smallpox Vaccine in Pregnancy Registry--United States, 2003. MMWR Morb Mortal Wkly Rep 2003; 52:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/96\">",
"      Wharton M, Strikas RA, Harpaz R, et al. Recommendations for using smallpox vaccine in a pre-event vaccination program. Supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP) and the Healthcare Infection Control Practices Advisory Committee (HICPAC). MMWR Recomm Rep 2003; 52:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/97\">",
"      Suarez VR, Hankins GD. Smallpox and pregnancy: from eradicated disease to bioterrorist threat. Obstet Gynecol 2002; 100:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/98\">",
"      Garde V, Harper D, Fairchok MP. Tertiary contact vaccinia in a breastfeeding infant. JAMA 2004; 291:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/99\">",
"      Rotz LD, Dotson DA, Damon IK, et al. Vaccinia (smallpox) vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2001. MMWR Recomm Rep 2001; 50:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/100\">",
"      Cono J, Casey CG, Bell DM, Centers for Disease Control and Prevention. Smallpox vaccination and adverse reactions. Guidance for clinicians. MMWR Recomm Rep 2003; 52:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/101\">",
"      Napolitano PG, Ryan MA, Grabenstein JD. Pregnancy discovered after smallpox vaccination: Is vaccinia immune globulin appropriate? Am J Obstet Gynecol 2004; 191:1863.",
"     </a>",
"    </li>",
"    <li>",
"     www.bt.cdc.gov/agent/smallpox/vaccination/preg-factsheet.asp (Accessed on October 01, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/103\">",
"      Sudarshan MK, Giri MS, Mahendra BJ, et al. Assessing the safety of post-exposure rabies immunization in pregnancy. Hum Vaccin 2007; 3:87.",
"     </a>",
"    </li>",
"    <li>",
"     Use of Anthrax Vaccine in the United States",
"Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009 file://www.cdc.gov/mmwr/preview/mmwrhtml/rr5906a1.htm?s_cid=rr5906a1_e (Accessed on July 22, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/105\">",
"      Ryan MA, Smith TC, Sevick CJ, et al. Birth defects among infants born to women who received anthrax vaccine in pregnancy. Am J Epidemiol 2008; 168:434.",
"     </a>",
"    </li>",
"    <li>",
"     CDC. Advisory Committee on Immunization Practices (ACIP) meeting minutes archive  file://www.cdc.gov/vaccines/recs/acip/mtg-minutes-archive.htm (Accessed on July 22, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/107\">",
"      Wiesen AR, Littell CT. Relationship between prepregnancy anthrax vaccination and pregnancy and birth outcomes among US Army women. JAMA 2002; 287:1556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/108\">",
"      The role of BCG vaccine in the prevention and control of tuberculosis in the United States. A joint statement by the Advisory Council for the Elimination of Tuberculosis and the Advisory Committee on Immunization Practices. MMWR Recomm Rep 1996; 45:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/109\">",
"      Marin M, G&uuml;ris D, Chaves SS, et al. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/110\">",
"      Black NA, Parsons A, Kurtz JB, et al. Post-partum rubella immunisation: a controlled trial of two vaccines. Lancet 1983; 2:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/111\">",
"      Pavelka R, Salzer H, Reinold E. [Post partum rubella vaccination and anti-D prevention]. Zentralbl Gynakol 1978; 100:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/112\">",
"      Edgar WM, Hambling MH. Rubella vaccination and anti-D immunoglobulin administration in the puerperium. Br J Obstet Gynaecol 1977; 84:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/113\">",
"      Maroni E, Kunz J, R&ouml;sli A, Munzinger J. [Investigations on the influence of Rh immunoglobulin prophylaxis on the immune response to postpartum rubella vaccination (author's transl)]. Geburtshilfe Frauenheilkd 1975; 35:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/114\">",
"      Maroni E, Munzinger J. Postpartum rubella vaccination and anti-D prophylaxis. Br Med J 1975; 2:541.",
"     </a>",
"    </li>",
"    <li>",
"     CDC. The Pink Book: Epidemiology and Prevention of Vaccine Preventable Diseases",
"Updated 11th Edition, (May 2009) file://www.cdc.gov/vaccines/pubs/pinkbook/downloads/rubella.pdf (Accessed on March 10, 2011).",
"    </li>",
"    <li>",
"     Sample pdf for Varicella Zoster IgG Release Form (Cangene) (PDF - 113KB) www.fda.gov/BiologicsBloodVaccines/SafetyAvailability/ucm176029.htm (Accessed on April 20, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/117\">",
"      Marin M, G&uuml;ris D, Chaves SS, et al. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007; 56:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/118\">",
"      Centers for Disease Control and Prevention (CDC). A new product (VariZIG) for postexposure prophylaxis of varicella available under an investigational new drug application expanded access protocol. MMWR Morb Mortal Wkly Rep 2006; 55:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?31/53/32602/abstract/119\">",
"      Centers for Disease Control and Prevention (CDC). FDA approval of an extended period for administering VariZIG for postexposure prophylaxis of varicella. MMWR Morb Mortal Wkly Rep 2012; 61:212.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 442 Version 47.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-C9BE2142DC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_53_32602=[""].join("\n");
var outline_f31_53_32602=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H39\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TYPES OF IMMUNIZATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Toxoids, inactivated vaccines, immune globulin preparations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Live vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      IMMUNIZATIONS THAT SHOULD BE GIVEN PRIOR TO CONCEPTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ACIP recommendations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Human papillomavirus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Special considerations for women planning a pregnancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Measles, mumps, rubella",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Varicella",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - MMRV vaccine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Zoster",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      IMMUNIZATION ISSUES DURING PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      General principles",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Lack of autism association with immunizations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Routine immunizations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Tetanus, diphtheria, pertussis (Tdap)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Influenza",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H624273493\">",
"      Inactivated vaccine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H624273469\">",
"      LAIV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Selective immunization of high risk groups",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Hepatitis B",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Hepatitis A",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Pneumococcus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Yellow fever",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Poliovirus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Haemophilus influenzae",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Meningococcal vaccine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Typhoid",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Smallpox",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Rabies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Cholera, plague, Japanese encephalitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11766764\">",
"      - Anthrax",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Tuberculosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Malaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      POSTPARTUM IMMUNIZATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      IMMUNE GLOBULINS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      RESOURCES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/442\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/442|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/52/37701\" title=\"figure 1\">",
"      Vax schedule healthy adult",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?41/17/42263\" title=\"figure 2\">",
"      Vaccine schedule based on medical conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/442|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/48/12046\" title=\"table 1\">",
"      Pneumococcal vaccination indications for adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/48/24328?source=related_link\">",
"      Assessing the immunologic response to vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/36/21066?source=related_link\">",
"      Autism and chronic disease: Little evidence for thimerosal as a contributing factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/14/26857?source=related_link\">",
"      Autism and chronic disease: Little evidence for vaccines as a contributing factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/12/40136?source=related_link\">",
"      BCG vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/38/1641?source=related_link\">",
"      Hepatitis A virus vaccination and postexposure prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/60/31690?source=related_link\">",
"      Hepatitis B virus vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/63/37881?source=related_link\">",
"      Hepatitis viruses and the newborn: Clinical manifestations and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/46/22247?source=related_link\">",
"      Identifying and managing casualties of biological terrorism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/21/2394?source=related_link\">",
"      Immunizations for travel",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/25/35224?source=related_link\">",
"      Influenza and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/30/14822?source=related_link\">",
"      Measles-mumps-rubella vaccination in high risk adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/32/23050?source=related_link\">",
"      Meningococcal vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/26/7591?source=related_link\">",
"      Overview of hepatitis A virus infection in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?42/52/43843?source=related_link\">",
"      Patient information: Avoiding infections in pregnancy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/39/33395?source=related_link\">",
"      Patient information: Avoiding infections in pregnancy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?32/61/33746?source=related_link\">",
"      Patient information: Tdap vaccine (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?17/7/17522?source=related_link\">",
"      Patient information: Vaccination during pregnancy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?7/52/8003?source=related_link\">",
"      Patient information: Vaccines and pregnancy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/12/21705?source=related_link\">",
"      Pneumococcal vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/52/17223?source=related_link\">",
"      Poliovirus vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/48/11016?source=related_link\">",
"      Prevention of anthrax",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/9/1177?source=related_link\">",
"      Prevention of sepsis in the asplenic patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/26/37289?source=related_link\">",
"      Prevention of varicella-zoster virus infection: Chickenpox",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/21/2393?source=related_link\">",
"      Rabies immune globulin and vaccine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/17/19738?source=related_link\">",
"      Recommendations for the use of human papillomavirus vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/60/6087?source=related_link\">",
"      Rubella in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/54/7014?source=related_link\">",
"      Tetanus-diphtheria toxoid vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/61/35797?source=related_link\">",
"      The epidemiology, pathogenesis, and clinical manifestations of smallpox",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/22/39271?source=related_link\">",
"      Treatment and prevention of Bordetella pertussis infection in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/13/20695?source=related_link\">",
"      Treatment and prevention of malaria in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/7/40057?source=related_link\">",
"      Vaccinia virus as the smallpox vaccine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/28/33225?source=related_link\">",
"      Varicella-zoster virus infection in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/21/15705?source=related_link\">",
"      Yellow fever",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f31_53_32603="Mortality per 1000 live births by plurality";
var content_f31_53_32603=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F75320&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F75320&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Infant, neonatal, postnatal mortality per 1000 live births by plurality",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"10%\">",
"     </colgroup>",
"     <colgroup span=\"3\" width=\"30%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Infant deaths",
"        <br/>",
"        (birth to 1 year)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Neonatal deaths",
"        <br/>",
"        (birth to day 28)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Postneonatal",
"        <br/>",
"        (day 29 to 1 year)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Singletons",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        11.2",
"       </td>",
"       <td class=\"centered\">",
"        7.8",
"       </td>",
"       <td class=\"centered\">",
"        3.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Twins",
"        </strong>",
"       </td>",
"       <td class=\"centered\">",
"        66.4",
"       </td>",
"       <td class=\"centered\">",
"        55.9",
"       </td>",
"       <td class=\"centered\">",
"        10.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Triplets",
"        </strong>",
"        *",
"       </td>",
"       <td class=\"centered\">",
"        190.4",
"       </td>",
"       <td class=\"centered\">",
"        168.8",
"       </td>",
"       <td class=\"centered\">",
"        21.6",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Triplets and higher order multiple gestations.",
"     <br/>",
"     Calculated from US Vital Statistics, 1998 and from US Public Health Service. Healthy People 2000: National Health Promotion and Disease Prevention Objectives, DHHS Pub. No. (PHS)90-50212. Washington, DC: US Department of Health and Human Services, Public Health Service; 1990.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Oleszczuk JJ, Oleszczuk AK, Keith LG. Twin and triplet birth: facts, figures, and costs. Female patient 2003; 28:11. Copyright &copy; 2003 Jaroslaw J Oleszczuk, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_53_32603=[""].join("\n");
var outline_f31_53_32603=null;
var title_f31_53_32604="Properties of dressings";
var content_f31_53_32604=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F60931&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F60931&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Properties of dressings",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Category (product examples)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Property",
"       </td>",
"       <td class=\"subtitle1\">",
"        Indication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Simple, low-adherance",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Cotton or Viscose backing and a non-adherent coating which may",
"be polyethylene, polypropylene or artificial silk. Generally are",
"nonabsorbent.",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Superficial dry wound, or wound with light exudate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        (Telfa, Cutinova Nonadherent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Paraffin gauze",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Gauze fiber coated with petrolatum. Generally are nonabsorbent.",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Superficial dry wound, or wound with exudate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        (Vaseline Adaptic)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Semipermeable adhesive films",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Thin layer of polyurethane alone",
"(Omiderm) or with an adhesive (Opsite). They permit the passage of",
"gases and water vapor but not exudate, have a slight drying effect of",
"the wound, and are transparent and allow visualization of the wound.",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Wound with light exudate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        (Omiderm, Opsite, Tegaderm, Bioocclusive)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Hydrogels",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Made of starch, giving them a large capacity for absorbing water without changing the shape of the dressing.",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        <p>",
"         Flat wound with moderate exudate",
"        </p>",
"        <p>",
"         Useful over crusted and dried surface exudate",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        (Vigilon, Spenco Second Skin)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Hydrocolloid",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Generally",
"composed of gelatin and pectin, which dissolve in the presence of an",
"exudate, absorbing it and becoming space occupying.",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Wounds with moderate exudate, and deep or cavity wounds",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        (DuoDerm, Granuflex, Tegasorb, Biofilm)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        Alginate",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Calcium",
"ions in the alginate fiber exchange with sodium ions of the exudate to",
"form a fibrous gel. Calcium ions in Kaltostat activate the clotting",
"cascade.",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Wounds with heavy exudate, and deep or cavity wounds",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        (Sorbsan, Kaltostat, Cutinova Cavity)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Ryan, TJ, Derm Clin 1993; 11:207, and Local applications for wounds - II, Drug Ther Bull 1991; 29:97.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_53_32604=[""].join("\n");
var outline_f31_53_32604=null;
var title_f31_53_32605="Cytokines which perpetuate RA";
var content_f31_53_32605=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F82586&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F82586&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cytokine networks in the perpetuation of rheumatoid arthritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 409px; height: 233px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The cytokine networks responsible for the perpetuation of rheumatoid arthritis are primarily based upon the interactions between macrophages and fibroblasts.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_53_32605=[""].join("\n");
var outline_f31_53_32605=null;
var title_f31_53_32606="Atlanto occipital disassociation";
var content_f31_53_32606=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F51624&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F51624&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Atlanto-occipital disassociation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 368px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Severe flexion injuries involving the atlas (C1) can cause an atlanto-occipital dislocation or disassociation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Mary Hochman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_53_32606=[""].join("\n");
var outline_f31_53_32606=null;
var title_f31_53_32607="Type II supracondylar fracture 1";
var content_f31_53_32607=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F64760&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F64760&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gartland type II supracondylar fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 298px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Type II extension supracondylar humeral fracture (left elbow). Anterior-posterior radiograph. A, ulna; B, humerus; C, capitellar epiphysis; D, radius.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Koval KJ, Zuckerman JD. Atlas of Orthopaedic Surgery: A Multimeidal Reference. Philadelphia: Lippincott Williams &amp; Wilkins, 2004. Copyright &copy; 2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f31_53_32607=[""].join("\n");
var outline_f31_53_32607=null;
